Teva Pharmaceutical Industries Limited (TEVA) 10-K 12 Feb 24 2023 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	FY
Document Annual Report	true
Entity Registrant Name	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Entity Central Index Key	0000818686
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding	1,121,094,011
Title of 12(b) Security	American Depositary Shares, each representing one Ordinary Share
Trading Symbol	TEVA
Security Exchange Name	NYSE
Entity File Number	001-16174
Entity Incorporation, State or Country Code	L3
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	124 Dvora HaNevi’a St.
Entity Address, City or Town	Tel Aviv
Entity Address, Postal Zip Code	6944020
Entity Address, Country	IL
City Area Code	+972 (3)
Local Phone Number	914-8213
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float		$ 8,380
ICFR Auditor Attestation Flag	true
Auditor Name	Kesselman & Kesselman
Auditor Firm ID	1309
Auditor Location	Israel
Document Financial Statement Error Correction [Flag]	true
Document Financial Statement Restatement Recovery Analysis [Flag]	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents		$ 3,226	$ 2,801
Accounts receivables, net of allowance for credit losses of $95 million and $91 million as of December 31, 2023 and December 31, 2022, respectively		3,408	3,696
Inventories		4,021	3,833
Prepaid expenses		1,255	1,162
Other current assets		504	549
Assets held for sale		70	10
Total current assets		12,485	12,051
Deferred income taxes		1,812	1,458
Other non-current assets		470	441
Property, plant and equipment, net		5,750	5,739
Operating lease right-of-use assets		397	419
Identifiable intangible assets, net		5,387	6,270
Goodwill	[1]	17,177	17,633
Total assets		43,479	44,011
Current liabilities:
Short-term debt		1,672	2,109
Sales reserves and allowances		3,535	3,750
Accounts payables		2,602	1,887
Employee-related obligations		611	566
Accrued expenses		2,771	2,151
Other current liabilities		1,056	1,005
Total current liabilities		12,247	11,469
Long-term liabilities:
Deferred income taxes		606	548
Other taxes and long-term liabilities		4,019	3,945
Senior notes and loans		18,161	19,103
Operating lease liabilities		320	349
Total long-term liabilities		23,106	23,944
Commitments and contingencies, see note 12
Total liabilities		35,353	35,413
Teva shareholders' equity:
Ordinary shares of NIS 0.10 par value per share; December 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively		57	57
Additional paid-in capital		27,807	27,688
Accumulated deficit		(13,534)	(12,975)
Accumulated other comprehensive loss		(2,697)	(2,838)
Treasury shares as of December 31, 2023 and December 31, 2022: 106 million ordinary shares		(4,128)	(4,128)
Stockholders' equity attributable to Teva shareholders		7,506	7,804
Non-controlling interests		620	794
Total equity		8,126	8,598
Total liabilities and equity		$ 43,479	$ 44,011
[1]Cumulative goodwill impairment as of December 31, 2023, December 31, 2022 and December 31, 2021 was approximately $28.3 billion, $27.6 billion and $25.6 billion respectively.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) $ in Millions	Dec. 31, 2023 USD ($) shares	Dec. 31, 2023 ₪ / shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 ₪ / shares
Allowance for credit losses | $	$ 95		$ 91
Common stock, par or stated value per share | ₪ / shares		₪ 0.1		₪ 0.1
Ordinary shares, authorized	2,495,000,000		2,495,000,000
Ordinary shares, issued	1,227,000,000		1,217,000,000
Treasury shares	106,000,000		106,000,000

Consolidated Statements of Inco

Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net revenues		$ 15,846	$ 14,925	$ 15,878
Cost of sales		8,200	7,952	8,284
Gross profit		7,645	6,973	7,594
Research and development expenses, net		953	838	967
Selling and marketing expenses		2,336	2,265	2,429
General and administrative expenses		1,162	1,180	1,099
Intangible assets impairments		350	355	424
Goodwill impairment		700	2,045	0
Other asset impairments, restructuring and other items	[1]	718	512	341
Legal settlements and loss contingencies		1,043	2,082	717
Other income		(49)	(107)	(98)
Operating (loss) income	[1]	433	(2,197)	1,716
Financial expenses – net		1,057	966	1,058
Income (loss) before income taxes	[1],[2]	(624)	(3,163)	658
Income taxes (benefit)	[2]	(7)	(643)	211
Share in (profits) losses of associated companies – net		(2)	(21)	(9)
Net income (loss)		(615)	(2,499)	456
Net income (loss) attributable to non-controlling interests		(56)	(53)	39
Net income (loss) attributable to Teva		$ (559)	$ (2,446)	$ 417
Earnings (loss) per share attributable to ordinary shareholders:
Basic		$ (0.5)	$ (2.2)	$ 0.38
Diluted		$ (0.5)	$ (2.2)	$ 0.38
Weighted average number of shares (in millions):
Basic		1,119	1,110	1,102
Diluted		1,119	1,110	1,107
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net income (loss)	$ (615)	$ (2,499)	$ 456
Other comprehensive income (loss), net of tax:
Currency translation adjustment	80	(356)	(462)
Unrealized gain (loss) on derivative financial instruments, net	29	29	39
Unrealized gain (loss) on defined benefit plans, net	(18)	57	32
Total other comprehensive income (loss)	91	(270)	(391)
Total comprehensive income (loss)	(524)	(2,769)	65
Comprehensive income (loss) attributable to non-controlling interests	(106)	(169)	(68)
Comprehensive income (loss) attributable to Teva	$ (418)	$ (2,600)	$ 133

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions		Total	Ordinary Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Shares [Member]	Total Teva Shareholders' Equity [Member]	Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2020		$ 11,061	$ 57	$ 27,443	$ (10,946)	$ (2,399)	$ (4,128)	$ 10,026	$ 1,035
Beginning balance, shares at Dec. 31, 2020			1,202
Net income (loss)		456			417			417	39
Other comprehensive income (loss)		(391)				(283)		(283)	(107)
Issuance of Shares, shares			7
Stock-based compensation expense		119		119				119
Transactions with non-controlling interests		(2)							(2)
Ending balance at Dec. 31, 2021		11,244	$ 57	27,561	(10,529)	(2,683)	(4,128)	10,278	966
Ending balance, shares at Dec. 31, 2021			1,209
Net income (loss)		(2,499)			(2,446)			(2,446)	(53)
Other comprehensive income (loss)		(270)				(154)		(154)	(116)
Issuance of Shares, value		1		1				1
Issuance of Shares, shares			8
Stock-based compensation expense		124		124				124
Transactions with non-controlling interests		(2)							(2)
Ending balance at Dec. 31, 2022		8,598	$ 57	27,688	(12,975)	(2,838)	(4,128)	7,804	794
Ending balance, shares at Dec. 31, 2022			1,217
Beginning balance at Jun. 30, 2022		9,810
Net income (loss)		63
Ending balance at Sep. 30, 2022		9,506
Net income (loss)		(1,333)
Ending balance at Dec. 31, 2022		8,598	$ 57	27,688	(12,975)	(2,838)	(4,128)	7,804	794
Ending balance, shares at Dec. 31, 2022			1,217
Net income (loss)		(253)
Ending balance at Mar. 31, 2023		8,504
Beginning balance at Dec. 31, 2022		8,598	$ 57	27,688	(12,975)	(2,838)	(4,128)	7,804	794
Beginning balance, shares at Dec. 31, 2022			1,217
Net income (loss)		(615)			(559)			(559)	(56)
Other comprehensive income (loss)		91				141		141	(50)
Issuance of Shares, shares			10
Stock-based compensation expense		121		121				121
Dividend to non-controlling interests	[1]	(68)							(68)
Ending balance at Dec. 31, 2023		8,126	$ 57	27,807	(13,534)	(2,697)	(4,128)	7,506	620
Ending balance, shares at Dec. 31, 2023			1,227
Beginning balance at Mar. 31, 2023		8,504
Net income (loss)		(905)
Ending balance at Jun. 30, 2023		7,592
Net income (loss)		78
Ending balance at Sep. 30, 2023		7,387
Ending balance at Dec. 31, 2023		$ 8,126	$ 57	$ 27,807	$ (13,534)	$ (2,697)	$ (4,128)	$ 7,506	$ 620
Ending balance, shares at Dec. 31, 2023			1,227
[1]Mainly in connection with a declaration of dividends to non-controlling interests in Teva’s joint venture in Japan.

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Maximum [Member] | Ordinary Shares [Member]
Exercise of options by employees and vested RSUs	$ 0.5	$ 0.5	$ 0.5

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Operating activities:
Net income (loss)	$ (615)	$ (2,499)	$ 456
Adjustments to reconcile net income (loss) to net cash provided by operations:
Impairment of goodwill, long-lived assets and assets held for sale	1,078	2,447	584
Depreciation and amortization	1,153	1,308	1,330
Net change in operating assets and liabilities	(72)	1,355	(1,701)
Deferred income taxes — net and uncertain tax positions	(317)	(1,064)	(120)
Stock-based compensation	121	124	119
Research and development in process	0	0	10
Net loss (gain) from investments and from sale of business and long-lived assets	(41)	10	104
Other items	61	(91)	16
Net cash provided by (used in) operating activities	1,368	1,590	798
Investing activities:
Beneficial interest collected in exchange for securitized trade receivables	1,477	1,140	1,648
Purchases of property, plant and equipment and intangible assets	(526)	(548)	(562)
Proceeds from sale of business and long-lived assets	68	68	311
Purchases of investments and other assets	(46)	(1)	(47)
Proceeds from sale of investments	0	4	172
Acquisitions of businesses, net of cash acquired	0	(7)	0
Other investing activities	(5)	0	1
Net cash provided by (used in) investing activities	968	656	1,523
Financing activities:
Repayment of senior notes and loans and other long term liabilities	(4,152)	(1,369)	(6,649)
Proceeds from senior notes, net of issuance costs	2,451	0	4,974
Proceeds from short term debt	700	0	700
Repayment of short term debt	(700)	0	(700)
Redemption of convertible debentures	0	0	(491)
Other financing activities	(212)	(118)	(6)
Net cash provided by (used in) financing activities	(1,913)	(1,487)	(2,172)
Translation adjustment on cash and cash equivalents	(30)	(123)	(128)
Net change in cash, cash equivalents and restricted cash	393	636	21
Balance of cash, cash equivalents and restricted cash at beginning of year	2,834	2,198	2,177
Balance of cash, cash equivalents and restricted cash at end of year	3,227	2,834	2,198
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents	3,226	2,801	2,165
Restricted cash included in other current assets	1	33	33
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	3,227	2,834	2,198
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized trade receivables	1,446	1,189	1,635
Dividend declared to non-controlling interests	67	0	0
Cash paid during the year for:
Interest	1,078	948	913
Income taxes, net of refunds	298	543	495
Net change in operating assets and liabilities:
Other current assets	(1,525)	(828)	(2,271)
Trade payables, accrued expenses, employee-related obligations and other liabilities	1,588	2,012	764
Trade receivables net of sales reserves and allowances	12	334	(574)
Inventories	(147)	(163)	380
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information	$ (72)	$ 1,355	$ (1,701)

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies	NOTE 1 — Significant accounting policies: a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The majority of the Group’s revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). In preparing the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Company’s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva’s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to: determining the valuation and recoverability of IPR&D assets, marketed product rights, contingent consideration and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva’s International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. As part of the Company’s annual goodwill analysis performed in the second quarter of 2023, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets reporting unit. This increase was due to an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge described above, during the year ended December 31, 2023, the impact of the Russia-Ukraine conflict on Teva’s results of operations and financial condition was immaterial. See also note 7. In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. Israel is included in Teva’s International Markets segment results. Teva’s global headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. Teva continues to maintain contingency plans with backup production locations for key products. During the year ended December 31, 2023, the impact of this war on Teva’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Functional currency A major part of the Group’s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”). The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results net of related income taxes are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). Principles of consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders’ interests are shown as non-controlling For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated. b. Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified errors in a single contingent consideration liability and related expenses in connection with estimated future royalty payments, along with corresponding deferred tax adjustments, that aggregated into an understatement of the contingent consideration liability of approximately million, of which million related to 2022 and $ million related to 2023. These errors resulted from the exclusion of royalty payments that should have been included in the fair value re-measurement year-to-date The Company evaluated the errors, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that these errors did not have a material impact on any of the prior periods stated above. However, the aggregate amount of the prior period errors in 2022, would have been material to the consolidated financial statements for fiscal year 2023. Therefore, the Company has revised the prior periods impacted for these errors. The impact of the revision on the Company’s unaudited quarterly financial data for 2023 and 2022 is presented in note 22. The tables below present the impact of the revision on the line items within the Company’s consolidated financial statements as of and for the year ended December 31, 2022: Consolidated Statements of Income Year ended December 31, 2022 Consolidated Balance Sheets December 31, 2022 Adjustment As Adjustment As U.S $ in millions (except per share U.S $ in millions (except per share Other asset impairments, restructuring and other items $ 414 98 512 Deferred income taxes $ 1,453 5 1,458 Operating income (loss) (2,099 ) (98 ) (2,197 ) Total assets 44,006 5 44,011 Income (loss) before income taxes (3,065 ) (98 ) (3,163 ) Other taxes and long-term liabilities 3,847 98 3,945 Income taxes (benefit) (638 ) (5 ) (643 ) Total long-term liabilities 23,846 98 23,944 Net income (loss) (2,406 ) (93 ) (2,499 ) Total liabilities 35,315 98 35,413 Net income (loss) attributable to Teva (2,353 ) (93 ) (2,446 ) Teva shareholders’ equity: Earnings (loss) per share attributable to ordinary shareholders: Accumulated deficit (12,882 ) (93 ) (12,975 ) Basic $ (2.12 ) (0.08 ) (2.20 ) Total equity 8,691 (93 ) 8,598 Diluted $ (2.12 ) (0.08 ) (2.20 ) Total liabilities and equity $ 44,006 5 44,011 c. New accounting pronouncements Recently adopted accounting pronouncements In September 2022, the FASB issued ASU 2022-04 405-50)”. In October 2021, the FASB issued ASU 2021-08 Recently issued accounting pronouncements, not yet adopted In December 2023, the FASB issued ASU 2023-09 2023-09 in foreign jurisdictions. ASU 2023-09 In November 2023, the FASB issued ASU 2023-07 In October 2023, the FASB issued ASU 2023-06 Regulation S-X Regulation S-K 2023-06 d. Acquisitions: Teva’s consolidated financial statements include the operations of acquired businesses from the date of the acquisition’s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed unless it has an alternative future use. Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is re-measured e. Collaborative arrangements: Collaborative arrangements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues and costs are recorded on a net basis. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaborative arrangements are recorded as research and development expenses. f. Equity investments: The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly for triggering events), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months. g. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. h. Investment in debt securities: Investment in securities consists of debt securities classified as available-for-sale Unrealized gains and losses for available-for-sale available-for-sale non-credit i. Cash and cash equivalents: All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents. j. Restricted cash: Restricted cash represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet under other current assets. k. Accounts Receivables: Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. Write-off l. Concentration of credit risks: Most of Teva’s cash and cash equivalents, along with investment in securities, at December 31, 2023 were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The U.S. market constituted approximately 51% of Teva’s consolidated revenues in 2023. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance. m. Inventories: Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. Inventories acquired in a business combination are stepped-up n. Long-lived assets: Teva’s long-lived, non-current right-of-use Goodwill Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any non-controlling The goodwill impairment test is performed according to the following principles: 1. An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. 2. If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized. An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company’s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company’s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. Identifiable intangible assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (“S&M”) expenses when separable. Indefinite life intangible assets are mainly comprised of IPR&D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. IPR&D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s or asset group’s cash flows and compares such value against the asset’s or asset group’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. For indefinite life intangible assets, Teva performs an impairment test annually in the second quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Teva determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i) for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. Property, plant and equipment Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly 20 years; and other assets, between 5 to 10 years. For property, plant and equipment and lease right-of-use Lease right-of-use See note 8 and note 1ee for further discussion. o. Contingencies: The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are reasonably estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. When applicable, the Company classifies the effect that the passage of time had on the net present value of a discounted legal accrual as legal expenses. Legal costs are expensed as incurred. The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved. p. Treasury shares: Treasury shares are presented as a reduction of Teva shareholders’ equity and carried at their cost to Teva, under treasury shares. q. Stock-based compensation: Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units (“PSUs”). Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the share-based award’s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. Teva measures compensation expense for RSUs and PSUs based on the market value of the underlying stock at the date of grant, less the present value of expected dividends not received during the vesting period, if applicable. Teva amortizes the value of RSUs to expense over the vesting period on a straight-line basis. The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. Teva records forfeitures for share-based awards, RSUs and PSUs as they occur. If an employee forfeits an award because he fails to complete the requisite service period, the Company will reverse the compensation cost previously recognized in the period the award is forfeited. r. Deferred income taxes: Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as non-current. Tax has not been provided on the following items: 1. Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company’s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. 2. Amounts of tax-exempt s. Uncertain tax positions: Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly re-evaluates Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss. t. Derivatives and hedging: The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company’s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. Derivative instruments are recognized on the balance sheet at their fair value. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses, net in the statements of income in the period that the changes in fair value occur. For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. For derivative instruments that are designated as net-investment portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial expenses, net. For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. Derivative instruments that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows. u. Revenue recognition: A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (“SR&A”) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&A components and how they are estimated, see “Variable Consideration” below. Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&M expenses. Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less, based on the practical expedient. The Company’s credit terms to customers are, on average, between thirty and ninety days. The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. Nature of revenue streams Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. Licensing arrangements performance obligations generally include intellectual property (“IP”) rights, certain R&D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct – i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been alloca

Certain transactions

Certain transactions	12 Months Ended
	Dec. 31, 2023
Certain transactions	NOTE 2 – Certain transactions: The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company’s most significant agreements of this nature are summarized below. Biolojic Design On November 26, 2023, Teva entered into a license agreement with Biolojic Design Ltd. (“Biolojic”), pursuant to which Teva received exclusive rights to develop, manufacture and commercialize worldwide a BD9 multibody for the potential treatment of Atopic Dermatitis and Asthma. In exchange, Teva agreed to pay an upfront payment in an amount of $ million, which was recorded as an R&D expense in the fourth quarter of 2023 and was paid in January 2024. Biolojic may be eligible to receive additional development and commercial milestones payments of up to approximately $ million, over the next several years, based on the achievement of certain pre-clinical, clinical and regulatory milestones, with the majority of the payments based on future revenue achievements. Royalty Pharma On November 9, 2023, Teva entered into a funding agreement with Royalty Pharma plc. (“Royalty Pharma”) to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-’749). (TEV-’749) Sanofi On October 3, 2023, Teva entered into an exclusive collaboration with Sanofi to co-develop co-commercialize (TEV-’574) MODAG In October 2021, Teva announced a license agreement with MODAG GmbH (“Modag”) that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag’s lead compound, emrusolmin (TEV-’286) (TEV-’287). (TEV-’286) (TEV-’286) Alvotech In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including proposed biosimilars to Humira ® ® Teva made an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 and January 2023, each of which were recorded as R&D expenses, the latter in the fourth quarter of 2022. Additional development and commercial milestone payments of up to approximately $400 million, royalty payments, and milestone payments related to the amendment of the collaboration agreement entered into in July 2023, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. The amendment of the collaboration agreement entered into in July 2023 includes increased involvement by Teva regarding manufacturing and quality at Alvotech’s manufacturing facility. In connection with Teva’s amendment of its strategic partnership with Alvotech, on September 29, 2023, Alvotech issued $40 million of subordinated convertible bonds to Teva. With respect to the proposed biosimilar to Humira ® ® With respect to the proposed biosimilar to Stelara ® ® ® Otsuka On May 12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) providing Otsuka with an exclusive license to develop and commercialize AJOVY in Japan. Otsuka paid Teva an upfront payment of $50 million in consideration for the transaction. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of $15 million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August 30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of $35 million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka also pays Teva royalties on AJOVY sales in Japan. Takeda In December 2016, Teva entered into a license agreement with a subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”), for the research, development, manufacture and commercialization of ATTENUKINE TM MedinCell In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable (“LAI”) products. Teva leads the clinical development and regulatory process and is responsible for commercialization of these products. The lead product is risperidone LAI (formerly known as TV-46000). The second selected product candidate is olanzapine LAI (TEV-’749) (TEV-’749). Assets and Liabilities Held For Sale: General Assets held for sale as of December 31, 2023 included businesses that are expected to be sold within the next year. Assets held for sale as of December 31, 2022 included certain manufacturing assets that were sold during the second and third quarters of 2023. The table below summarizes all of Teva’s assets and liabilities included as held for sale as of December 31, 2023 and December 31, 2022: December 31, December 31, (U.S. $ in millions) Inventories $ 12 $ 2 Property, plant and equipment, net and others 28 18 Goodwill 30 —  Adjustments of assets held for sale to fair value —  (10 ) Total assets of the disposal group classified as held for sale in the consolidated balance sheets $ 70 $ 10 Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under other current liabilities $ (13 ) $ —

Revenue from contracts with cus

Revenue from contracts with customers	12 Months Ended
	Dec. 31, 2023
Revenue from contracts with customers	NOTE 3 – Revenue from contracts with customers: Disaggregation of revenue The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. Year ended December 31, 2023 North Europe International Other Total (U.S.$ in millions) Sale of goods 5,944 4,631 1,840 565 12,979 Licensing arrangements * 601 51 24 5 681 Distribution 1,577 § 38 —  1,615 Other** 2 155 56 357 570 $ 8,124 $ 4,837 $ 1,958 $ 926 $ 15,846 * Revenues from licensing arrangements in North America segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2. ** “Other” revenues in Europe segment mainly related to the sale of certain product rights. § Represents an amount less than $ 0.5 Year ended December 31, 2022 North Europe International Other Total (U.S.$ in millions) Sale of goods 5,834 4,455 1,806 671 12,766 Licensing arrangements 139 51 19 4 212 Distribution 1,471 1 46 —  1,519 Other 8 18 33 370 428 $ 7,452 $ 4,525 $ 1,903 $ 1,045 $ 14,925 Year ended December 31, 2021 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,394 4,807 1,889 739 13,829 Licensing arrangements 92 50 13 4 160 Distribution 1,323 1 65 —  1,390 Other (1) 27 65 408 500 $ 7,809 $ 4,886 $ 2,032 $ 1,151 $ 15,878 Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. For description of the nature of each deduction and how provisions are estimated see note 1. SR&A to U.S. customers comprised approximately 65% of the Company’s total SR&A as of December 31, 2023, with the remaining balance primarily in Canada and Germany. The changes in SR&A for third-party sales for the years ended December 31, 2023 and 2022 were as follows: Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2023 $ 67 $ 1,575 $ 663 $ 991 $ 455 $ 66 $ 3,750 $ 3,817 Provisions related to sales made in current year period 354 4,015 654 7,579 264 109 12,621 12,975 Provisions related to sales made in prior periods —  (31 ) (33 ) (54 ) 17 —  (101 ) (101 ) Credits and payments (360 ) (3,974 ) (748 ) (7,662 ) (304 ) (77 ) (12,765 ) (13,125 ) Translation differences —  18 4 5 4 (1 ) 30 30 Balance at December 31, 2023 $ 61 $ 1,603 $ 540 $ 859 $ 436 $ 97 $ 3,535 $ 3,596 Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2022 $ 68 $ 1,655 $ 854 $ 1,085 $ 535 $ 112 $ 4,241 $ 4,309 Provisions related to sales made in current year period 363 3,823 871 7,819 317 85 12,915 13,278 Provisions related to sales made in prior periods —  (69 ) (35 ) (44 ) (3 ) (51 ) (202 ) (202 ) Credits and payments (364 ) (3,798 ) (1,023 ) (7,861 ) (390 ) (77 ) (13,149 ) (13,513 ) Translation differences —  (36 ) (4 ) (8 ) (4 ) (3 ) (55 ) (55 ) Balance at December 31, 2022 $ 67 $ 1,575 $ 663 $ 991 $ 455 $ 66 $ 3,750 $ 3,817 Allowance for credit losses Accounts receivables are recognized net of allowance for credit losses. Allowances for credit losses were $95 million and $91 million as of December 31, 2023 and December 31, 2022, respectively. Pledged accounts receivables Accounts receivables, net of allowance for credit losses, include $437 million and $436 million as of December 31, 2023 and December 31, 2022, respectively, which are pledged in connection with the U.S. securitization program entered into in November 2022. See note 10f.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventories	NOTE 4 —Inventories: Inventories, net of reserves, consisted of the following: December 31,  2023   2022  (U.S. $ in millions) Finished products $ 2,346 $ 1,987 Raw and packaging materials 993 1,059 Products in process 500 555 Materials in transit and payments on account 183 232 $ 4,021 $ 3,833

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment	NOTE 5 —Property, plant and equipment: Property, plant and equipment, net, consisted of the following: December 31, 2023 2022 (U.S. $ in millions) Machinery and equipment $ 4,807 $ 5,026 Buildings 2,488 2,463 Computer equipment and other assets 2,419 2,323 Assets under construction and payments on account 1,427 1,199 Land 246 246 11,387 11,257 Less- accumulated depreciation (5,637 ) (5,518 ) $ 5,750 $ 5,739 Depreciation expenses were $537 million, $576 million and $528 million in the years ended December 31, 2023, 2022 and 2021, respectively. During the years ended December 31, 2023, 2022 and 2021, Teva recorded impairments of property, plant and equipment in the amount of $28 million, $47 million and $160 million, respectively. See note 15.

Identifiable Intangible Assets

Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2023
Identifiable Intangible Assets	NOTE 6—Identifiable intangible assets: Identifiable intangible assets consisted of the following: Gross carrying Accumulated Net carrying amount December 31,  2023   2022  2023 2022  2023   2022  (U.S. $ in millions) Product rights $ 17,981 $ 18,067 $ 13,274 $ 12,630 $ 4,707 $ 5,437 Trade names 583 577 269 231 314 346 In-process 366 487 —  —  366 487 Total $ 18,930 $ 19,131 $ 13,543 $ 12,861 $ 5,387 $ 6,270 Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 9 years. Amortization of intangible assets was $616 million, $732 million and $802 million in the years ended December 31, 2023, 2022 and 2021, respectively. As of December 31, 2023, the estimated aggregate amortization of intangible assets for the years 2024 to 2028 is as follows: 2024—$503 million; 2025—$460 million; 2026—$462 million; 2027—$451 million and 2028—$398 million. These estimates do not include the impact of IPR&D that is expected to be successfully completed and reclassified to product rights. IPR&D Teva’s IPR&D are assets that have not yet been approved in major markets. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. Intangible assets impairment Impairments of identifiable intangible assets were $350 million, $355 million and $424 million in the years ended December 31, 2023, 2022 and 2021, respectively. These amounts are recorded in the statement of income (loss) under intangible assets impairments. The fair value measurement of the impaired intangible assets in 2023 is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The discount rate applied ranged from 8.5% to 10%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D. Impairments in 2023 consisted of: (a) Identifiable product rights of $260 million due to: (i) $148 million related to updated market assumptions regarding price and volume of products; and (ii) $112 million in Japan, mainly related to regulatory pricing reductions; and (b) IPR&D assets of $90 million, mainly related to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). Impairments in 2022 consisted of: (a) Identifiable product rights of $310 million due to: (i) $256 million related to updated market assumptions regarding price and volume of products, and (ii) $54 million related to a change in Teva’s commercial plans regarding a certain program, as part of portfolio optimization efforts, which also included an inventory write-off (b) IPR&D assets of $45 million, due to generic pipeline products resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape and launch date). Impairments in 2021 consisted of: (a) Identifiable product rights and trade names of $297 million due to: (i) $267 million, mainly related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States, and, (ii) $30 million related to lenalidomide (generic equivalent of Revlimid ® (b) IPR&D assets of $127 million, mainly due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2023
Goodwill	NOTE 7 – Goodwill: Changes in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 were as follows: Other North Europe International Teva’s API Medis Total (U.S. $ in millions) Balance as of December 31, 2021 (1) $ 6,474 $ 8,544 $ 2,328 $ 2,417 $ 277 $ 20,040 Changes during the period: Goodwill impairment —  —  (979 ) (1,066 ) —  (2,045 ) Goodwill acquired —  —  —  12 —  12 Translation differences (24 ) (242 ) (10 ) (70 ) (28 ) (374 ) Balance as of December 31, 2022 (1) $ 6,450 $ 8,302 $ 1,339 $ 1,293 $ 249 $ 17,633 Changes during the period: Goodwill impairment —  —  (700 ) —  —  (700 ) Goodwill reclassified as assets held for sale —  —  (30 ) —  —  (30 ) Translation differences 9 164 66 20 16 275 Balance as of December 31, 2023 (1) $ 6,459 $ 8,466 $ 675 $ 1,313 $ 265 $ 17,177 (1) Cumulative goodwill impairment as of December 31, 2023, December 31, 2022 and December 31, 2021 was approximately $28.3 billion, $27.6 billion and $25.6 billion respectively. Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva’s production and sale of APIs to third parties (“Teva API”) and an out-licensing Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva begins with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva’s estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital (“WACC”), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva’s assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. First Quarter Developments During the first quarter of 2023, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of March 31, 2023. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. Following the goodwill impairment charges recorded in the fourth quarter of 2022 in relation to Teva’s International Markets and Teva’s API reporting units, the carrying values of those reporting units equaled their fair value as of December 31, 2022. Additionally, as part of the quantitative analysis Teva conducted as part of its annual goodwill impairment test in the second quarter of 2022, it concluded that the estimated fair value of Teva’s Europe reporting unit exceeded its estimated carrying amount by 9%. Second Quarter Developments Pursuant to Company policy, Teva conducted the annual goodwill impairment test for all reporting units during the second quarter of 2023. Management considered all information available, including information gathered from its latest long-range planning (“LRP”) process and annual operating plan (“AOP”), which are parts of Teva’s internal financial planning and budgeting processes, as well as Teva’s newly launched “Pivot to Growth” strategy. The LRP, the AOP and Teva’s Pivot to Growth strategy were discussed and reviewed by Teva’s management and its board of directors. Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. Based on this quantitative analysis, in the second quarter of 2023, Teva recorded a goodwill impairment charge of $700 million related to its International Markets reporting unit, mainly due to an increase in the discount rate due to higher risk associated with country-specific characteristics of several countries. Following the goodwill impairment charge recorded in relation to Teva’s International Markets reporting unit, the carrying value of this reporting unit equaled its fair value as of June 30, 2023. Therefore, if business conditions or expectations were to change materially, it may be necessary to record further impairment charges to Teva’s International Markets reporting unit in the future. The excess of the estimated fair value of Teva’s API reporting unit over its estimated carrying amount as of June 30, 2023, was negligible. Therefore, if business conditions or expectations were to change materially, it may be necessary to record impairment charges to Teva’s API reporting unit in the future. The estimated fair value of Teva’s Europe reporting unit exceeds its estimated carrying amount by 3% based on a terminal growth rate of 1.56% and a discount rate of 9.96%. If Teva holds all other assumptions constant, a reduction in the terminal growth rate of 0.25% to 1.31% or an increase in the discount rate of 0.25% to 10.21% would result in a reduction of the excess of fair value over carrying amount with respect to Teva’s Europe reporting unit to 1%. Teva’s North America and Medis reporting units have fair values in excess of 10% over their respective book values as of June 30, 2023. Teva noted its market capitalization has been below management’s assessment of the aggregated fair value of the Company’s reporting units. However, as of June 30, 2023, the Company’s market capitalization plus a reasonable control premium exceeded its book value. Third Quarter Developments During the third quarter of 2023, management evaluated whether there were any developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount as of September 30, 2023. Management concluded that no triggering event had occurred and, therefore, no quantitative assessment was performed. Fourth Quarter Developments During the fourth quarter of 2023, Teva completed its AOP process. The AOP was used as a base for an update of the LRP and Teva’s Pivot to Growth strategy, incorporating the changes for future years in the fair value model. Additionally, management evaluated whether there were any developments that occurred during the quarter to determine if it is more likely than not that the fair value of any of its reporting units was below its carrying amount as of December 31, 2023. Management noted the following main triggering events during the fourth quarter for its International Markets reporting unit and its Teva’s API reporting unit: (i) fluctuations in exchange rates between certain currencies in which Teva operates in its International Markets reporting unit, and the U.S. dollar, are expected to significantly lower projected operating results; and (ii) updated assumptions supporting the cash flow projections of Teva’s API reporting unit, including certain revenue growth assumptions, and the associated operating profit margins, mainly resulting from changes in market conditions. Management performed a quantitative assessment in the fourth quarter of 2023, which resulted in no recognition of a goodwill impairment. Following the quantitative assessment performed in relation to Teva’s International Markets reporting unit, the excess of its estimated fair value over its estimated carrying amount as of December 31, 2023, was 6%, based on a terminal growth rate of 1.79% and a discount rate of 12.23%. If Teva holds all other assumptions constant, a reduction in the terminal growth rate of 0.25% to 1.54% or an increase in the discount rate of 0.25% to 12.48% would result in a reduction of the excess of fair value over carrying amount with respect to Teva’s International Markets reporting unit to 4%. Following the quantitative assessment performed in relation to Teva’s API reporting unit, the excess of its estimated fair value over its estimated carrying amount as of December 31, 2023, was negligible. Therefore, if business conditions or expectations (such as growth rate or discount rate) were to adversely change, it may be necessary to record impairment charges to Teva’s API reporting unit in the future. With respect to the remaining reporting units, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying amounts as of December 31, 2023 and, therefore, no quantitative assessment was performed.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases	NOTE 8 – Leases: The components of operating lease cost for the years ended December 31, 2023, 2022 and 2021 were as follows: Year ended Year ended Year ended 2023 2022 2021 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Operating lease cost: Fixed payments and variable payments that depend on an index or rate $ 132 $ 142 $ 135 Variable lease payments not included in the lease liability 5 4 4 Short-term lease cost 3 2 2 $ 139 $ 148 $ 141 Supplemental cash flow information related to operating leases was as follows: Year ended Year ended Year ended 2023 2022 2021 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 141 $ 140 $ 143 Right-of-use (non-cash): Operating leases $ 121 $ 81 $ 81 Supplemental balance sheet information related to operating leases was as follows: December 31, December 31, 2023 2022 (U.S. $ in millions) (U.S. $ in millions) Operating leases: Operating lease ROU assets $ 397 $ 419 Other current liabilities 97 93 Operating lease liabilities 320 349 Total operating lease liabilities $ 417 $ 442 December 31, December 31, 2023 2022 Weighted average remaining lease term Operating leases 6.1 years 6.8 years Weighted average discount rate Operating leases 6.0 % 5.6 % Maturities of operating lease liabilities were as follows: December 31, 2023 (U.S. $ in millions) 2024 $ 116 2025 98 2026 80 2027 62 2028 and thereafter 140 Total operating lease payments $ 496 Less: imputed interest 79 Present value of lease liabilities $ 417 As of December 31, 2023, Teva’s total finance lease assets finance lease liabilities finance lease assets finance lease liabilities

Debt obligations

Debt obligations	12 Months Ended
	Dec. 31, 2023
Debt obligations	NOTE 9—Debt obligations: a. Short-term debt: December 31, Weighted average Maturity 2023 2022 (U.S. $ in millions) Convertible debentures 0.25 % 2026 $ 23 $ 23 Current maturities of long-term liabilities 1,649 2,086 Total short term debt $ 1,672 $ 2,109 Convertible senior debentures The principal amount of Teva’s 0.25% convertible senior debentures due 2026 was $23 million as of December 31, 2023 and December 31, 2022. These convertible senior debentures include a “net share settlement” feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the “net share settlement” feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. b. Long-term debt: Interest rate as of Maturity December 31, December 31, (U.S. $ in millions) Senior notes EUR 1,500 million 1.13 % 2024 693 670 Sustainability-linked senior notes EUR 1,500 million (6)(*) 4.38 % 2030 1,656 1,606 Senior notes EUR 1,300 million (9) 1.25 % 2023 —  633 Sustainability-linked senior notes EUR 1,100 million (7)(*) 3.75 % 2027 1,215 1,177 Senior notes EUR 1,000 million (5) 6.00 % 2025 453 1,070 Senior notes EUR 900 million (5) 4.50 % 2025 547 963 Sustainability-linked senior notes EUR 800 million (1)(*) 7.38 % 2029 884 —  Senior notes EUR 750 million 1.63 % 2028 826 800 Senior notes EUR 700 million 1.88 % 2027 771 748 Sustainability-linked senior notes EUR 500 million (2)(*) 7.88 % 2031 552 —  Senior notes USD 3,500 million (5) 3.15 % 2026 3,374 3,496 Senior notes USD 3,000 million (5)(10) 2.80 % 2023 —  1,453 Senior notes USD 2,000 million 4.10 % 2046 1,986 1,986 Senior notes USD 1,250 million (5) 6.00 % 2024 956 1,250 Senior notes USD 1,250 million 6.75 % 2028 1,250 1,250 Senior notes USD 1,000 million (5) 7.13 % 2025 427 1,000 Sustainability-linked senior notes USD 1,000 million (7)(*) 4.75 % 2027 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (6)(*) 5.13 % 2029 1,000 1,000 Senior notes USD 789 million 6.15 % 2036 783 783 Sustainability-linked senior notes USD 600 million (3)(*) 7.88 % 2029 600 —  Sustainability-linked senior notes USD 500 million (4)(*) 8.13 % 2031 500 —  Senior notes CHF 350 million 1.00 % 2025 416 382 Total senior notes 19,889 21,266 Other long-term debt 1 1 Less current maturities (1,649 ) (2,086 ) Less debt issuance costs (8) (80 ) (78 ) Total senior notes and loans $ 18,161 $ 19,103 (1) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (2) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500 million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (3) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (4) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (5) In March 2023, Teva consummated a cash tender offer and extinguished $631 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $574 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $454 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026. (6) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% (7) If Teva fails to achieve certain sustainability performance targets, a one-time 0.15%-0.45% (8) Debt issuance costs as of December 31, 2023 include $26 million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6 million acceleration of issuance costs related to the cash tender offer. (9) In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity. (10) In July 2023, Teva repaid $1,000 million of its 2.8% senior notes at maturity. * Interest rate adjustments and a potential one-time Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any. The long-term debt outlined in the above table is generally redeemable at any time at varying redemption prices plus accrued and unpaid interest. Teva’s debt as of December 31, 2023 was effectively denominated in the following currencies: U.S. dollar 60%, euro 38% and Swiss franc 2%. Teva’s principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its $1.8 billion unsecured syndicated sustainability-linked revolving credit facility entered into in April 2022, as amended in February 2023 (“RCF”). The RCF has a maturity date of April 2026 one-year On February 6, 2023, the terms of the RCF were amended to update the Company’s maximum leverage ratio under the RCF for certain periods. Under the terms of the RCF, as amended, the Company’s leverage ratio shall not exceed 4.00x in the fourth quarter of 2023, 4.00x in the first, second and third quarters of 2024, and 3.50x in the fourth quarter of 2024 and onwards. The RCF can be used for general corporate purposes, including repaying existing debt. In July 2023, a total amount of $700 million was withdrawn under the RCF, of which $200 million was repaid in September 2023 and the remaining amount of $500 million was repaid in the fourth quarter of 2023. As of December 31, 2023, and as of the date of this Annual Report on Form 10-K, Under specified circumstances, including non-compliance Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that the financial statements are issued. As of December 31, 2023, the required annual principal payments of long-term debt (excluding debt issuance costs), including convertible senior debentures, starting from the year 2025, are as follows: December 31, (U.S. $ in millions) 2025 $ 1,843 2026* 3,397 2027 2,986 2028 2,076 2029 and thereafter 7,961 $ 18,263 * Including $23 million convertible notes. See note 9a.

Derivative instruments and hedg

Derivative instruments and hedging activities	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities	NOTE 10—Derivative instruments and hedging activities: a. Foreign exchange risk management: In 2023, approximately 47% of Teva’s revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks. The Company enters into forward exchange contracts and purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce its exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty, new Israeli shekel, Indian rupee and other currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt. The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets (“net investment hedge”) and has in the past entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure. Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes. b. Interest risk management: The Company raises capital through various debt instruments, including senior notes, sustainability-linked senior notes, bank loans and convertible debentures that bear fixed or variable interest rates, as well as a syndicated sustainability-linked revolving credit facility and securitization programs that bear a variable interest rate. In some cases, the Company has swapped from a fixed to a variable interest rate (“fair value hedge”) and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency (“cash flow hedge”), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations. As of December 31, 2023, all outstanding senior notes, sustainability-linked senior notes and convertible debentures bear a fixed interest rate. c. Bifurcated embedded derivatives: Upon issuance of sustainability-linked senior notes, Teva recognized embedded derivatives related to interest rate adjustments and a potential one-time low-to-middle-income d. Derivative instrument outstanding: The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: December 31, 2023 December 31, 2022 (U.S. $ in millions) Cross-currency swap-cash flow hedge (1) $ 169 $ —  The following table summarizes the classification and fair values of derivative instruments: Fair value Designated as hedging Not designated as hedging instruments December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Reported under (U.S. $ in millions) (U.S. $ in millions) Asset derivatives: Other current assets: Option and forward contracts $ —  $ —  $ 38 $ 29 Other non-current Cross-currency swaps - cash flow hedge (1) 8 —  —  —  Liability derivatives: Other current liabilities: Option and forward contracts $ —  $ —  $ (39 ) $ (101 ) The table below provides information regarding the location and amount of pre-tax Reported under Financial expenses, net Other comprehensive income (loss) Year ended December 31, Year ended December 31,  2023   2022   2021   2023   2022   2021  (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,057 $ 966 $ 1,058 $ 91 $ (270 ) $ (391 ) Cross-currency swaps - cash flow hedge (1) (11 ) —  —  1 —  —  The table below provides information regarding the location and amount of pre-tax Reported under Financial expenses, net Net revenues Year ended December 31, Year ended December 31,  2023   2022   2021   2023   2022   2021  (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,057 $ 966 $ 1,058 $ (15,846 ) $ (14,925 ) $ (15,878 ) Option and forward contracts (2) (54 ) (12 ) (45 ) —  —  —  Option and forward contracts economic hedge (3) —  —  —  2 (11 ) (31 ) (1) On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen. (2) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net. (3) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2023 and 2024. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2023, the negative impact from these derivatives recognized under revenues was $2 million. In 2022, the positive impact from these derivatives recognized under revenues e. Amortizations due to terminated derivative instruments: Forward starting interest rate swaps and treasury lock agreements In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position With respect to these forward starting interest rate swaps and treasury lock agreements, losses of $31 million, $30 million and $37 million were recognized under financial expenses, net for the years ended December 31, 2023, 2022 and 2021, respectively. f. Securitization: U.S. securitization program On November 7, 2022, Teva and a bankruptcy-remote special purpose vehicle (“SPV”) entered into an accounts receivable securitization facility (“AR Facility”) with PNC Bank, National Association (“PNC”) with a three-year term. The AR Facility initially provided for purchases of accounts receivable by PNC in an amount of up to $1 billion through November 2023, and up to $500 million from November 2023 through November 2025, provided that the SPV may increase the commitment amount up to $1 billion if additional credit providers participate in the AR facility. On June 30, 2023, the AR Facility agreement was amended to include an additional receivables purchaser under the agreement, in an amount of up to $250 million through November 2025, increasing the commitment size to $750 million from November 2023 to November 2025. On November 7, 2023, the SPV amended the AR Facility agreement by including an additional receivables purchaser and increased the commitment in an amount of up to $250 million, to $1 billion through March 2024, and in an amount of $125 million, to $875 million from March 2024 through November 2025. The SPV may amend the agreement and increase the commitment amount up to $1 billion from March 2024 through November 2025 if additional commitments are provided under the AR facility. Under the AR Facility, Teva’s subsidiaries continuously sell their accounts receivables, originated in the U.S., to the SPV and the SPV on-sells The SPV is a variable interest entity (“VIE”) for which Teva is considered to be the primary beneficiary. The SPV’s sole business consists of the purchase of receivables from Teva’s subsidiaries and the subsequent transfer of such receivables to the receivables purchasers. Although the SPV is included in Teva’s consolidated financial statements, it is a separate legal entity with separate creditors. The assets of the SPV are not available to pay creditors of Teva or its subsidiaries. Upon the transfer of ownership and control of the receivables to the SPV, Teva and its subsidiaries have no retained interests in the receivables sold, and they become unavailable to Teva’s creditors should the relevant seller become insolvent. Teva has collection and administrative responsibilities for the receivables sold to the SPV. The fair value of these servicing arrangements as well as the fees earned was immaterial. The Company accounts for receivables sold from the SPV to the receivables purchasers as a sale of financial assets under ASC 860 and derecognizes the trade receivables from the Company’s Consolidated Balance Sheet. The total balance of accounts receivables sold to the receivables purchasers and derecognized by the SPV, as of December 31, 2023 and 2022, was $864 million and $820 million, respectively. In addition to the accounts receivables sold, as of December 31, 2023 and 2022, an amount of $437 million and $436 million of the SPV’s accounts receivables was pledged by the SPV as a seller guarantee, and is included under “Accounts receivables, net”, in the Consolidated Balance Sheet. In the years ended December 31, 2023 and 2022, Teva received proceeds of $861 million and $820 million, respectively, under the AR facility, which are included in cash from operating activities in the Consolidated Statements of Cash Flows for the year ended December 31, 2023 and 2022, respectively. EU securitization program In April 2011, Teva established a trade receivables securitization program (the “EU securitization program”) to sell accounts receivables, mainly originated in Europe, to BNP Paribas Bank (“BNP”). Under the EU securitization program, Teva, on a consolidated basis through its participating subsidiaries, receives an initial cash purchase price and the right to a deferred purchase price (“DPP”), according to the purchase price for the receivables sold by it. On an individual seller basis, each Teva subsidiary participating in the EU securitization program sells receivables to BNP at their nominal amount. BNP then immediately on-sells The SPE is a VIE for which Teva is considered to be the primary beneficiary. The SPE’s sole business consists of the purchase of receivables from Teva subsidiaries and the subsequent sale of such receivables to the conduit. Although the SPE is included in Teva’s consolidated financial statements, it is a separate legal entity with separate creditors. The conduit and other designated creditors of the SPE are entitled, both before and upon the SPE’s liquidation, to be paid out of the SPE’s assets prior to the DPP payable to Teva. The SPE’s assets are not available to pay Teva’s or its subsidiaries’ creditors. In August 2021, Teva extended the EU securitization program by an additional five years, to August 2026. Once a Teva subsidiary sells receivables to BNP, such subsidiary does not retain any interests in the receivables sold and does not have access to such receivables upon its insolvency. The conduit has all the rights in the securitized trade receivables, including the right to pledge or dispose such receivables. Consequently, receivables sold under this agreement are de-recognized The portion of the purchase price for the receivables which is not paid in cash by the conduit is a DPP asset. The conduit pays the SPE the DPP from collections received by the conduit from the securitized trade receivables (after paying senior costs and expenses, including the conduit’s debt service obligations), which the SPE then pays to Teva. The DPP asset represents a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The DPP asset is included in other current assets on Teva’s Consolidated Balance Sheet. Teva has collection and administrative responsibilities for the sold receivables. The fair value of these servicing arrangements as well as the fees earned was immaterial. The DPP asset as of December 31, 2023 and 2022 was $247 million and $270 million, respectively. As of December 31, 2023 and 2022, the outstanding principal amount of receivables sold, net of DPP, was $686 million and $636 million, respectively. The following table summarizes the change in the sold receivables outstanding balance, net of DPP, under the outstanding securitization program: As of and for the year ended  2023   2022  (U.S. $ in millions) Sold receivables at the beginning of the year $ 636 $ 685 Proceeds from sale of receivables 4,391 4,653 Cash collections (remitted to the owner of the receivables) (4,365 ) (4,665 ) Effect of currency exchange rate changes 24 (37 ) Sold receivables at the end of the year $ 686 $ 636 g. Supplier Finance Program Obligation Teva maintains supply chain finance agreements with participating financial institutions. Under these agreements, participating suppliers may voluntarily elect to sell their accounts receivable with Teva to these financial institutions. Teva’s suppliers negotiate their financing agreements directly with the respective financial institutions and Teva is not a party to these agreements. Teva has no economic interest in its suppliers’ decisions to participate in the program and Teva pays the financial institutions the stated amount of confirmed invoices on the maturity dates, which is generally within 120 days from the date the invoice was received. The agreements with the financial institutions do not require Teva to provide assets pledged as security or other forms of guarantees for the supplier finance program. All outstanding amounts related to suppliers participating in the supplier finance program are recorded under accounts payables in Teva’s consolidated balance sheets. As of December 31, 2023 and December 31, 2022, the outstanding accounts payables to suppliers

Legal Settlements and Loss Cont

Legal Settlements and Loss Contingencies	12 Months Ended
	Dec. 31, 2023
Legal Settlements and Loss Contingencies	NOTE 11—Legal settlements and loss contingencies: Legal settlements and loss contingencies in 2023 were expenses of $1,043 million, compared to expenses of $2,082 million in 2022 and expenses of $717 million in 2021. Expenses in 2023 were mainly related to an estimated provision for the U.S. DOJ patient assistance program litigation, an update to the estimated settlement provision for the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products, and the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. Legal settlements and loss contingencies in 2022 were mainly related to updates of the estimated settlement provision recorded in connection with the remaining opioid cases. Legal settlements and loss contingencies in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12b. As of December 31, 2023 and 2022, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,771 million and $4,186 million, respectively.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and contingencies	NOTE 12—Commitments and contingencies: a. Commitments: Royalty commitments: The Company is committed to pay royalties to owners of know-how, Royalty expenses in each of the years ended December 31, 2023, 2022 and 2021 were $543 million, $560 million and $522 million, respectively. Milestone commitments: Teva has committed to make potential future milestone payments to third parties under various agreements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, Teva may be required to pay such amounts. As of December 31, 2023, if all development milestones and targets, for compounds in phase 2 and more advanced stages of development, are achieved, the total contingent payments could reach an aggregate amount of up to $20 million. Additional contingent payments are owed upon achievement of product approval or launch milestones. b. Contingencies: General From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action. Teva records a provision in its consolidated financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is reasonably estimable. Based upon the status of the cases described below, management’s assessments of the likelihood of damages, and the advice of legal counsel, no material provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and substantial damages or other relief may be awarded. Accordingly, management’s assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved. If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the consolidated financial statements. In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva’s agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts. Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA data. Intellectual Property Litigation From time to time, Teva seeks to develop generic and biosimilar versions of patent-protected pharmaceuticals and biopharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator’s patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. For many biosimilar products that are covered by patents, Teva participates in the “patent dance” procedures of the Biologics Price Competition and Innovation Act (“BPCIA”), which allow for the challenge to originator patents prior to obtaining biosimilar product approval. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator’s patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents. Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic or biosimilar version of the product even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period. Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act or BPCIA. For example, Teva could be sued for patent infringement after commencing sales of a product. This type of litigation can involve any of Teva’s pharmaceutical products, not just its generic and biosimilar products. The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva’s product. The amount of lost profits would generally be based on the lost sales of the patentee’s product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples. Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available. In July 2014, GlaxoSmithKline (“GSK”) filed claims against Teva in the U.S. District Court for the District of Delaware for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva began selling its carvedilol tablets (the generic version of GSK’s Coreg ® pre- In January 2021, Teva initiated a patent invalidity action against the compound patent and Supplementary Protection Certificate (“SPC”) asserted to cover Bristol-Myers Squibb Company’s (“BMS”) Eliquis ® ® Product Liability Litigation Teva’s business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both types of insurance, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in certain or all of its markets. Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan were allegedly found in the active pharmaceutical ingredient (“API”) supplied to Teva by multiple API manufacturers, including by Zhejiang Huahai Pharmaceuticals Co. Ltd. (“Huahai”). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. Multiple lawsuits have been filed in connection with this matter. Teva’s products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations (“MDL”) pending against Teva and other manufacturers, including one MDL in the U.S. District Court for the District of New Jersey related to, with respect to Teva, valsartan and losartan, and another MDL in the U.S. District Court for the Southern District of Florida related to ranitidine. The claims against Teva in these MDLs include individual personal injury and/or product liability claims, economic damages claims brought by consumers and end payors as putative class actions, and medical monitoring class claims. The district court in the valsartan MDL certified a series of subclasses on plaintiffs’ economic loss claims as well as a medical monitoring class, and has ordered that the first trial commence on March 18, 2024, which will include third-party payor economic loss claims brought by a class representative on behalf of several subclasses of payors against Teva and two other defendants. The claims against the generic manufacturers (including Teva) in the ranitidine MDL have been dismissed on preemption grounds but are subject to appeal. The district court in the ranitidine MDL also excluded all of plaintiffs’ general causation experts and granted summary judgment to the brand defendants on preemption grounds and later applied that general causation ruling to all defendants. This ruling is on appeal in the Eleventh Circuit Court of Appeals. Certain generic manufacturers, including Teva, have also been named in state court actions asserting allegations similar to those in the aforementioned MDLs. In particular, state court valsartan and losartan actions are pending in New Jersey and Delaware and are currently stayed, with the exception of a single-plaintiff case originally filed in the MDL alleging non-cancer In addition to the valsartan and ranitidine MDLs and coordinated state court proceedings, Teva has been named in a consolidated proceeding pending in the U.S. District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva’s, as well as other generic manufacturers’ metformin products. The parties are now engaged in discovery related to the surviving metformin claims. Teva was recently named in a related proceeding pending in the same district brought by individuals and end payors also seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva’s, as well as other generic manufacturers’ metformin products. Teva, along with the other defendants, will be moving to dismiss the claims in this related proceeding. Similar lawsuits are pending in Canada and Germany. Competition Matters As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva’s patent challenges have resulted in litigation relating to Teva’s attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire. Teva and its subsidiaries have been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases are usually direct and indirect purchasers of pharmaceutical products, some of whom assert claims on behalf of classes of all direct and indirect purchasers, and they typically allege that (i) Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (ii) significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These plaintiffs seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are often automatically tripled under the relevant statutes, plus attorneys’ fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial, potentially measured in multiples of the annual brand sales, particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved. Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva’s experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue. In June 2013, the U.S. Supreme Court held, in Federal Trade Commission (“FTC”) v. Actavis, Inc., that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This test has resulted in increased scrutiny of Teva’s patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva’s currently pending antitrust litigations. In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling euro 60.5 million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021, and a judgment was issued on October 18, 2023 rejecting Teva’s grounds of appeal. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines. In December 2011, three groups of plaintiffs filed claims against Wyeth and Teva for alleged violations of the antitrust laws in connection with their November 2005 settlement of patent litigation involving extended release venlafaxine (generic Effexor XR ® ® ® In February 2012, two purported classes of direct-purchaser plaintiffs filed claims against GSK and Teva in the U.S. District Court for the District of New Jersey for alleged violations of the antitrust laws in connection with their February 2005 settlement of patent litigation involving lamotrigine (generic Lamictal ® ® ® In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan ® opt-out re-hearing. ® ® Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of end-payers ® ® end-payers’ ® ® ® ® ® ® Putative classes of direct-purchaser and end-payer ® end-payer ® ® In August 2019, certain direct-purchaser plaintiffs filed claims in federal court in Philadelphia against Teva and its affiliates alleging that the September 2006 patent litigation settlement relating to AndroGel ® ® ® Between September 1, 2020 and December 20, 2020, plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out ® ® ® In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV (the “New Mexico litigation”). Between September 2021 and April 2022, several private plaintiffs including retailers and health insurance providers filed similar claims in various courts, which were all removed and/or consolidated into the U.S. District Court for the Northern District of California (the “California litigation”). As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and/or 2014 to resolve patent litigation relating to Teva’s generic versions of Viread ® ® ® ® ® ® ® ® ® ® In March 2021, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. On October 10, 2022, the European Commission issued a Statement of Objections, which sets forth its preliminary allegations that Teva had engaged in anti-competitive practices. Teva responded in writing to the Statement of Objections on February 8, 2023 and orally at a hearing on March 23, 2023. The European Commission issued further Requests for Information, to which Teva is responding. Annual sales of COPAXONE in the European Economic Area in 2021 were approximately $373 million. On June 29, 2021, Mylan Pharmaceuticals (“Mylan”) filed claims against Teva in the U.S. District Court for the District of New Jersey. On March 11, 2022 and March 15, 2022, purported purchasers of COPAXONE filed claims against Teva in the U.S. District Court for the District of New Jersey on behalf of themselves and similarly situated direct and indirect purchasers of COPAXONE. On August 22, 2022, additional purported purchasers of COPAXONE sued Teva in the U.S. District Court for the District of Vermont on behalf of themselves and similarly situated indirect purchasers of COPAXONE. The complaints variously assert claims for alleged violations of the Lanham Act, state and federal unfair competition and monopolization laws, tortious interference, trade libel, and a violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO Act”). Additionally, plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, restitution, treble damages, attorneys’ fees and costs, and injunctive relief. Teva moved to dismiss all of the complaints, and on January 22, 2024, Teva’s motion to dismiss the complaint in the District of Vermont was granted as to certain state law claims but was otherwise denied. Decisions on Teva’s remaining motions to dismiss are pending. On July 15, 2021, the U.K. Competition and Markets Authority (“CMA”) issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK, Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA’s three prior investigations into the supply of hydrocortisone tablets in the U.K., as well as the CMA’s subsequent investigation relating to an anti-competitive agreement with Waymade. On January 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to two of the three statements of objection from the CMA (dated December 16, 2016 and March 3, 2017), and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. On October 6, 2021, Accord UK (previously Actavis UK) and Auden Mckenzie appealed the CMA’s decision. The hearing for the appeal concluded in the first quarter of 2023, with a partial judgment handed down on September 18, 2023. That partial judgment will be made operative by the remaining portion of the judgment, which is expected in the first half of 2024. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements. In August 2021, a plaintiff purporting to represent a class of direct purchasers filed a putative class action suit in the U.S. District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys ® end-payors end-payor ® In November 2022, two complaints filed by plaintiffs purporting to represent retailer purchasers and a putative class of end-payor ® pre-trial Opt-Out ® On December 2, 2022, plaintiffs purporting to represent putative classes of indirect purchasers of EpiPen ® ® ® ® ® In May 2023, certain end-payor state and federal antitrust laws and state consumer protection laws. Teva moved to dismiss these claims on October 18, 2023, and that motion remains pending. Government Investigations and Litigation Relating to Pricing and Marketing Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States. In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice (“DOJ”) Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three-count indictment charging Teva USA with criminal felony Sherman Act violations. The indictment alleged that Teva USA had participated in three separate conspiracies with other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: pravastatin, carbamazepine, clotrimazole, etodolac (IR and ER), fluocinonide (cream, e-cream, 3-year In May 2018, Teva received a civil investigative demand from the DOJ Civil Division pursuant to the federal False Claims Act, seeking documents and information produced since January 1, 2009 relevant to the Civil Division’s investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions. In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. On December 15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States, which was subsequently amended to include 49 states, as well as the District of Columbia and Puerto Rico as plaintiffs, and to add new allegations and state law claims against both Actavis and Teva. On May 10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, which was subsequently amended on November 1, 2019, alleging that Teva was at the center of a conspiracy in the generic pharmaceutical industry and asserting that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain products. On June 10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the U.S. District Court for the District of Connecticut naming, among other defendants, Actavis, in a similar complaint relating to dermatological generics products, and that complaint was later amended to, among other things, add California as a plaintiff. In the various complaints described above, which also include claims against certain former employees of Actavis and Teva USA, the states seek a finding that the defendants’ actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints were transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania (“Pennsylvania MDL”). On May 7, 2021, the Court chose the attorneys’ general third complaint filed on June 10, 2020, as subsequently amended, to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. The schedule set by the Court to govern the bellwether cases does not include trial dates, but provides for the parties to complete briefing on motions for summary judgment in the third quarter of 2024. On June 7, 2022, the Court dismissed the attorneys’ general claims for monetary relief under federal law, concluding that the federal statute under which the attorneys general brought suit authorizes injunctive relief only. However, the attorneys general have pending claims for monetary relief under state law. On February 27, 2023, the Court largely denied defendants’ motions to dismiss the federal claims asserted by the attorneys general in their bellwether complaint. Another motion to dismiss related to the state law claims asserted by the attorneys general in their bellwether complaint remains pending. The attorneys general have also moved for their complaints to be remanded to the U.S. District Court for the District of Connecticut, and that motion remains pending. Teva has settled with the states of Mississippi (in June 2021), Louisiana (in March 2022), Georgia (in September 2022), Arkansas (in October 2022), Florida (in February 2023), and Kentucky (in June 2023). Teva paid each state an amount proportional to its share of the national population (approximately $1,000,000 for each 1% share of the national population), and the states have dismissed their claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to these settlements. These settlements, in addition to the status of ongoing negotiations with several other U.S. state attorneys general to settle on comparable terms, caused management to consider settlement of the claims filed by the remaining attorneys general to be probable, and management recorded an estimated provision in the third quarter of 2022. The States of Alabama (in March 2022) and Hawaii (in August 2023) and the territories of American Samoa (in July 2020) and Guam (in February 2023) have all voluntarily dismissed all of their claims in the litigation against Actavis and Teva USA. The dismissals by Alabama, Hawaii and Guam were with prejudice and the dismissal by American Samoa was without prejudice. Beginning on March 2, 2016, and continuing through July 2023, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out opt-out In March 2017, Teva received a subpoena from the U.S. Attorney’s office in Boston, Massachusetts requesting documents related to Teva’s donations to patient assistance programs. In August 2020, the U.S. Attorney’s office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging causes of action under the federal False Claims Act and for unjust enrichment (the “DOJ PAP Complaint”). It is alleged that Teva’s donations to certain 501(c)(3) charities that provided financial assistance to multiple sclerosis patients violated the Anti-Kickback Statute. On April 24, 2023, both parties filed summary judgment motions, and on July 14, 2023 the court denied Teva’s motion and granted the DOJ’s motion, adopting the DOJ’s positions on materiality, causation, and damages. Under that ruling, if the DOJ can prove that any specific claim for reimbursement resulted from an illegal kickback, then the DOJ will be entitled to recover the full amount of that claim as damages. The DOJ is seeking a maximum of over $1 billion in damages, which would automatically be trebled in the event of an adverse verdict, and Teva would also be subject to mandatory statutory penalties for each false claim, the amount of which (potentially billions of U.S. dollars in additional penalties, at the high end) will be determined by the court within a statutory range. On August 14, 2023, the district court granted Teva’s motion to certify the summary judgment ruling for an immediate appeal and stayed the trial that was scheduled to start in September 2023, while Teva seeks an appeal as to the causation standard that should govern the case. On August 24, 2023, Teva filed a petition to appeal the summary judgment ruling with the First Circuit Court of Appeals, which was granted on November 17, 2023. In the third quarter of 2023, Teva updated its provision based on its offer to settle this matter. Additionally, on January 8, 2021, Humana, Inc. (“Humana”) filed an action against Teva in the U.S. District Court for the Middle District of Florida based on the allegations raised in the DOJ PAP Complaint. Teva’s motion to dismiss Humana’s claims was denied as moot in May 2023 in light of the amended complaint filed by Humana in May 2023. In June 2023, Teva filed a joint motion to dismiss, together with co-defendant In April 2021, a city and county in Washington filed claims against Teva in the U.S. District Court for the Western District of Washington for alleged violations of the RICO Act, Washington’s Consumer Protection Act, and unjust enrichment concerning Teva’s sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On November 17, 2021, Teva moved to dismiss the suit, on the grounds that plaintiffs’ claims are barred by the applicable statutes of limitations and the direct purchaser rule, suffer from jurisdictional defects, and fail to plausibly allege fraud or other elements of their claims. On March 9, 2023, the court held a hearing on the motion to dismiss, and a decision remains pending. On December 1, 2022, Teva received a civil subpoena from the U.S. Attorney’s office in Boston, Massachusetts requesting certain documents related to the sale and marketing of AUSTEDO and risperidone LAI. Teva is cooperating with the request for documents. Opioids Litigation Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. The vast majority of these cases have been resolved. The remaining, non-settled ® ® In addition, over 950 personal injury plaintiffs, including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding. Furthermore, approxim

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2023
Income taxes	NOTE 13—Income taxes: a. Income (loss) before income taxes: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Parent Company and its Israeli subsidiaries $ (767 ) $ (119 ) $ 126 Non-Israeli 143 (3,044 ) 532 $ (624 ) $ (3,163 ) $ 658 The financial data presented in the table above for the year ended December 31, 2022 have been revised as discussed in note 1b. b. Income taxes: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) In Israel $ (402 ) $ 33 $ 124 Outside Israel 395 (676 ) 87 $ (7 ) $ (643 ) $ 211 Current $ 333 $ 430 $ 270 Deferred (340 ) (1,073 ) (59 ) $ (7 ) $ (643 ) $ 211 2023 2022 2021 (U.S. $ in millions) Income (loss) before income taxes (***) $ (624 ) $ (3,163 ) $ 658 Statutory tax rate in Israel 23 % 23 % 23 % Theoretical provision for income taxes (***) $ (144 ) $ (727 ) $ 151 Increase (decrease) in the provision for income taxes due to: The Parent Company and its Israeli subsidiaries - Tax benefits arising from net deferred taxes, resulting from intellectual property related integration plans, including carryforward losses (272) —  —  Tax benefits arising from reduced tax rates under benefit programs 14 15 (12) Mainly nondeductible items and prior year tax —  35 20 Non-Israeli 372 941 117 Worthless stock deduction (**) —  (909) —  Increase (decrease) in other uncertain tax positions - net 23 2 (65) Effective consolidated income taxes (***) $ (7) $ (643) $ 211 * In 2023 and 2022, income before income taxes includes goodwill impairment in non-Israeli ** In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million. *** The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b. Teva’s effective tax rate is the result of a variety of factors, including the geographic mix and type of products sold during the year, different effective tax rates applicable to non-Israeli c. Deferred income taxes: December 31, 2023 2022 (U.S. $ in millions) Deferred tax assets (liabilities), net: Inventory related $ 76 $ 125 Sales reserves and allowances 81 89 Provision for legal settlements 702 703 Intangible assets (*) (118 ) (567 ) Carryforward losses and deductions and credits (**) 2,463 2,850 Property, plant and equipment (225 ) (238 ) Deferred interest 799 800 Provisions for employee related obligations 80 82 Other (***) 357 138 4,215 3,982 Valuation allowance—in respect of carryforward losses and deductions that may not be utilized (3,009 ) (3,072 ) $ 1,206 $ 910 (*) The increase in deferred tax is mainly due to intellectual property related integration. (**) The amounts are shown following a reduction for unrecognized tax benefits of $2 million and $1 million as of December 31, 2023 and 2022, respectively. The amount as of December 31, 2023 represents the tax effect of gross carryforward losses and deductions with the following expirations: 2024 2025 2026 2033 2034 (***) The amounts shown are primarily comprised of Capitalization of R&D Expenses. Other deferred income taxes presented in the table above as of December 31, 2022, have been revised as discussed in note 1b. The deferred income taxes are reflected in the balance sheets among: December 31, 2023 2022 (U.S. $ in millions) Long-term assets—deferred income taxes (*) 1,812 1,458 Long-term liabilities—deferred income taxes (606 ) (548 ) $ 1,206 $ 910 (*) Long-term assets—deferred income taxes presented in the tables above as of December 31, 2022, have been revised as discussed in note 1b. d. Uncertain tax positions: The following table summarizes the activity of Teva’s gross unrecognized tax benefits: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Balance at the beginning of the year $ 638 $ 672 $ 888 Increase (decrease) related to prior year tax positions, net (1 ) (46 ) (106 ) Increase related to current year tax positions 15 42 7 Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations (15 ) (31 ) (115 ) Other 14 1 (2 ) Balance at the end of the year $ 651 $ 638 $ 672 Uncertain tax positions, mainly of a long-term nature, include accrued potential penalties and interest of $224 million, $212 million and $210 million as of December 31, 2023, 2022 and 2021, respectively. The total amount of interest and penalties reflected in the consolidated statements of income was a net increase of $12 million, $2 million and $37 million for the years ended December 31, 2023, 2022 and 2021, respectively. Substantially all the above uncertain tax benefits, if recognized, would reduce Teva’s annual effective tax rate. Teva does not expect uncertain tax positions to change significantly over the next 12 months, except in the case of settlements with tax authorities or court decisions, the likelihood and timing of which is difficult to estimate. e. Tax assessments: Teva files income tax returns in various jurisdictions with varying statutes of limitations. Teva and its subsidiaries in Israel have received final tax assessments through tax year 2011. The Israeli tax authorities (“ITA”) issued tax assessment decrees for 2008-2011, 2012 and 2013-2016, challenging the Company’s positions on several issues. Teva has protested the 2008-2011, 2012 and 2013-2016 decrees before the Central District Court in Israel. On April 17, 2023, the ITA issued a tax assessment for 2017-2020 challenging the Company’s positions on several issues, which the Company intends to challenge. In October 2021, the Central District Court in Israel held in favor of the ITA with respect to 2008-2011 decrees. Teva appealed this decision to the Israeli Supreme Court and the appeal hearing is expected to begin in March 2024. On December 6, 2023, the Central District Court issued a partial judgment on the 2012-2016 decrees, to apply the court’s findings in the judgment for the 2008-2011 decrees on the overlapping issues. The case with respect to the other issues under dispute for the 2012-2016 decrees remains pending. The next court hearing is scheduled for September 18, 2024. The tax liability resulting from the October 2021 and the December 2023 Central District Court decisions, with respect to the decrees for 2008-2011 and 2012-2016 was approximately $350 million, of which a portion has been paid during 2022 and 2023, with the remainder to be paid during 2024 and 2025. Teva believes it has adequately provided for all of its uncertain tax positions, including those items currently under dispute, however, adverse results could be material. In the U.S., Teva is subject to ongoing examination of its U.S. subsidiaries by federal and state tax authorities. The years 2015 to 2019 are open years, currently under IRS examination. Additionally, Teva is currently under examination by various state tax authorities for open years from 2014 to 2021. In addition to ongoing audits, Teva and its subsidiaries have tax years 2009 to 2014 that are in administrative suspense for one open matter, pending the outcome of the court cases discussed further below. Teva believes it has adequately provided for all uncertain tax positions for open years, and that any other adverse results of examinations or litigation would have an immaterial impact on the Company’s financial statements. Teva currently has a legal proceeding in the U.S. Tax Court, one on appeal to the Third Circuit, which has ruled favorably for another taxpayer on a substantially similar matter, and one on appeal to the U.S. District Court of Appeals for the Federal Circuit. Each dispute with the IRS addresses the question of whether certain legal fees incurred related to Abbreviated New Drug Applications (“ANDAs”) were eligible to be deducted in the year incurred for tax purposes or were required to be amortized over longer periods under U.S. tax law. Teva received a favorable ruling in the Court of Federal Claims in August 2022, and the Department of Justice filed a notice of appeal in December 2022. The U.S. Tax Court case remains in the pre-trial more-likely-than-not Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is ongoing. A final and binding decision against Teva in this case may lead to an impairment in an amount up to $126 million. The Company’s subsidiaries in Europe have received final tax assessments mainly through tax year 2015. f. Basis of taxation: The Company and its subsidiaries are subject to tax in many jurisdictions, and estimation is required in recording the assets and liabilities related to income taxes. The Company believes that its accruals for tax liabilities are adequate for all open years. The Company considers various factors in making these assessments, including past history, recent interpretations of tax law, and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these assessments can involve a series of complex judgments regarding future events. An assessment of the tax that would have been payable had the Company’s foreign subsidiaries distributed their income to the Company is not practicable because of the multiple levels of corporate ownership and multiple tax jurisdictions involved in each hypothetical dividend distribution. Incentives Applicable until 2013 Under the incentives regime applicable to the Company until 2013, industrial projects of Teva and certain of its Israeli subsidiaries were eligible for “Approved Enterprise” status. Most of the projects in Israel have been granted Approved Enterprise status under the “alternative” tax benefit track which offered tax exemption on undistributed income for a period of two to ten years, depending on the location of the enterprise. Upon distribution of such exempt income, the distributing company is subject to corporate tax at the rate ordinarily applicable to the Approved Enterprise’s income. Amendment 69 to the Investment Law Pursuant to Amendment 69 to the Investment Law (“Amendment 69”), a company that elected by November 11, 2013 to pay a corporate tax rate as set forth in that amendment (rather than the tax rate applicable to Approved Enterprise income) with respect to undistributed exempt income accumulated by the company up until December 31, 2011 is entitled to distribute a dividend from such income without being required to pay additional corporate tax with respect to such dividend. A company that has so elected must make certain qualified investments in Israel over the five-year period commencing in 2013. Teva invested the entire required amount in 2013. During 2013, Teva applied the provisions of Amendment 69 to certain exempt profits Teva accrued prior to 2012. Consequently, Teva paid $577 million in corporate tax on exempt income of $9.4 billion. Part of this income was distributed as dividends during 2013-2018, while the remainder is available to be distributed as dividends in future years with no additional corporate tax liability. Incentives Applicable starting 2014 : The Incentives Regime – Amendment 68 to the Investment Law Under Amendment 68 to the Investment Law, which Teva started applying in 2014, upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company (“Preferred Enterprise”), as opposed to the previous law’s incentives, which were limited to income from Approved Enterprises during the benefits period. Under the law, when the election is made, the uniform tax rate for 2014 until 2016 was 9% in areas in Israel designated as Development Zone A and 16% elsewhere in Israel. The uniform tax rate for Development Zone A, as of January 1, 2017, is 7.5% (as part of changes enacted in Amendment 73, as described below). The profits of these “Preferred Enterprise” will be freely distributable as dividends, subject to a 20% or lower withholding tax, under an applicable tax treaty. Certain “Special Preferred Enterprises” that meet more stringent criteria (significant investment, R&D or employment thresholds) will enjoy further reduced tax rates of 5% in Zone A and 8% elsewhere. In order to be classified as a “Special Preferred Enterprises,” the approval of three governmental authorities in Israel is required. The New Technological Enterprise Incentives Regime – Amendment 73 to the Investment Law Since 2017, a portion of the Company’s taxable income in Israel is entitled to a preferred 6% tax rate under Amendment 73 to the Investment Law as it pertains to Special Preferred Technological Enterprises. The new incentives regime applies to “Preferred Technological Enterprises” or “Special Preferred Technological Enterprises.” A “Preferred Technological Enterprise” is an enterprise that meet certain conditions, including, inter alia: • Investment of at least 7% of income, or at least NIS 75 million (approximately $22 million) in R&D activities; and • One of the following: a. At least 20% of the workforce (or at least 200 employees) are employed in R&D; b. A venture capital investment approximately equivalent to at least $2 million was previously made in the company; or c. Growth in sales or workforce by an average of 25% over the three years preceding the tax year. A “Special Preferred Technological Enterprise” is an enterprise that meets, inter alia conditions 1 and 2 above, and in addition has total annual consolidated revenues above NIS 10 billion (approximately $2.9 billion). Preferred Technological Enterprises are subject to a corporate tax rate of 7.5% on their income derived from intellectual property in areas in Israel designated as Zone A and 12% elsewhere, while Special Preferred Technological Enterprises are subject to 6% on such income. The withholding tax on dividends from these enterprises is 4% to foreign companies (or a lower rate under a tax treaty, if applicable). Income not eligible for Preferred Technological Enterprise benefits is taxed at the regular corporate tax rate, which is 23%, or the preferred tax rate, as the case may be. The Parent Company and its Israeli subsidiaries elected to compute their taxable income in accordance with Income Tax Regulations (Rules for Accounting for Foreign Investors Companies and Certain Partnerships and Setting their Taxable Income), 1986. Accordingly, the taxable income or loss is calculated in U.S. dollars. Applying these regulations reduces the effect of U.S. dollar – NIS exchange rate on the Company’s Israeli taxable income. Non-Israeli The 2021 Budget Law On November 15, 2021, the Israeli Parliament released its 2021-2022 Budget Law (“2021 Budget Law”). The 2021 Budget Law introduces a new dividend ordering rule that apportions every dividend between previously tax-exempt tax-exempt tax-exempt Pillar Two Taxation The OECD introduced Base Erosion and Profit Shifting (“BEPS”) Pillar Two rules that impose a global minimum tax rate Two in the foreseeable future

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Equity	NOTE 14—Equity: a. Ordinary shares and ADSs As of December 31, 2023 and 2022, Teva had approximately 1.2 billion ordinary shares issued. Teva ordinary shares are traded on the Tel-Aviv b. Stock-based compensation plans Stock-based compensation plans are comprised of stock options, RSUs, PSUs, and other equity-based awards to employees, officers, directors and consultants of the Company and its affiliates. The purpose of the plans is to (a) attract, retain, motivate, and reward such individuals, and (b) promote the creation of long-term value for shareholders of the Company by closely aligning the interests of such individuals with those of the shareholders. On June 29, 2010, the Teva 2010 Long-Term Equity-Based Incentive Plan (“2010 Plan”) was approved by Teva’s shareholders, under which 70 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2010 Plan expired on June 28, 2015 (except with respect to awards outstanding on that date), and no additional awards under the 2010 Plan may be made. On September 3, 2015, the Teva 2015 Long-Term Equity-Based Incentive Plan (“2015 Plan”) was approved by Teva’s shareholders, under which 43.7 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. On April 18, 2016, Teva’s shareholders approved an increase of an additional 33.3 million equivalent share units to the share reserve of the 2015 Plan, so that 77 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. On July 13, 2017, Teva’s shareholders approved an increase of an additional 65 million equivalent share units to the share reserve of the 2015 Plan, so that 142 million equivalent share units, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. The 2015 Plan expired on June 30, 2020 (except with respect to awards outstanding on that date), and no additional awards under the 2015 Plan may be made. On June 11, 2020, the Teva 2020 Long-Term Equity-Based Incentive Plan (“2020 Plan”) was approved by Teva’s shareholders and became effective on July 1, 2020. Under the 2020 Plan, 68 million shares, including options exercisable into ordinary shares, RSUs and PSUs, were approved for grant. As of December 31, 2023, 65.8 million shares remain available for future awards under the 2020 Plan. In the past, Teva had various employee-stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards granted under such prior plans continue in accordance with the terms of the respective plans. The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from date of grant. The vesting period of PSUs is generally 3 years from date of grant. The rights of ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of other ordinary shares of the Company. The contractual term of these options is primarily for ten years. Status of options A summary of the status of the options granted by Teva as of December 31, 2023, 2022 and 2021, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). Year ended December 31, 2023 2022 2021 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 24,119 $ 36.83 29,015 $ 36.96 35,234 $ 37.27 Changes during the year: Forfeited (885 ) 34.65 (2,378 ) 33.77 (3,644 ) 36.09 Expired (531 ) 37.57 (2,518 ) 41.26 (2,575 ) 42.40 Balance outstanding at end of year 22,703 36.89 24,119 36.83 29,015 36.96 Balance exercisable at end of year 22,703 36.89 24,119 36.83 26,989 38.30 No options were The following table summarizes information as of December 31, 2023 regarding the number of ordinary shares issuable upon vested options: Number of ordinary shares issuable upon exercise of vested options Range of exercise prices Balance at end of Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 3.84 $15.01 - $25.00 7,374 18.95 4.14 $25.01 - $35.00 5,470 34.66 3.17 $35.01 - $45.00 61 37.97 2.78 $45.01 - $55.00 5,707 51.26 1.36 $55.01 - $65.00 3,500 59.04 1.34 Total 22,703 36.89 2.76 The aggregate intrinsic value represents the total pre-tax in-the-money. No options were exercised during 2023, 2022 and 2021. Status of non-vested The following table summarizes information about the number of RSUs and PSUs granted and outstanding: Year ended December 31, 2023 2022 2021 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 32,302 $ 9.11 24,412 $ 11.58 20,720 $ 13.81 Granted 16,608 9.77 18,755 7.42 12,748 10.42 Vested (10,195 ) 10.28 (7,571 ) 13.02 (6,818 ) 15.60 Forfeited (3,052 ) 9.81 (3,293 ) 9.81 (2,238 ) 12.18 Balance outstanding at end of year 35,664 9.07 32,302 9.11 24,412 11.58 The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2023, 2022 and 2021, the Company recorded stock-based compensation costs as follows: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Employee stock options $ —  $ 2 $ 16 RSUs and PSUs 121 122 103 Total stock-based compensation expense 121 124 119 Tax effect on stock-based compensation expense 11 9 12 Net effect $ 110 $ 115 $ 107 As of December 31, 2023, the total unrecognized compensation cost before tax on RSUs/PSUs amounted to $192 million. The cost is expected to be recognized over a weighted average period of approximately 2.5 years. There were no unrecognized compensation costs related to employee stock options. c. Dividends Teva has not paid dividends on Teva ordinary shares or ADSs since December 2017. d. Accumulated other comprehensive loss The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: Net Unrealized Gains/(Losses) Benefit Plans Foreign Derivative Actuarial Total (U.S. $ in millions) Balance as of January 1, 2021 $ (1,919 ) (363 ) (117 ) (2,399 ) Other comprehensive income/(loss) before reclassifications (386 ) —  18 (368 ) Amounts reclassified to the statements of income —  39 18 57 Net other comprehensive income/(loss) before tax (386 ) 39 36 (311 ) Corresponding income tax 31 —  (4 ) 27 Net other comprehensive income/(loss) after tax* (355 ) 39 32 (284 ) Balance as of December 31, 2021 (2,274 ) (324 ) (85 ) (2,683 ) Other comprehensive income/(loss) before reclassifications (223 ) —  40 (183 ) Amounts reclassified to the statements of income —  29 27 56 Net other comprehensive income/(loss) before tax (223 ) 29 67 (127 ) Corresponding income tax (17 ) —  (10 ) (27 ) Net other comprehensive income/(loss) after tax* (240 ) 29 57 (154 ) Balance as of December 31, 2022 (2,514 ) (295 ) (28 ) (2,838 ) Other comprehensive income/(loss) before reclassifications 167 (1 ) (17 ) 149 Amounts reclassified to the statements of income —  30 (4 ) 26 Net other comprehensive income/(loss) before tax 167 29 (21 ) 175 Corresponding income tax (37 ) —  3 (34 ) Net other comprehensive income/(loss) after tax* 130 29 (18 ) 141 Balance as of December 31, 2023 $ (2,384 ) $ (266 ) $ (46 ) $ (2,697 ) * Amounts do not include foreign currency translation adjustments attributable to non-controlling

Other assets impairments, restr

Other assets impairments, restructuring and other items	12 Months Ended
	Dec. 31, 2023
Other assets impairments, restructuring and other items	NOTE 15—Other asset impairments, restructuring and other items: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Impairment (1) $ 28 $ 47 $ 160 Contingent consideration (see note 20) (2) 548 261 7 Restructuring 111 146 133 Other 30 57 41 Total $ 718 $ 512 $ 341 (1) Including impairments related to exit and disposal activities. (2) The contingent consideration presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b. Impairments Impairments of tangible assets for the years ended December 31, 2023, 2022 and 2021 were $28 million, $47 million and $160 million, respectively. Impairments for the year ended December 31, 2023 were mainly related to certain assets in Europe and North America. Impairments for the year ended December 31, 2022 were mainly related to certain assets North America. Impairments for the year ended December 31, 2021 were mainly related to certain assets in Europe and North America. Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities and its “Pivot to Growth Strategy”. Contingent consideration In 2023, Teva recorded expenses of $548 million for contingent consideration, compared to expenses of $261 million in 2022 and $7 million in 2021. Expenses in 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid ® ® Restructuring In 2023, Teva recorded $111 million of restructuring expenses, compared to $146 million in 2022 and $133 million in 2021. Expenses in 2023 and 2022 were primarily related to network consolidation activities. Expenses in 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017. The following table provides the components of restructuring costs: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Restructuring Employee termination $ 52 $ 117 $ 117 Other 59 29 16 Total $ 111 $ 146 $ 133 The following table provides the components of and changes in the Company’s restructuring accruals: Employee Other Total (U.S. $ in millions ) Balance as of January 1, 2021 $ (115 ) $ (7 ) $ (122 ) Provision (117 ) (16 ) (133 ) Utilization and other* 101 16 117 Balance as of December 31, 2021 $ (131 ) $ (7 ) $ (138 ) Provision (117 ) (29 ) (146 ) Utilization and other* 136 29 165 Balance as of December 31, 2022 $ (112 ) $ (7 ) $ (119 ) Provision (52 ) (59 ) (111 ) Utilization and other* 90 59 149 Balance as of December 31, 2023 $ (75 ) $ (7 ) $ (82 ) * Includes adjustments for foreign currency translation.

Other income

Other income	12 Months Ended
	Dec. 31, 2023
Other income	NOTE 16 – Other income: Year ended 2023 2022 2021 (U.S. $ in millions) Gain on divestitures, net of divestitures related costs (1) $ 3 $ 46 $ 51 Section 8 and similar payments 5 13 19 Gain (loss) on sale of assets (2) 25 18 7 Other, net (3) 16 31 22 Total other income $ 49 $ 107 $ 98 (1) In 2022 mainly related to the divestment of several activities in North America and International Markets. In 2021, mainly due to capital gains related to the sale of certain OTC assets. (2) In 2023 mainly related to the divestment of assets in International Markets. (3) In 2022 mainly the result of settlement proceeds related to the International Markets segment.

Financial expenses, net

Financial expenses, net	12 Months Ended
	Dec. 31, 2023
Financial expenses, net	NOTE 17—Financial expenses, net: Year ended December, 31 2023 2022 2021 (U.S. $ in millions) Interest expenses and other bank charges $ 1,029 $ 930 $ 891 (Income) loss from investments (1) (68 ) (10 ) 90 Foreign exchange (gains) losses, net 30 (16 ) 7 Other, net (2) 66 61 71 Total finance expense, net $ 1,057 $ 966 $ 1,058 (1) Loss from investments in 2021 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). (2) Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share

Earnings (Loss) per Share	12 Months Ended
	Dec. 31, 2023
Earnings (Loss) per Share	NOTE 18—Earnings (loss) per share: The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2023, 2022 and 2021 are as follows: Year ended December, 31 2023 2022 2021 (U.S. $ in millions, except share data) Net income (loss) used for the computation of basic and diluted earnings (loss) per share* $ (559 ) $ (2,446 ) $ 417 Weighted average number of shares used in the computation of basic earnings (loss) per share 1,119 1,110 1,102 Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,119 1,110 1,107 * Net income (loss) presented in the table above for the year ended December 31, 2022 has been revised as discussed in note 1b. Basic earnings (loss) per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested RSUs and PSUs during the period), net of treasury shares. In computing diluted loss per share for the year ended December 31, 2023 and 2022, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested In computing diluted earnings per share for the year ended December 31, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested Basic and diluted loss per share was $0.50 for the year ended December 31, 2023, compared to basic and diluted loss per share of $2.20 for the year ended December 31, 2022 and basic and diluted earnings per share of $0.38 for the year ended December 31, 202 1

Segments

Segments	12 Months Ended
	Dec. 31, 2023
Segments	NOTE 19—Segments: Teva operates its business and reports its financial results in three segments: (a) North America segment, which includes the United States and Canada. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries other than those in the North America and Europe segments. In addition to these three segments, Teva has other sources of revenues included in other activities, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing Teva’s Chief Executive Officer (“CEO”), who is the chief operating decision maker (“CODM”), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance. Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva’s CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment. Teva’s CEO may review its strategy and organizational structure from time to time. Based on such review, in May 2023 Teva launched its new Pivot to Growth strategy. Any additional changes in strategy may lead to a reevaluation of the Company’s segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 7. In conjunction with a recent shift in executive management responsibilities and in alignment with Teva’s Pivot to Growth strategy, Teva decided that Canada will no longer be included as part of Teva’s North America segment as of January 1, 2024. From that date, Teva’s North America segment will be comprised solely of the United States, while Canada will be reported as part of the Company’s International Markets segment. Teva will align its internal financial and segment reporting and its reporting units in coordination with this shift effective January 1, 2024. On January 31, 2024, Teva announced that it intends to divest its API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025. The intention to divest is in alignment with Teva’s Pivot to Growth strategy. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be agreed or completed at all. a. Segment information: Year ended December 31, 2023 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,124 $ 4,837 $ 1,958 Gross profit 4,421 2,726 1,050 R&D expenses 625 220 83 S&M expenses 1,005 767 420 G&A expenses 403 263 118 Other income (8 ) (2 ) (35 ) Segment profit $ 2,396 $ 1,478 $ 464 Year ended December 31, 2022 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,452 $ 4,525 $ 1,903 Gross profit 3,926 2,700 1,033 R&D expenses 532 213 72 S&M expenses 941 748 405 G&A expenses 474 246 119 Other income (15 ) (3 ) (43 ) Segment profit $ 1,993 $ 1,496 $ 479 Year ended December 31, 2021 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,809 $ 4,886 $ 2,032 Gross profit 4,226 2,823 1,118 R&D expenses 618 244 68 S&M expenses 988 846 417 G&A expenses 427 244 109 Other income (31 ) (5 ) (5 ) Segment profit $ 2,224 $ 1,494 $ 529 Year ended December 31, 2023 2022 2021 (U.S. $ in millions) North America profit $ 2,396 $ 1,993 $ 2,224 Europe profit 1,478 1,496 1,494 International Markets profit 464 479 529 Total reportable segments profit 4,338 3,968 4,246 Profit of other activities 24 172 154 Total segments profit 4,361 4,139 4,401 Amounts not allocated to segments: Amortization 616 732 802 Other asset impairments, restructuring and other items (1) 718 512 341 Goodwill impairment 700 2,045 —  Intangible assets impairments 350 355 424 Legal settlements and loss contingencies 1,043 2,082 717 Other unallocated amounts 502 610 402 Consolidated operating income (loss) (1) 433 (2,197 ) 1,716 Financial expenses, net 1,057 966 1,058 Consolidated income (loss) before income taxes (1) $ (624 ) $ (3,163 ) $ 658 (1) The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b. b. Segment revenues by major products and activities: The following tables present revenues by major products and activities for each segment for the year ended December 31, 2023, 2022 and 2021: North America segment: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Generic products $ 3,475 $ 3,549 $ 3,769 AJOVY 230 218 176 AUSTEDO 1,225 963 802 BENDEKA and TREANDA 241 316 385 COPAXONE 320 387 577 Anda 1,577 1,471 1,323 Other* 1,056 549 777 Total $ 8,124 $ 7,452 $ 7,809 * Other revenues were mainly comprised of a $ 500 Europe segment: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Generic products $ 3,664 $ 3,466 $ 3,569 AJOVY 160 124 87 COPAXONE 231 268 391 Respiratory products 265 273 356 Other* 516 393 483 Total $ 4,837 $ 4,525 $ 4,886 * Other revenues in 2023 were mainly related to the sale of certain product rights. International Markets segment: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Generic products $ 1,594 $ 1,586 $ 1,649 AJOVY 44 35 50 COPAXONE 39 36 37 Other 281 246 295 Total $ 1,958 $ 1,903 $ 2,032 Revenues are attributable to countries based on sales to third parties in such countries. Revenues within the United States constituted 49%, 47% and 46% of Teva’s consolidated revenues for the years ended December 31, 2023, 2022 and 2021, respectively. Revenues within the Company’s country of domicile (Israel) constituted 2%, 2% and 2% of Teva’s consolidated revenues for the years ended December 31, 2023, 2022 and 2021, respectively. c. Supplemental data—major customers: The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2023, 2022 and 2021. Percentage of Third Party Net Sales 2023 2022 2021 McKesson Corporation 9 % 10 % 11 % AmerisourceBergen Corporation 9 % 10 % 11 % Most of Teva’s revenues from these customers were in the North America segment. d. Property, plant and equipment—by geographical location were as follows: December 31, 2023 2022 (U.S. $ in millions) Israel $ 1,312 $ 1,401 Germany 1,318 1,143 United States 596 625 Croatia 447 445 Czech republic 309 318 Hungary 279 294 Ireland 266 268 Other 1,222 1,245 Total property, plant and equipment $ 5,750 $ 5,739

Fair value measurement

Fair value measurement	12 Months Ended
	Dec. 31, 2023
Fair value measurement	NOTE 20—Fair value measurement: Financial items carried at fair value as of December 31, 2023 and 2022 are classified in the tables below in one of the three categories described in note 1g: December 31, 2023 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 1,704 —  —  $ 1,704 Cash, deposits and other 1,522 —  —  1,522 Investment in securities: Investment in convertible bond security —  —  40 40 Equity securities 7 —  —  7 Other 1 —  —  1 Restricted cash 1 —  —  1 Derivatives: Asset derivatives Options and forward contracts —  38 —  38 Cross-currency interest rate swap —  8 —  8 Liabilities derivatives —  Options and forward contracts —  (39 ) —  (39 ) Bifurcated embedded derivatives —  —  § —  Contingent consideration* —  —  (517 ) (517 ) Total $ 3,235 $ 7 $ (477 ) $ 2,765 December 31, 2022 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 1,222 —  —  $ 1,222 Cash, deposits and other 1,579 —  —  1,579 Investment in securities: Equity securities 9 —  —  9 Other 5 —  1 6 Restricted cash 33 —  —  33 Derivatives: Asset derivatives: Options and forward contracts —  29 —  29 Liability derivatives: Options and forward contracts (101 ) (101 ) Bifurcated embedded derivatives —  —  § —  Contingent consideration* —  —  (251 ) (251 ) Total $ 2,848 $ (73 ) $ (250 ) $ 2,525 § Represents an amount less than $0.5 million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. The contingent consideration liability is recorded under accrued expenses and other taxes and long-term liabilities. The financial data presented in the tables above as of December 31, 2022 have been revised as discussed in note 1b. Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. The discount rate applied ranged from 8.5% to 11%. The weighted average discount rate, calculated based on the relative fair value of Teva’s contingent consideration liabilities, was 8.8%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the cash flows projected, could result in material changes to the contingent consideration liabilities. A change of the discount rate by % would have not resulted in material changes to the contingent consideration liabilities. The convertible debt security is accounted for as available for sale with changes in fair value reflected in other comprehensive income. As of December 31, 2023, the fair value of the conversion option is negligible. The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs. December 31, December 31, (U.S. $ in millions) Fair value at the beginning of the period $ (250 ) $ (175 ) Investment in convertible bond ** 40 —  Bifurcated embedded derivatives § § Additional contingent consideration resulting from Novetide acquisition* —  (11 ) Adjustments to provisions for contingent consideration: Allergan transaction*** (422 ) (240 ) Eagle transaction (132 ) (21 ) Novetide transaction 2 —  Settlement of contingent consideration: Allergan transaction 207 109 Eagle transaction 76 88 Novetide transaction 2 —  Fair value at the end of the period $ (477 ) $ (250 ) § Represents an amount less than $ 0.5 * In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies.” This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net,” reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. ** On September 29, 2023, Teva invested $40 million in subordinated convertible bonds, which were issued by Alvotech, pursuant to a convertible bond instrument dated December 20, 2022. (see note 2). *** The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan in 2022 have been revised as discussed in note 1b. Teva’s financial instruments consist mainly of cash and cash equivalents, investments in securities, current and non-current The fair value of the financial instruments included in working capital and non-current Financial instruments not measured at fair value Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value: Estimated fair value* December 31, 2023 2022 (U.S. $ in millions) Senior notes and sustainability-linked senior notes included under senior notes and loans $ 17,214 $ 16,694 Senior notes and convertible senior debentures included under short-term debt 1,651 2,075 Total $ 18,865 $ 18,769 * The fair value was estimated based on quoted market prices.

Long-term Employee-related Obli

Long-term Employee-related Obligations	12 Months Ended
	Dec. 31, 2023
Long-term Employee-related Obligations	NOTE 21—Long-term employee-related obligations: a. Long-term employee-related obligations consisted of the following: December 31,  2023   2022  (U.S. $ in millions) Accrued severance obligations $ 74 $ 74 Defined benefit plans 73 58 Total $ 148 $ 132 As of December 31, 2023 and 2022, Teva had $90 million and $79 million, respectively, deposited in funds managed by financial institutions and earmarked by management to cover severance pay liability. Such deposits are not considered to be “plan assets” and are therefore included in other non-current Most of the change resulted from actuarial updates, as well as from exiting from several defined benefit plans in several countries. The Company expects to expense an approximate contribution of $115 million in 2024 to pension funds and insurance companies in connection with its severance and pension pay obligations. The main terms of the different arrangements with employees are described in below. b. Terms of arrangements: Israel Israeli law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Parent Company and its Israeli subsidiaries make ongoing deposits into employee pension plans to fund their severance liabilities. Generally, employees that joined the Company after 2005, have signed an arrangement, pursuant to which such deposits are made in lieu of the Company’s severance liability. Therefore, no obligation is provided for in the financial statements. Severance pay liabilities with respect to employees who were employed by the Parent Company and its Israeli subsidiaries prior to that date, as well as employees who have special contractual arrangements, are provided for in the financial statements based upon the number of years of service and the latest monthly salary of such employees. Europe Many of the employees in the Company’s European subsidiaries are entitled to a retirement grant when they leave the Company. In the consolidated financial statements, the liability of the European subsidiaries is accrued, based on the length of service and remuneration of each employee at the balance sheet date. Other employees in Europe are entitled to a pension according to a defined benefit scheme providing benefits based on final or average pensionable pay or according to a hybrid pension scheme that provides retirement benefits on a defined benefit and a defined contribution basis. Independent certified actuaries value these schemes and determine the rates of contribution payable. Pension costs for the defined benefit section of the scheme are accounted for on the basis of charging the expected cost of providing pensions over the period during which the subsidiaries benefit from the employees’ services. The Company uses December 31 as the measurement date for defined benefit plans. North America The Company’s North American subsidiaries mainly provide various defined contribution plans for the benefit of their employees. Under these plans, contributions are based on specified percentages of pay. Additionally, a multi-employer plan is maintained in accordance with various union agreements. Latin America The majority of the employees in Latin America are entitled to severance under local law. The severance payments are calculated based on service term and employee remuneration, and accruals are maintained to reflect these amounts. In some Latin American countries, it is Teva’s practice to offer retirement health benefits to qualifying employees. Based on the specific plan requirements, benefits accruals are maintained to reflect the estimated amounts or adjusted if future plans are modified. The Company expects to pay the following future minimum benefits to its employees: $14 million in 2024; $13 million in 2025; $13 million in 2026; $13 million in 2027; $15 million in 2028; and $80 million in the aggregate between 2029 to 2033. These amounts do not include amounts that may be paid to employees who cease working with the Company before their normal retirement age.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2023
Quarterly Financial Data (Unaudited)	NOTE 22—Quarterly financial data (Unaudited): As discussed in note 1b, the Company identified errors in a single contingent consideration liability and related expenses in connection with estimated future royalty payments, along with corresponding deferred tax adjustments, and determined that certain line items in connection with the Company’s unaudited quarterly financial data for 2023 and 2022 needed to be revised. The following tables, which present unaudited quarterly financial data for 2023 and 2022, reflect such revision: Three months ended December 31, September 30, June 30, March 31, U.S $ in millions (except per share amounts) Net revenues $ 4,457 3,850 3,878 3,661 Gross profit 2,416 1,851 1,796 1,582 Net income (loss)* 465 78 (905 ) (253 ) Net income (loss) attributable to Teva* 461 70 (871 ) (220 ) Earnings (loss) per share attributable to ordinary shareholders: Basic* $ 0.41 0.06 (0.78 ) (0.20 ) Diluted* $ 0.41 0.06 (0.78 ) (0.20 ) Three months ended December 31, September 30, June 30, March 31, U.S $ in millions (except per share amounts) Net revenues $ 3,884 3,595 3,786 3,661 Gross profit 1,770 1,669 1,794 1,740 Net income (loss)* (1,333 ) 63 (278 ) (952 ) Net income (loss) attributable to Teva* (1,301 ) 61 (251 ) (955 ) Earnings (loss) per share attributable to ordinary shareholders: Basic* $ (1.17 ) 0.05 (0.23 ) (0.86 ) Diluted* $ (1.17 ) 0.05 (0.23 ) (0.86 ) * The data presented for the above quarterly periods (except for the three months ended March 31, 2022 and the three months ended December 31, 2023) have been revised to reflect a revision of the line items in the consolidated financial statements. See tables below and note 1b. The tables below present the impact of the revision on the line items within the Company’s unaudited quarterly financial data for 2023 and 2022: Consolidated Statements of Income (loss) Three months ended September 30, 2023 June 30, 2023 March 31, 2023 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Other asset impairments, restructuring and other items $ 46 11 57 $ 100 8 108 $ 96 15 110 Operating income (loss) 355 (11 ) 344 (646 ) (8 ) (654 ) 2 (15 ) (13 ) Income (loss) before income taxes 75 (11 ) 64 (914 ) (8 ) (923 ) (258 ) (15 ) (272 ) Income taxes (benefit) (12 ) § (12 ) (16 ) § (16 ) (19 ) § (19 ) Net income (loss) 88 (11 ) 78 (898 ) (8 ) (905 ) (238 ) (15 ) (253 ) Net income (loss) attributable to Teva 80 (11 ) 70 (863 ) (8 ) (871 ) (205 ) (15 ) (220 ) Earnings per share attributable to ordinary shareholders: Basic $ 0.07 (0.01 ) 0.06 $ (0.77 ) (0.01 ) (0.78 ) $ (0.18 ) (0.02 ) (0.20 ) Diluted $ 0.07 (0.01 ) 0.06 $ (0.77 ) (0.01 ) (0.78 ) $ (0.18 ) (0.02 ) (0.20 ) § Represents an amount less than $0.5 million. Three months ended December 31, 2022 September 30, 2022 June 30, 2022 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Other asset impairments, restructuring and other items $ 132 85 217 $ 36 (5 ) 31 $ 118 18 137 Operating income (loss) (855 ) (85 ) (940 ) 419 5 424 (949 ) (18 ) (967 ) Income (loss) before income taxes (1,100 ) (85 ) (1,185 ) 166 5 171 (1,160 ) (18 ) (1,178 ) Income taxes (benefit) 154 (5 ) 149 107 § 107 (900 ) § (900 ) Net income (loss) (1,254 ) (80 ) (1,333 ) 58 5 63 (259 ) (18 ) (278 ) Net income (loss) attributable to Teva (1,221 ) (80 ) (1,301 ) 56 5 61 (232 ) (18 ) (251 ) Basic $ (1.10 ) (0.07 ) (1.17 ) $ 0.05 —  0.05 $ (0.21 ) (0.02 ) (0.23 ) Diluted $ (1.10 ) (0.07 ) (1.17 ) $ 0.05 —  0.05 $ (0.21 ) (0.02 ) (0.23 ) § Represents an amount less than $0.5 million. Consolidated Balance Sheets September 30, 2023 June 30, 2023 March 31, 2023 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Deferred income taxes $ 1,748 7 1,755 $ 1,578 5 1,583 $ 1,572 5 1,577 Total assets 42,088 7 42,095 43,095 5 43,100 43,456 5 43,461 Other taxes and long-term liabilities 3,818 132 3,950 3,973 121 4,094 3,869 113 3,982 Total long-term liabilities 23,182 132 23,314 23,543 121 23,664 24,433 113 24,546 Total liabilities 34,576 132 34,708 35,387 121 35,508 34,844 113 34,957 Teva shareholders’ equity: Accumulated deficit (13,870 ) (125 ) (13,995 ) (13,950 ) (116 ) (14,066 ) (13,086 ) (108 ) (13,194 ) Total equity 7,512 (125 ) 7,387 7,708 (116 ) 7,592 8,612 (108 ) 8,504 Total liabilities and equity $ 42,088 7 42,095 $ 43,095 5 43,100 $ 43,456 5 43,461 December 31, 2022 September 30, 2022 June 30, 2022 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Deferred income taxes $ 1,453 5 1,458 $ 1,546 § 1,546 $ 1,595 § 1,595 Total assets 44,006 5 44,011 44,252 § 44,252 45,932 § 45,932 Other taxes and long-term liabilities 3,847 98 3,945 3,846 13 3,859 3,842 18 3,860 Total long-term liabilities 23,846 98 23,944 23,200 13 23,213 25,107 18 25,125 Total liabilities 35,315 98 35,413 34,734 13 34,747 36,103 18 36,121 Accumulated deficit (12,882 ) (93 ) (12,975 ) (11,660 ) (13 ) (11,673 ) (11,716 ) (18 ) (11,734 ) Total equity 8,691 (93 ) 8,598 9,519 (13 ) 9,506 9,828 (18 ) 9,810 Total liabilities and equity $ 44,006 5 44,011 $ 44,252 —  44,252 $ 45,932 —  45,932 § Represents an amount less than $0.5 million.

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2023
Schedule of Valuation and Qualifying Accounts	Column A Column B Column C Column D Column E Balance at Charged to costs Charged to other Deductions Balance at end Allowance for doubtful accounts including credit losses: Year ended December 31, 2023 $ 162 $ 10 $ (6 ) $ (2 ) 164 Year ended December 31, 2022 $ 164 $ 8 $ (2 ) $ (8 ) $ 162 Year ended December 31, 2021 $ 200 $ (8 ) $ —  $ (28 ) $ 164 Allowance in respect of carryforward tax losses and deductions that may not be utilized: Year ended December 31, 2023 $ 3,072 $ 161 $ —  $ (224 ) $ 3,009 Year ended December 31, 2022 $ 2,723 $ 443 $ —  $ (93 ) $ 3,072 Year ended December 31, 2021 $ 2,547 $ 336 $ —  $ (160 ) $ 2,723

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
General	a. General: Operations Teva Pharmaceutical Industries Limited (the “Parent Company”), headquartered in Israel, together with its subsidiaries and associated companies (the “Company,” “Teva” or the “Group”), is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The majority of the Group’s revenues are in the United States and Europe. Basis of presentation and use of estimates The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). In preparing the Company’s consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Company’s consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva’s third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to: determining the valuation and recoverability of IPR&D assets, marketed product rights, contingent consideration and goodwill, assessing sales reserves and allowances in the United States, uncertain tax positions, valuation allowances and contingencies. These estimates could be impacted by higher costs and the ability to pass on such higher costs to customers, which is highly uncertain. In February 2022, Russia launched an invasion of Ukraine. As of the date of these consolidated financial statements, sustained conflict and disruption in the region is ongoing. Russia and Ukraine markets are included in Teva’s International Markets segment results. Teva has no manufacturing or R&D facilities in these markets. As part of the Company’s annual goodwill analysis performed in the second quarter of 2023, it identified an increase in the discount rate, which led to a goodwill impairment charge in its International Markets reporting unit. This increase was due to an increase in certain components of the discount rate that were partially attributed to higher risk associated with country-specific characteristics of several countries, such as Russia, that might be a consequence of the conflict. Other than its impact on the goodwill impairment charge described above, during the year ended December 31, 2023, the impact of the Russia-Ukraine conflict on Teva’s results of operations and financial condition was immaterial. See also note 7. In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. Israel is included in Teva’s International Markets segment results. Teva’s global headquarters and several manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. Teva continues to maintain contingency plans with backup production locations for key products. During the year ended December 31, 2023, the impact of this war on Teva’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts. Functional currency A major part of the Group’s operations is carried out by the Company in the United States, Israel and certain other countries. The functional currency of these entities is the U.S. dollar (“dollar” or “$”). The functional currency of certain subsidiaries and associated companies is their local currency. The financial statements of those companies are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end In the event of a divestiture of a foreign subsidiary, the related foreign currency translation results net of related income taxes are reversed from equity to income. Foreign currency exchange gains and losses are included in net income (loss). Principles of consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries, joint ventures and variable interest entities (“VIEs”) for which the Company is considered the primary beneficiary. For those consolidated entities where Teva owns less than 100%, the outside shareholders’ interests are shown as non-controlling For VIEs, the Company performs an analysis to determine whether the variable interests give a controlling financial interest in a VIE. The Company periodically reassesses whether it controls its VIEs. Intercompany transactions and balances are eliminated on consolidation; profits from intercompany sales, not yet realized outside the Group, are also eliminated.
Revision of Previously Reported Consolidated Financial Statements	b. Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of the consolidated financial statements as of and for the year ended December 31, 2023, the Company identified errors in a single contingent consideration liability and related expenses in connection with estimated future royalty payments, along with corresponding deferred tax adjustments, that aggregated into an understatement of the contingent consideration liability of approximately million, of which million related to 2022 and $ million related to 2023. These errors resulted from the exclusion of royalty payments that should have been included in the fair value re-measurement year-to-date The Company evaluated the errors, individually and in the aggregate, considering both qualitative and quantitative factors, and concluded that these errors did not have a material impact on any of the prior periods stated above. However, the aggregate amount of the prior period errors in 2022, would have been material to the consolidated financial statements for fiscal year 2023. Therefore, the Company has revised the prior periods impacted for these errors. The impact of the revision on the Company’s unaudited quarterly financial data for 2023 and 2022 is presented in note 22. The tables below present the impact of the revision on the line items within the Company’s consolidated financial statements as of and for the year ended December 31, 2022: Consolidated Statements of Income Year ended December 31, 2022 Consolidated Balance Sheets December 31, 2022 Adjustment As Adjustment As U.S $ in millions (except per share U.S $ in millions (except per share Other asset impairments, restructuring and other items $ 414 98 512 Deferred income taxes $ 1,453 5 1,458 Operating income (loss) (2,099 ) (98 ) (2,197 ) Total assets 44,006 5 44,011 Income (loss) before income taxes (3,065 ) (98 ) (3,163 ) Other taxes and long-term liabilities 3,847 98 3,945 Income taxes (benefit) (638 ) (5 ) (643 ) Total long-term liabilities 23,846 98 23,944 Net income (loss) (2,406 ) (93 ) (2,499 ) Total liabilities 35,315 98 35,413 Net income (loss) attributable to Teva (2,353 ) (93 ) (2,446 ) Teva shareholders’ equity: Earnings (loss) per share attributable to ordinary shareholders: Accumulated deficit (12,882 ) (93 ) (12,975 ) Basic $ (2.12 ) (0.08 ) (2.20 ) Total equity 8,691 (93 ) 8,598 Diluted $ (2.12 ) (0.08 ) (2.20 ) Total liabilities and equity $ 44,006 5 44,011
New accounting pronouncements	c. New accounting pronouncements Recently adopted accounting pronouncements In September 2022, the FASB issued ASU 2022-04 405-50)”. In October 2021, the FASB issued ASU 2021-08 Recently issued accounting pronouncements, not yet adopted In December 2023, the FASB issued ASU 2023-09 2023-09 in foreign jurisdictions. ASU 2023-09 In November 2023, the FASB issued ASU 2023-07 In October 2023, the FASB issued ASU 2023-06 Regulation S-X Regulation S-K 2023-06
Acquisitions	d. Acquisitions: Teva’s consolidated financial statements include the operations of acquired businesses from the date of the acquisition’s consummation. Acquired businesses are accounted for using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When Teva acquires net assets that do not constitute a business, as defined under U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed unless it has an alternative future use. Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of its fair value as of the acquisition date. The fair value of the contingent consideration is re-measured
Collaborative arrangements	e. Collaborative arrangements: Collaborative arrangements are contractual arrangements in which the parties are active participants to the arrangement and are exposed to the significant risks and rewards that are dependent on the ultimate commercial success of the endeavor. The Company recognizes revenue generated and costs incurred on sales to third parties as it relates to collaborative agreements as gross or net. If the Company is the principal participant in a transaction, revenues and costs are recorded on a gross basis; otherwise, revenues and costs are recorded on a net basis. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaborative arrangements are recorded as research and development expenses.
Equity investments	f. Equity investments: The Company measures equity investments at fair value with changes in fair value recognized in net income. The Company accounts for equity investments that do not have a readily determinable fair value as cost method investments under the measurement alternative to the extent such investments are not subject to consolidation or the equity method. Under the measurement alternative, these financial instruments are carried at cost, less any impairment (assessed quarterly for triggering events), adjusted for changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. In addition, income is recognized when dividends are received only to the extent they are distributed from net accumulated earnings of the investee. Otherwise, such distributions are considered returns of investment and are recorded as a reduction of the cost of the investment. The Company accounts for equity investments as current when the Company has the intent and ability to sell such assets within the next twelve months.
Fair value measurement	g. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Investment in debt securities	h. Investment in debt securities: Investment in securities consists of debt securities classified as available-for-sale Unrealized gains and losses for available-for-sale available-for-sale non-credit
Cash and cash equivalents	i. Cash and cash equivalents: All highly liquid investments, which include short-term bank deposits and money market instruments, that are not restricted as to withdrawal or use, and investment in short-term debentures, the period to maturity of which did not exceed three months at the time of investment, are considered to be cash equivalents.
Restricted cash	j. Restricted cash: Restricted cash represents amounts which are legally restricted to withdrawal or usage and is presented in the Consolidated Balance Sheet under other current assets.
Accounts receivables	k. Accounts Receivables: Accounts receivable have been reduced by an allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses, and future expectations. Write-off
Concentration of credit risks	l. Concentration of credit risks: Most of Teva’s cash and cash equivalents, along with investment in securities, at December 31, 2023 were deposited with European, U.S. and Israeli banks and financial institutions and were comprised mainly of cash deposits. The U.S. market constituted approximately 51% of Teva’s consolidated revenues in 2023. The exposure of credit risks relating to other trade receivables outside the U.S. is limited, due to the relatively large number of group customers and their wide geographic distribution. Teva performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts and generally does not require collateral and from time to time the Company may choose to purchase trade credit insurance.
Inventories	m. Inventories: Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials, purchased products, manufactured finished products, products in process and capitalized production costs are determined predominantly on a standard cost basis, approximating actual costs. Other methods which are utilized for determining the value of inventories are moving average, cost basis and the first in first out method. Teva regularly reviews its inventories for obsolescence and other impairment risks and reserves are established when necessary. Inventories acquired in a business combination are stepped-up
Long-lived assets	n. Long-lived assets: Teva’s long-lived, non-current right-of-use Goodwill Goodwill reflects the excess of the consideration transferred, including the fair value of any contingent consideration and any non-controlling The goodwill impairment test is performed according to the following principles: 1. An initial qualitative assessment may be performed to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. 2. If the Company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying mount, a quantitative fair value test is performed. An impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized. An interim goodwill impairment test may be required in advance or after of the annual impairment test if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. For example, a substantial decline in the Company’s market capitalization, unexpected adverse business conditions, economic factors and unanticipated competitive activities may indicate that an interim impairment test is required. In the event that the Company’s market capitalization declines below its book value, the Company considers the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. Identifiable intangible assets Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets. Definite life intangible assets consist mainly of acquired product rights and other rights relating to products for which marketing approval was received from the U.S. Food and Drug Administration (“FDA”) or the equivalent agencies in other countries. These assets are amortized mainly using the straight-line method over their estimated period of useful life, or based on economic benefit models, if more appropriate, which is determined by identifying the period and manner in which substantially all of the cash flows are expected to be generated. Amortization of acquired developed products is recorded under cost of sales. Amortization of marketing and distribution rights is recorded under selling and marketing (“S&M”) expenses when separable. Indefinite life intangible assets are mainly comprised of IPR&D assets. Teva monitors these assets for items such as research and development progress and for indicators of fair value change such as level of expected competition and or pricing, to identify any triggering events. IPR&D acquired in a business combination is capitalized as an indefinite life intangible asset until the related research and development efforts are either completed or abandoned. In the reporting periods where they are treated as indefinite life intangible assets, they are not amortized but rather are monitored triggering events and tested for impairment at least on an annual basis, in the second quarter of the fiscal year. Upon completion of the related research and development efforts, management determines the useful life of the intangible assets and amortizes them accordingly. In case of abandonment or a reduction in the expected realizable value of the asset, the related research and development assets are impaired. Whenever impairment indicators are identified for definite life intangible assets, Teva reconsiders the asset’s estimated life, calculates the undiscounted value of the asset’s or asset group’s cash flows and compares such value against the asset’s or asset group’s carrying amount. If the carrying amount is greater, Teva records an impairment loss for the excess of book value over fair value based on the discounted cash flows. For indefinite life intangible assets, Teva performs an impairment test annually in the second quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Teva determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. In determining the estimated fair value of identifiable intangible assets, Teva utilized a discounted cash flow model. The key assumptions within the model related to forecasting future revenue and operating income, an appropriate discount rate and an appropriate terminal value based on the nature of the long-lived asset. The Company’s updated forecasts of net cash flows for the impaired assets reflect, among others, the following: (i) for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risks associated with these assets; and (ii) for product rights, pricing and volume projections, as well as patent life and any significant changes to the competitive environment. Property, plant and equipment Property, plant and equipment are stated at cost, after deduction of the related investment grants, and depreciated using the straight-line method over the estimated useful life of the assets: buildings, mainly 40 years; machinery and equipment, mainly 20 years; and other assets, between 5 to 10 years. For property, plant and equipment and lease right-of-use Lease right-of-use See note 8 and note 1ee for further discussion.
Contingencies	o. Contingencies: The Company is involved in various patent, product liability, commercial, government investigations, environmental claims and other legal proceedings that arise from time to time in the ordinary course of business. Except for income tax contingencies, contingent consideration, other contingent liabilities incurred or acquired in a business combination, Teva records accruals for these types of contingencies to the extent that Teva concludes their occurrence is probable and that the related liabilities are reasonably estimable. When accruing these costs, the Company will recognize an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range. Teva records anticipated recoveries under existing insurance contracts that are probable of occurring at the gross amount that is expected to be collected. When applicable, the Company classifies the effect that the passage of time had on the net present value of a discounted legal accrual as legal expenses. Legal costs are expensed as incurred. The Company recognizes gain contingencies when they are realized or when all related contingencies have been resolved.
Treasury shares	p. Treasury shares: Treasury shares are presented as a reduction of Teva shareholders’ equity and carried at their cost to Teva, under treasury shares.
Stock-based compensation	q. Stock-based compensation: Teva recognizes stock based compensation for the estimated fair value of share-based awards, restricted share units (“RSUs”) and performance share units (“PSUs”). Teva measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the share-based award’s expected term and the price volatility of the underlying stock. Teva amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. Teva measures compensation expense for RSUs and PSUs based on the market value of the underlying stock at the date of grant, less the present value of expected dividends not received during the vesting period, if applicable. Teva amortizes the value of RSUs to expense over the vesting period on a straight-line basis. The compensation expense for PSUs is recognized only if it is probable that the performance condition will be achieved. Teva records forfeitures for share-based awards, RSUs and PSUs as they occur. If an employee forfeits an award because he fails to complete the requisite service period, the Company will reverse the compensation cost previously recognized in the period the award is forfeited.
Deferred income taxes	r. Deferred income taxes: Deferred income taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of temporary differences between the financial accounting and tax basis of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred income taxes are expected to be paid or realized. A valuation allowance is provided if, based upon the weight of available evidence, it is more likely than not that a portion of the deferred income tax assets will not be realized. In determining whether a valuation allowance is needed, Teva considers all available evidence, including historical information, long range forecast of future taxable income and evaluation of tax planning strategies. Amounts recorded for valuation allowance can result from a complex series of judgments about future events and can rely on estimates and assumptions. Deferred income tax liabilities and assets are classified as non-current. Tax has not been provided on the following items: 1. Taxes that would apply in the event of disposal of investments in subsidiaries, as it is generally the Company’s intention to hold these investments, not to realize them. The determination of the amount of related unrecognized deferred tax liability is not practicable. 2. Amounts of tax-exempt
Uncertain tax positions	s. Uncertain tax positions: Teva recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. Teva regularly re-evaluates Provisions for uncertain tax positions, whereas Teva has net operating losses to offset additional income taxes that would result from the settlement of the tax position, are presented as a reduction of the deferred tax assets for such net operating loss.
Derivatives and hedging	t. Derivatives and hedging: The Group carries out transactions involving derivative financial instruments (mainly forward exchange contracts, currency options, cross-currency swap contracts, interest rate swap contracts and treasury locks). The transactions are designed to hedge the Company’s currency and interest rate exposures. The Company does not enter into derivative transactions for trading purposes. Derivative instruments are recognized on the balance sheet at their fair value. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative instrument as well as the offsetting gain or loss on the hedged item attributable to the hedged risk is recognized in financial expenses, net in the statements of income in the period that the changes in fair value occur. For derivative instruments that are designated and qualify as a cash-flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the anticipated transaction in the same period or periods during which the hedged transaction affects earnings. For derivative instruments that are designated as net-investment portion is determined by looking into changes in spot exchange rate. The change in fair value attributable to changes other than those due to fluctuations in the spot exchange rate are excluded from the assessment of hedge effectiveness and are recognized in the statement of income under financial expenses, net. For derivative instruments that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidated statements of cash flows consistently with the classification of the cash flows from the underlying hedged items that these derivatives are hedging. Derivative instruments that do not qualify for hedge accounting are recognized on the balance sheet at their fair value, with changes in the fair value recognized as a component of financial expenses, net in the statements of income. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.
Revenue recognition	u. Revenue recognition: A contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer, excluding amounts collected on behalf of other third parties and sales taxes. The amount of consideration to which Teva expects to be entitled varies as a result of rebates, chargebacks, returns and other sales reserves and allowances (“SR&A”) that the Company offers to its customers and their customers, as well as the occurrence or nonoccurrence of future events, including milestone events. A minimum amount of variable consideration is recorded by the Company concurrently with the satisfaction of performance obligations to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Estimates of variable consideration are based on historical experience and the specific terms in the individual agreements (which the Company believes approximates expected value). Rebates and chargebacks are the largest components of SR&A. If a minimum cannot be reasonably estimated, such revenue may be deferred to a future period when better information is available. For further description of SR&A components and how they are estimated, see “Variable Consideration” below. Shipping and handling costs, after control of the product has transferred to a customer, are accounted for as a fulfillment cost and are recorded under S&M expenses. Teva does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less, based on the practical expedient. The Company’s credit terms to customers are, on average, between thirty and ninety days. The Company generally recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under S&M expenses. Similarly, Teva does not disclose the value of unsatisfied performance obligations for contracts with original expected duration of one year or less. Nature of revenue streams Revenue from sales of goods, including sales to distributors is recognized when the customer obtains control of the product. This generally occurs when products are shipped once the Company has a present right to payment and legal title, and risk and rewards of ownership are obtained by the customer. Licensing arrangements performance obligations generally include intellectual property (“IP”) rights, certain R&D and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct – i.e. if they are separately identifiable from other items in the arrangement and if the customer can benefit from them on their own or with other resources that are readily available to the customer. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Distribution revenues are derived from sales of third-party products for which the Company acts as distributor, mostly in the United States via Anda and in Israel via Salomon Levin and Elstein Ltd. (SLE). In the United States, the Company is generally the principal in these arrangements and therefore records revenue on a gross basis as it controls the promised goods before transferring these goods to the customer. In Israel, the Company is the agent in these arrangements and therefore records revenue on a net basis as it has no discretion in establishing prices for any specified goods or services, limited inventory risk and is not primarily responsible for contract fulfillment. Revenue is recognized when the customer obtains control of the products. This generally occurs when products are shipped once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Other revenues are primarily comprised of contract manufacturing services, sales of IP rights, sales of medical devices and other miscellaneous items. Revenue is recognized when the customer obtains control of such rights or products. This generally occurs when products are shipped, once the Company has a present right to payment and legal title and risk and rewards of ownership are obtained by the customer. Trade receivables and contract liabilities Trade receivables are presented net of allowance for credit losses, which include amounts billed and currently due from customers. Contract liabilities are mainly comprised of deferred revenues (defined as obligations to provide products or services to customers when payment has been made in advance and delivery or performance has not yet occurred), which were immaterial as of December 31, 2023 and 2022. Variable consideration Variable consideration mainly includes SR&A, comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against trade receivables. The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions. The following describes the nature of each deduction and how provisions are estimated: Rebates Rebates are primarily related to volume incentives and are offered to key customers to promote loyalty. These rebate programs provide that, upon the attainment of pre-established Medicaid and Other Governmental Rebates Pharmaceutical manufacturers whose products are covered by the Medicaid program are required to provide a rebate to each state as a percentage of their average manufacturer’s price for generic products dispensed and “best price” for innovative products dispensed. Many states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. The Company estimates these rebates based on historical trends of rebates paid, as well as on changes in wholesaler inventory levels and increases or decreases in sales. Chargebacks The Company has arrangements with various third parties, such as managed care organizations and drug store chains, establishing prices for certain of Teva’s products. While these arrangements are made between the Company and the customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with Teva’s concurrence, which establish the pricing for certain products which the wholesalers provide. Under either arrangement, Teva will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract prices. Provisions for chargebacks involve estimates of contract prices of over 2,000 products and multiple contracts with multiple wholesalers. Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers. The provision for chargebacks varies in relation to changes in product mix, pricing and the level of inventory at the wholesalers and, therefore, will not necessarily fluctuate in proportion to an increase or decrease in sales. Provisions for estimating chargebacks are calculated using historical chargeback experience and/or expected chargeback levels for new products and anticipated pricing changes. Teva considers current and expected price competition when evaluating the provision for chargebacks. Chargeback provisions are compared to externally obtained distribution channel reports for reasonableness. The Company regularly monitors the provision for chargebacks and makes adjustments when the Company believes that actual chargebacks may differ from estimated provisions. Other Promotional Arrangements Other promotional or incentive arrangements are periodically offered to customers, specifically related to the launch of products or other targeted promotions. Provisions are made in the period for which the Company can estimate the incentive earned by the customer, in accordance with the contractual terms. The Company regularly monitors the provision for other promotional arrangements and makes adjustments when it believes that the actual provision may differ from the estimated provisions. Shelf Stock Adjustments The custom in the pharmaceutical industry is generally to grant customers a shelf stock adjustment based on the customers’ existing inventory contemporaneously with decreases in the market price of the related product. The most significant of these relate to products for which an exclusive or semi-exclusive period exists. Provisions for price reductions depend on future events, including price competition, new competitive launches and the level of customer inventories at the time of the price decline. Teva regularly monitors the competitive factors that influence the pricing of its products and customer inventory levels and adjust these estimates where appropriate. Returns Returns primarily relate to customer returns of expired products which, the customer has the right to return up to one year following the expiration date. Such returned products are destroyed and credits and/or refunds are issued to the customer for the value of the returns. Accordingly, no returned assets are recoded in connection with those products. The returns provision is estimated by applying a historical return rate to the amounts of revenue estimated to be subject to returns. Revenue subject to returns is estimated based on the lag time from time of sale to date of return. The estimated lag time is developed by analyzing historical experience. Additionally, The Company considers specific factors, such as estimated levels of inventory in the distribution channel, product dating and expiration, size and maturity of launch, entrance of new competitors, changes in formularies or packaging and any changes to customer terms, for determining the overall expected levels of returns. Prompt Pay Discounts Prompt pay discounts are offered to most customers to encourage timely payment. Discounts are estimated at the time of invoice based on historical discounts in relation to sales. Prompt pay discounts are almost always utilized by customers. As a result, the actual discounts do not vary significantly from the estimated amount.
Research and development	v. Research and development: Research and development expenses are charged to statement of income (loss) as incurred. Participations and grants in respect of research and development expenses are recognized as a reduction of research and development expenses as the related costs are incurred, or as the related milestone is met. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as an expense as the related goods are used or the services are rendered. Research and development in-process The Company accounts for grants received to perform research and development services in accordance with ASC 730-20,
Shipping and handling costs	w. Shipping and handling costs: Shipping and handling costs to end customers, which are included in S&M expenses, were $124 million, $118 million and $111 million for the years ended December 31, 2023, 2022 and 2021, respectively.
Advertising costs	x. Advertising costs: Advertising costs are expensed as incurred. Advertising costs for the years ended December 31, 2023, 2022 and 2021 were $162 million, $168 million and $246 million, respectively.
Restructuring	y. Restructuring: Restructuring provisions are recognized for the direct expenditures arising from restructuring initiatives, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. Costs for one-time Contractual termination benefits are provided to employees when employment is terminated due to an event specified in the provisions of an existing plan or agreement. A liability is recorded and the expense is recognized when it is probable that employees will be entitled to the benefits and the amount is reasonably estimable. Special termination benefits arise when the Company offers, for a short period of time, to provide certain additional benefits to employees electing voluntary termination. A liability is recorded and the expense is recognized in the period the employees irrevocably accept the offer and the amount of the termination liability is reasonably estimable.
Segment reporting	z. Segment reporting: The Company’s business includes three reporting segments based on three geographical areas: (a) North America segment, which includes the United States and Canada. (b) Europe segment, which includes the European Union, the United Kingdom and certain other European countries. (c) International Markets segment, which includes all countries in which Teva operates other than those in the North America and Europe segments. Each business segment manages the entire product portfolio in its region, including generic products, innovative medicines and over-the-counter In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing
Earnings per share	aa. Earnings per share: Basic earnings (loss) per share are computed by dividing net income (loss) attributable to Teva’s ordinary shareholders by the weighted average number of ordinary shares outstanding, including fully vested RSUs and PSUs during the period, net of treasury shares. In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i) the exercise of options and non-vested “if-converted”
Securitization and factoring	bb. Securitization and factoring Teva accounts for transfers of its trade receivable as sales when it has surrendered control over the related assets in accordance with ASC Topic 860 “Transfer and Servicing” of Financial Assets. Whether control has been relinquished requires, among other things, an evaluation of relevant legal considerations and an assessment of the nature and extent of the Company’s continuing involvement with the assets transferred. Assets obtained and liabilities incurred in connection with transfers reported as sales are initially recognized in the balance sheet at fair value. Refer to note 10f.
Divestitures	cc. Divestitures The Company nets the proceeds on the divestitures of businesses and tangible assets with the carrying amount of the related assets and records gain or loss on sale within other income. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when it is probable that a significant reversal of income will not occur, or in the case of a business, when such payments are realizable. For divestures of businesses, including divestitures of products that qualify as a business, the Company reflects the relative fair value of goodwill associated with the businesses in the determination of gain or loss on sale.
Debt instruments	dd. Debt instruments Debt instruments are initially recognized at the fair value of the consideration received. Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liability. They are subsequently recognized at amortized cost using the effective interest method. Debt may be considered extinguished when it has been modified and the terms of the new debt instruments and old debt instruments are “substantially different” (as defined in the debt modification guidance in ASC 470-50 non-current 470-50
Leases	ee. Leases Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. classifies the lease as an operating lease. When determining lease classification, Teva’s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease ROU assets, other current liabilities and operating lease liabilities in the consolidated balance sheet. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated balance sheet. ROU assets represent Teva’s right to use an underlying asset for the lease term and lease liabilities represent Teva’s obligation to make lease payments arising from the lease. Operating lease ROU and finance lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, which may include options to extend or terminate the lease, when it is reasonably certain at the commencement date whether the Company will or will not exercise the option to renew or terminate the lease. Teva uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. For finance leases, Teva recognizes interest on the lease liability separately from amortization of the assets in the consolidated statement of income. For operating leases, lease expenses are recognized on a straight-line basis over the lease term. Teva elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, Teva does not recognize ROU assets or lease liabilities, but recognizes lease expenses over the lease term on a straight line basis. Teva also elected the practical expedient to not separate lease and non-lease Lease terms will include options to extend or terminate the lease when it is reasonably certain that Teva will either exercise or not exercise the option to renew or terminate the lease. Teva’s lease agreements have remaining lease terms ranging from 1 year to 76 years. Some of these agreements include options to extend the leases for up to 10 years and some include options to terminate the leases immediately. Certain leases also include options to purchase the leased property. The depreciable life of leasehold improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise. Some of Teva’s vehicle lease agreements include rental payments based on the actual usage of the vehicles and other lease agreements include rental payments adjusted periodically for inflation. Teva’s lease agreements do not contain any material residual value guarantees. Teva rents out or subleases certain assets to third parties, which has an immaterial impact on Teva’s consolidated financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet	Consolidated Statements of Income Year ended December 31, 2022 Consolidated Balance Sheets December 31, 2022 Adjustment As Adjustment As U.S $ in millions (except per share U.S $ in millions (except per share Other asset impairments, restructuring and other items $ 414 98 512 Deferred income taxes $ 1,453 5 1,458 Operating income (loss) (2,099 ) (98 ) (2,197 ) Total assets 44,006 5 44,011 Income (loss) before income taxes (3,065 ) (98 ) (3,163 ) Other taxes and long-term liabilities 3,847 98 3,945 Income taxes (benefit) (638 ) (5 ) (643 ) Total long-term liabilities 23,846 98 23,944 Net income (loss) (2,406 ) (93 ) (2,499 ) Total liabilities 35,315 98 35,413 Net income (loss) attributable to Teva (2,353 ) (93 ) (2,446 ) Teva shareholders’ equity: Earnings (loss) per share attributable to ordinary shareholders: Accumulated deficit (12,882 ) (93 ) (12,975 ) Basic $ (2.12 ) (0.08 ) (2.20 ) Total equity 8,691 (93 ) 8,598 Diluted $ (2.12 ) (0.08 ) (2.20 ) Total liabilities and equity $ 44,006 5 44,011

Certain transactions (Tables)

Certain transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Major Classes of Assets and Liabilities Included as Held for Sale	The table below summarizes all of Teva’s assets and liabilities included as held for sale as of December 31, 2023 and December 31, 2022: December 31, December 31, (U.S. $ in millions) Inventories $ 12 $ 2 Property, plant and equipment, net and others 28 18 Goodwill 30 —  Adjustments of assets held for sale to fair value —  (10 ) Total assets of the disposal group classified as held for sale in the consolidated balance sheets $ 70 $ 10 Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under other current liabilities $ (13 ) $ —

Revenue from contracts with c_2

Revenue from contracts with customers (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of disaggregates revenues by major revenue streams	The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19. Year ended December 31, 2023 North Europe International Other Total (U.S.$ in millions) Sale of goods 5,944 4,631 1,840 565 12,979 Licensing arrangements * 601 51 24 5 681 Distribution 1,577 § 38 —  1,615 Other** 2 155 56 357 570 $ 8,124 $ 4,837 $ 1,958 $ 926 $ 15,846 * Revenues from licensing arrangements in North America segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2. ** “Other” revenues in Europe segment mainly related to the sale of certain product rights. § Represents an amount less than $ 0.5 Year ended December 31, 2022 North Europe International Other Total (U.S.$ in millions) Sale of goods 5,834 4,455 1,806 671 12,766 Licensing arrangements 139 51 19 4 212 Distribution 1,471 1 46 —  1,519 Other 8 18 33 370 428 $ 7,452 $ 4,525 $ 1,903 $ 1,045 $ 14,925 Year ended December 31, 2021 North Europe International Other Total (U.S.$ in millions) Sale of goods 6,394 4,807 1,889 739 13,829 Licensing arrangements 92 50 13 4 160 Distribution 1,323 1 65 —  1,390 Other (1) 27 65 408 500 $ 7,809 $ 4,886 $ 2,032 $ 1,151 $ 15,878
Summary of Sales Reserves and Allowances	SR&A to U.S. customers comprised approximately 65% of the Company’s total SR&A as of December 31, 2023, with the remaining balance primarily in Canada and Germany. The changes in SR&A for third-party sales for the years ended December 31, 2023 and 2022 were as follows: Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2023 $ 67 $ 1,575 $ 663 $ 991 $ 455 $ 66 $ 3,750 $ 3,817 Provisions related to sales made in current year period 354 4,015 654 7,579 264 109 12,621 12,975 Provisions related to sales made in prior periods —  (31 ) (33 ) (54 ) 17 —  (101 ) (101 ) Credits and payments (360 ) (3,974 ) (748 ) (7,662 ) (304 ) (77 ) (12,765 ) (13,125 ) Translation differences —  18 4 5 4 (1 ) 30 30 Balance at December 31, 2023 $ 61 $ 1,603 $ 540 $ 859 $ 436 $ 97 $ 3,535 $ 3,596 Sales Reserves and Allowances Reserves Rebates Medicaid and Chargebacks Returns Other Total Total (U.S.$ in millions) Balance at January 1, 2022 $ 68 $ 1,655 $ 854 $ 1,085 $ 535 $ 112 $ 4,241 $ 4,309 Provisions related to sales made in current year period 363 3,823 871 7,819 317 85 12,915 13,278 Provisions related to sales made in prior periods —  (69 ) (35 ) (44 ) (3 ) (51 ) (202 ) (202 ) Credits and payments (364 ) (3,798 ) (1,023 ) (7,861 ) (390 ) (77 ) (13,149 ) (13,513 ) Translation differences —  (36 ) (4 ) (8 ) (4 ) (3 ) (55 ) (55 ) Balance at December 31, 2022 $ 67 $ 1,575 $ 663 $ 991 $ 455 $ 66 $ 3,750 $ 3,817

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Inventories	Inventories, net of reserves, consisted of the following: December 31,  2023   2022  (U.S. $ in millions) Finished products $ 2,346 $ 1,987 Raw and packaging materials 993 1,059 Products in process 500 555 Materials in transit and payments on account 183 232 $ 4,021 $ 3,833

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Property, Plant and Equipment, Net	Property, plant and equipment, net, consisted of the following: December 31, 2023 2022 (U.S. $ in millions) Machinery and equipment $ 4,807 $ 5,026 Buildings 2,488 2,463 Computer equipment and other assets 2,419 2,323 Assets under construction and payments on account 1,427 1,199 Land 246 246 11,387 11,257 Less- accumulated depreciation (5,637 ) (5,518 ) $ 5,750 $ 5,739

Identifiable Intangible Assets

Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Identifiable Intangible Assets	Identifiable intangible assets consisted of the following: Gross carrying Accumulated Net carrying amount December 31,  2023   2022  2023 2022  2023   2022  (U.S. $ in millions) Product rights $ 17,981 $ 18,067 $ 13,274 $ 12,630 $ 4,707 $ 5,437 Trade names 583 577 269 231 314 346 In-process 366 487 —  —  366 487 Total $ 18,930 $ 19,131 $ 13,543 $ 12,861 $ 5,387 $ 6,270

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Changes in the Carrying Amount of Goodwill by Segment	Changes in the carrying amount of goodwill for the years ended December 31, 2023 and 2022 were as follows: Other North Europe International Teva’s API Medis Total (U.S. $ in millions) Balance as of December 31, 2021 (1) $ 6,474 $ 8,544 $ 2,328 $ 2,417 $ 277 $ 20,040 Changes during the period: Goodwill impairment —  —  (979 ) (1,066 ) —  (2,045 ) Goodwill acquired —  —  —  12 —  12 Translation differences (24 ) (242 ) (10 ) (70 ) (28 ) (374 ) Balance as of December 31, 2022 (1) $ 6,450 $ 8,302 $ 1,339 $ 1,293 $ 249 $ 17,633 Changes during the period: Goodwill impairment —  —  (700 ) —  —  (700 ) Goodwill reclassified as assets held for sale —  —  (30 ) —  —  (30 ) Translation differences 9 164 66 20 16 275 Balance as of December 31, 2023 (1) $ 6,459 $ 8,466 $ 675 $ 1,313 $ 265 $ 17,177 (1) Cumulative goodwill impairment as of December 31, 2023, December 31, 2022 and December 31, 2021 was approximately $28.3 billion, $27.6 billion and $25.6 billion respectively.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Components Of Lease Expense	The components of operating lease cost for the years ended December 31, 2023, 2022 and 2021 were as follows: Year ended Year ended Year ended 2023 2022 2021 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Operating lease cost: Fixed payments and variable payments that depend on an index or rate $ 132 $ 142 $ 135 Variable lease payments not included in the lease liability 5 4 4 Short-term lease cost 3 2 2 $ 139 $ 148 $ 141
Supplemental cash flow information related to leases	Supplemental cash flow information related to operating leases was as follows: Year ended Year ended Year ended 2023 2022 2021 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 141 $ 140 $ 143 Right-of-use (non-cash): Operating leases $ 121 $ 81 $ 81
Supplemental Balance Sheet Information Related To Leases	Supplemental balance sheet information related to operating leases was as follows: December 31, December 31, 2023 2022 (U.S. $ in millions) (U.S. $ in millions) Operating leases: Operating lease ROU assets $ 397 $ 419 Other current liabilities 97 93 Operating lease liabilities 320 349 Total operating lease liabilities $ 417 $ 442 December 31, December 31, 2023 2022 Weighted average remaining lease term Operating leases 6.1 years 6.8 years Weighted average discount rate Operating leases 6.0 % 5.6 %
Maturities of lease liabilities	Maturities of operating lease liabilities were as follows: December 31, 2023 (U.S. $ in millions) 2024 $ 116 2025 98 2026 80 2027 62 2028 and thereafter 140 Total operating lease payments $ 496 Less: imputed interest 79 Present value of lease liabilities $ 417

Debt obligations (Tables)

Debt obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Short-term Debt	a. Short-term debt: December 31, Weighted average Maturity 2023 2022 (U.S. $ in millions) Convertible debentures 0.25 % 2026 $ 23 $ 23 Current maturities of long-term liabilities 1,649 2,086 Total short term debt $ 1,672 $ 2,109
Schedule of Senior Notes and Loans	b. Long-term debt: Interest rate as of Maturity December 31, December 31, (U.S. $ in millions) Senior notes EUR 1,500 million 1.13 % 2024 693 670 Sustainability-linked senior notes EUR 1,500 million (6)(*) 4.38 % 2030 1,656 1,606 Senior notes EUR 1,300 million (9) 1.25 % 2023 —  633 Sustainability-linked senior notes EUR 1,100 million (7)(*) 3.75 % 2027 1,215 1,177 Senior notes EUR 1,000 million (5) 6.00 % 2025 453 1,070 Senior notes EUR 900 million (5) 4.50 % 2025 547 963 Sustainability-linked senior notes EUR 800 million (1)(*) 7.38 % 2029 884 —  Senior notes EUR 750 million 1.63 % 2028 826 800 Senior notes EUR 700 million 1.88 % 2027 771 748 Sustainability-linked senior notes EUR 500 million (2)(*) 7.88 % 2031 552 —  Senior notes USD 3,500 million (5) 3.15 % 2026 3,374 3,496 Senior notes USD 3,000 million (5)(10) 2.80 % 2023 —  1,453 Senior notes USD 2,000 million 4.10 % 2046 1,986 1,986 Senior notes USD 1,250 million (5) 6.00 % 2024 956 1,250 Senior notes USD 1,250 million 6.75 % 2028 1,250 1,250 Senior notes USD 1,000 million (5) 7.13 % 2025 427 1,000 Sustainability-linked senior notes USD 1,000 million (7)(*) 4.75 % 2027 1,000 1,000 Sustainability-linked senior notes USD 1,000 million (6)(*) 5.13 % 2029 1,000 1,000 Senior notes USD 789 million 6.15 % 2036 783 783 Sustainability-linked senior notes USD 600 million (3)(*) 7.88 % 2029 600 —  Sustainability-linked senior notes USD 500 million (4)(*) 8.13 % 2031 500 —  Senior notes CHF 350 million 1.00 % 2025 416 382 Total senior notes 19,889 21,266 Other long-term debt 1 1 Less current maturities (1,649 ) (2,086 ) Less debt issuance costs (8) (80 ) (78 ) Total senior notes and loans $ 18,161 $ 19,103 (1) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (2) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500 million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (3) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (4) In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% (5) In March 2023, Teva consummated a cash tender offer and extinguished $631 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $574 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $454 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026. (6) If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% (7) If Teva fails to achieve certain sustainability performance targets, a one-time 0.15%-0.45% (8) Debt issuance costs as of December 31, 2023 include $26 million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6 million acceleration of issuance costs related to the cash tender offer. (9) In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity. (10) In July 2023, Teva repaid $1,000 million of its 2.8% senior notes at maturity. * Interest rate adjustments and a potential one-time
Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost	As of December 31, 2023, the required annual principal payments of long-term debt (excluding debt issuance costs), including convertible senior debentures, starting from the year 2025, are as follows: December 31, (U.S. $ in millions) 2025 $ 1,843 2026* 3,397 2027 2,986 2028 2,076 2029 and thereafter 7,961 $ 18,263 * Including $23 million convertible notes. See note 9a.

Derivative instruments and he_2

Derivative instruments and hedging activities (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Notional Amounts for Hedged Items	The following table summarizes the notional amounts for hedged items, when transactions are designated as hedge accounting: December 31, 2023 December 31, 2022 (U.S. $ in millions) Cross-currency swap-cash flow hedge (1) $ 169 $ —
Summary of Classification and Fair Values of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments: Fair value Designated as hedging Not designated as hedging instruments December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Reported under (U.S. $ in millions) (U.S. $ in millions) Asset derivatives: Other current assets: Option and forward contracts $ —  $ —  $ 38 $ 29 Other non-current Cross-currency swaps - cash flow hedge (1) 8 —  —  —  Liability derivatives: Other current liabilities: Option and forward contracts $ —  $ —  $ (39 ) $ (101 )
Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships	The table below provides information regarding the location and amount of pre-tax Reported under Financial expenses, net Other comprehensive income (loss) Year ended December 31, Year ended December 31,  2023   2022   2021   2023   2022   2021  (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,057 $ 966 $ 1,058 $ 91 $ (270 ) $ (391 ) Cross-currency swaps - cash flow hedge (1) (11 ) —  —  1 —  —
Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments	The table below provides information regarding the location and amount of pre-tax Reported under Financial expenses, net Net revenues Year ended December 31, Year ended December 31,  2023   2022   2021   2023   2022   2021  (U.S. $ in millions) Line items in which effects of hedges are recorded $ 1,057 $ 966 $ 1,058 $ (15,846 ) $ (14,925 ) $ (15,878 ) Option and forward contracts (2) (54 ) (12 ) (45 ) —  —  —  Option and forward contracts economic hedge (3) —  —  —  2 (11 ) (31 )
Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program	The following table summarizes the change in the sold receivables outstanding balance, net of DPP, under the outstanding securitization program: As of and for the year ended  2023   2022  (U.S. $ in millions) Sold receivables at the beginning of the year $ 636 $ 685 Proceeds from sale of receivables 4,391 4,653 Cash collections (remitted to the owner of the receivables) (4,365 ) (4,665 ) Effect of currency exchange rate changes 24 (37 ) Sold receivables at the end of the year $ 686 $ 636

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Income Before Income Taxes	a. Income (loss) before income taxes: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Parent Company and its Israeli subsidiaries $ (767 ) $ (119 ) $ 126 Non-Israeli 143 (3,044 ) 532 $ (624 ) $ (3,163 ) $ 658
Schedule of the Provision for Income Taxes	b. Income taxes: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) In Israel $ (402 ) $ 33 $ 124 Outside Israel 395 (676 ) 87 $ (7 ) $ (643 ) $ 211 Current $ 333 $ 430 $ 270 Deferred (340 ) (1,073 ) (59 ) $ (7 ) $ (643 ) $ 211
Accumulated Other Comprehensive Income/(Loss) (Net of Tax)	2023 2022 2021 (U.S. $ in millions) Income (loss) before income taxes (***) $ (624 ) $ (3,163 ) $ 658 Statutory tax rate in Israel 23 % 23 % 23 % Theoretical provision for income taxes (***) $ (144 ) $ (727 ) $ 151 Increase (decrease) in the provision for income taxes due to: The Parent Company and its Israeli subsidiaries - Tax benefits arising from net deferred taxes, resulting from intellectual property related integration plans, including carryforward losses (272) —  —  Tax benefits arising from reduced tax rates under benefit programs 14 15 (12) Mainly nondeductible items and prior year tax —  35 20 Non-Israeli 372 941 117 Worthless stock deduction (**) —  (909) —  Increase (decrease) in other uncertain tax positions - net 23 2 (65) Effective consolidated income taxes (***) $ (7) $ (643) $ 211 * In 2023 and 2022, income before income taxes includes goodwill impairment in non-Israeli ** In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million. *** The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.
Schedule of Deferred Income Taxes	c. Deferred income taxes: December 31, 2023 2022 (U.S. $ in millions) Deferred tax assets (liabilities), net: Inventory related $ 76 $ 125 Sales reserves and allowances 81 89 Provision for legal settlements 702 703 Intangible assets (*) (118 ) (567 ) Carryforward losses and deductions and credits (**) 2,463 2,850 Property, plant and equipment (225 ) (238 ) Deferred interest 799 800 Provisions for employee related obligations 80 82 Other (***) 357 138 4,215 3,982 Valuation allowance—in respect of carryforward losses and deductions that may not be utilized (3,009 ) (3,072 ) $ 1,206 $ 910 (*) The increase in deferred tax is mainly due to intellectual property related integration. (**) The amounts are shown following a reduction for unrecognized tax benefits of $2 million and $1 million as of December 31, 2023 and 2022, respectively. (***) The amounts shown are primarily comprised of Capitalization of R&D Expenses. Other deferred income taxes presented in the table above as of December 31, 2022, have been revised as discussed in note 1b.
Schedule of Deferred Tax Assets and Liabilities By Report Caption	The deferred income taxes are reflected in the balance sheets among: December 31, 2023 2022 (U.S. $ in millions) Long-term assets—deferred income taxes (*) 1,812 1,458 Long-term liabilities—deferred income taxes (606 ) (548 ) $ 1,206 $ 910 (*) Long-term assets—deferred income taxes presented in the tables above as of December 31, 2022, have been revised as discussed in note 1b.
Schedule of Unrecognized Tax Benefits	d. Uncertain tax positions: The following table summarizes the activity of Teva’s gross unrecognized tax benefits: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Balance at the beginning of the year $ 638 $ 672 $ 888 Increase (decrease) related to prior year tax positions, net (1 ) (46 ) (106 ) Increase related to current year tax positions 15 42 7 Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations (15 ) (31 ) (115 ) Other 14 1 (2 ) Balance at the end of the year $ 651 $ 638 $ 672

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Stock Option Activity	A summary of the status of the options granted by Teva as of December 31, 2023, 2022 and 2021, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof). Year ended December 31, 2023 2022 2021 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 24,119 $ 36.83 29,015 $ 36.96 35,234 $ 37.27 Changes during the year: Forfeited (885 ) 34.65 (2,378 ) 33.77 (3,644 ) 36.09 Expired (531 ) 37.57 (2,518 ) 41.26 (2,575 ) 42.40 Balance outstanding at end of year 22,703 36.89 24,119 36.83 29,015 36.96 Balance exercisable at end of year 22,703 36.89 24,119 36.83 26,989 38.30 No options were
Schedule of Ordinary Shares Issued Upon Vested Options	The following table summarizes information as of December 31, 2023 regarding the number of ordinary shares issuable upon vested options: Number of ordinary shares issuable upon exercise of vested options Range of exercise prices Balance at end of Weighted average Weighted average Number of shares $ Years Lower than $15.01 592 11.40 3.84 $15.01 - $25.00 7,374 18.95 4.14 $25.01 - $35.00 5,470 34.66 3.17 $35.01 - $45.00 61 37.97 2.78 $45.01 - $55.00 5,707 51.26 1.36 $55.01 - $65.00 3,500 59.04 1.34 Total 22,703 36.89 2.76
Schedule of the Number of RSUs Issued and Outstanding	The following table summarizes information about the number of RSUs and PSUs granted and outstanding: Year ended December 31, 2023 2022 2021 Number (in thousands) Weighted Number (in thousands) Weighted Number (in thousands) Weighted Balance outstanding at beginning of year 32,302 $ 9.11 24,412 $ 11.58 20,720 $ 13.81 Granted 16,608 9.77 18,755 7.42 12,748 10.42 Vested (10,195 ) 10.28 (7,571 ) 13.02 (6,818 ) 15.60 Forfeited (3,052 ) 9.81 (3,293 ) 9.81 (2,238 ) 12.18 Balance outstanding at end of year 35,664 9.07 32,302 9.11 24,412 11.58
Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value	The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2023, 2022 and 2021, the Company recorded stock-based compensation costs as follows: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Employee stock options $ —  $ 2 $ 16 RSUs and PSUs 121 122 103 Total stock-based compensation expense 121 124 119 Tax effect on stock-based compensation expense 11 9 12 Net effect $ 110 $ 115 $ 107
Accumulated Other Comprehensive Income/(Loss) (Net of Tax)	The components of accumulated other comprehensive loss attributable to Teva are presented in the table below: Net Unrealized Gains/(Losses) Benefit Plans Foreign Derivative Actuarial Total (U.S. $ in millions) Balance as of January 1, 2021 $ (1,919 ) (363 ) (117 ) (2,399 ) Other comprehensive income/(loss) before reclassifications (386 ) —  18 (368 ) Amounts reclassified to the statements of income —  39 18 57 Net other comprehensive income/(loss) before tax (386 ) 39 36 (311 ) Corresponding income tax 31 —  (4 ) 27 Net other comprehensive income/(loss) after tax* (355 ) 39 32 (284 ) Balance as of December 31, 2021 (2,274 ) (324 ) (85 ) (2,683 ) Other comprehensive income/(loss) before reclassifications (223 ) —  40 (183 ) Amounts reclassified to the statements of income —  29 27 56 Net other comprehensive income/(loss) before tax (223 ) 29 67 (127 ) Corresponding income tax (17 ) —  (10 ) (27 ) Net other comprehensive income/(loss) after tax* (240 ) 29 57 (154 ) Balance as of December 31, 2022 (2,514 ) (295 ) (28 ) (2,838 ) Other comprehensive income/(loss) before reclassifications 167 (1 ) (17 ) 149 Amounts reclassified to the statements of income —  30 (4 ) 26 Net other comprehensive income/(loss) before tax 167 29 (21 ) 175 Corresponding income tax (37 ) —  3 (34 ) Net other comprehensive income/(loss) after tax* 130 29 (18 ) 141 Balance as of December 31, 2023 $ (2,384 ) $ (266 ) $ (46 ) $ (2,697 ) * Amounts do not include foreign currency translation adjustments attributable to non-controlling

Other assets impairments, res_2

Other assets impairments, restructuring and other items (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Other Assets Impairments, Restructuring and Other Items	Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Impairment (1) $ 28 $ 47 $ 160 Contingent consideration (see note 20) (2) 548 261 7 Restructuring 111 146 133 Other 30 57 41 Total $ 718 $ 512 $ 341 (1) Including impairments related to exit and disposal activities. (2) The contingent consideration presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.
Summary of Restructuring Plan Including Costs Related to Exit and Disposal	The following table provides the components of restructuring costs: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Restructuring Employee termination $ 52 $ 117 $ 117 Other 59 29 16 Total $ 111 $ 146 $ 133
Summary of Restructuring Accruals	The following table provides the components of and changes in the Company’s restructuring accruals: Employee Other Total (U.S. $ in millions ) Balance as of January 1, 2021 $ (115 ) $ (7 ) $ (122 ) Provision (117 ) (16 ) (133 ) Utilization and other* 101 16 117 Balance as of December 31, 2021 $ (131 ) $ (7 ) $ (138 ) Provision (117 ) (29 ) (146 ) Utilization and other* 136 29 165 Balance as of December 31, 2022 $ (112 ) $ (7 ) $ (119 ) Provision (52 ) (59 ) (111 ) Utilization and other* 90 59 149 Balance as of December 31, 2023 $ (75 ) $ (7 ) $ (82 ) * Includes adjustments for foreign currency translation.

Other income (Tables)

Other income (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Other Income	Year ended 2023 2022 2021 (U.S. $ in millions) Gain on divestitures, net of divestitures related costs (1) $ 3 $ 46 $ 51 Section 8 and similar payments 5 13 19 Gain (loss) on sale of assets (2) 25 18 7 Other, net (3) 16 31 22 Total other income $ 49 $ 107 $ 98 (1) In 2022 mainly related to the divestment of several activities in North America and International Markets. In 2021, mainly due to capital gains related to the sale of certain OTC assets. (2) In 2023 mainly related to the divestment of assets in International Markets. (3) In 2022 mainly the result of settlement proceeds related to the International Markets segment.

Financial expenses, net (Tables

Financial expenses, net (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Financial Expenses	Year ended December, 31 2023 2022 2021 (U.S. $ in millions) Interest expenses and other bank charges $ 1,029 $ 930 $ 891 (Income) loss from investments (1) (68 ) (10 ) 90 Foreign exchange (gains) losses, net 30 (16 ) 7 Other, net (2) 66 61 71 Total finance expense, net $ 1,057 $ 966 $ 1,058 (1) Loss from investments in 2021 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”). (2) Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Earnings per Share	The net income (loss) attributable to Teva and the weighted average number of ordinary shares used in the computation of basic and diluted earnings (loss) per share for the years ended December 31, 2023, 2022 and 2021 are as follows: Year ended December, 31 2023 2022 2021 (U.S. $ in millions, except share data) Net income (loss) used for the computation of basic and diluted earnings (loss) per share* $ (559 ) $ (2,446 ) $ 417 Weighted average number of shares used in the computation of basic earnings (loss) per share 1,119 1,110 1,102 Weighted average number of shares used in the computation of diluted earnings (loss) per share 1,119 1,110 1,107 * Net income (loss) presented in the table above for the year ended December 31, 2022 has been revised as discussed in note 1b.

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Segment Profit	Year ended December 31, 2023 North America Europe International Markets (U.S. $ in millions) Revenues $ 8,124 $ 4,837 $ 1,958 Gross profit 4,421 2,726 1,050 R&D expenses 625 220 83 S&M expenses 1,005 767 420 G&A expenses 403 263 118 Other income (8 ) (2 ) (35 ) Segment profit $ 2,396 $ 1,478 $ 464 Year ended December 31, 2022 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,452 $ 4,525 $ 1,903 Gross profit 3,926 2,700 1,033 R&D expenses 532 213 72 S&M expenses 941 748 405 G&A expenses 474 246 119 Other income (15 ) (3 ) (43 ) Segment profit $ 1,993 $ 1,496 $ 479 Year ended December 31, 2021 North America Europe International Markets (U.S. $ in millions) Revenues $ 7,809 $ 4,886 $ 2,032 Gross profit 4,226 2,823 1,118 R&D expenses 618 244 68 S&M expenses 988 846 417 G&A expenses 427 244 109 Other income (31 ) (5 ) (5 ) Segment profit $ 2,224 $ 1,494 $ 529 Year ended December 31, 2023 2022 2021 (U.S. $ in millions) North America profit $ 2,396 $ 1,993 $ 2,224 Europe profit 1,478 1,496 1,494 International Markets profit 464 479 529 Total reportable segments profit 4,338 3,968 4,246 Profit of other activities 24 172 154 Total segments profit 4,361 4,139 4,401 Amounts not allocated to segments: Amortization 616 732 802 Other asset impairments, restructuring and other items (1) 718 512 341 Goodwill impairment 700 2,045 —  Intangible assets impairments 350 355 424 Legal settlements and loss contingencies 1,043 2,082 717 Other unallocated amounts 502 610 402 Consolidated operating income (loss) (1) 433 (2,197 ) 1,716 Financial expenses, net 1,057 966 1,058 Consolidated income (loss) before income taxes (1) $ (624 ) $ (3,163 ) $ 658 (1) The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.
Schedule of Net Sales by Product Line	The following tables present revenues by major products and activities for each segment for the year ended December 31, 2023, 2022 and 2021: North America segment: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Generic products $ 3,475 $ 3,549 $ 3,769 AJOVY 230 218 176 AUSTEDO 1,225 963 802 BENDEKA and TREANDA 241 316 385 COPAXONE 320 387 577 Anda 1,577 1,471 1,323 Other* 1,056 549 777 Total $ 8,124 $ 7,452 $ 7,809 * Other revenues were mainly comprised of a $ 500 Europe segment: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Generic products $ 3,664 $ 3,466 $ 3,569 AJOVY 160 124 87 COPAXONE 231 268 391 Respiratory products 265 273 356 Other* 516 393 483 Total $ 4,837 $ 4,525 $ 4,886 * Other revenues in 2023 were mainly related to the sale of certain product rights. International Markets segment: Year ended December 31, 2023 2022 2021 (U.S. $ in millions) Generic products $ 1,594 $ 1,586 $ 1,649 AJOVY 44 35 50 COPAXONE 39 36 37 Other 281 246 295 Total $ 1,958 $ 1,903 $ 2,032
Schedule of Sales Percentage by Therapeutic Category	The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2023, 2022 and 2021. Percentage of Third Party Net Sales 2023 2022 2021 McKesson Corporation 9 % 10 % 11 % AmerisourceBergen Corporation 9 % 10 % 11 %
Schedule of Property, Plant and Equipment by Geographic Location	December 31, 2023 2022 (U.S. $ in millions) Israel $ 1,312 $ 1,401 Germany 1,318 1,143 United States 596 625 Croatia 447 445 Czech republic 309 318 Hungary 279 294 Ireland 266 268 Other 1,222 1,245 Total property, plant and equipment $ 5,750 $ 5,739

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Financial Items Carried at Fair Value	Financial items carried at fair value as of December 31, 2023 and 2022 are classified in the tables below in one of the three categories described in note 1g: December 31, 2023 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 1,704 —  —  $ 1,704 Cash, deposits and other 1,522 —  —  1,522 Investment in securities: Investment in convertible bond security —  —  40 40 Equity securities 7 —  —  7 Other 1 —  —  1 Restricted cash 1 —  —  1 Derivatives: Asset derivatives Options and forward contracts —  38 —  38 Cross-currency interest rate swap —  8 —  8 Liabilities derivatives —  Options and forward contracts —  (39 ) —  (39 ) Bifurcated embedded derivatives —  —  § —  Contingent consideration* —  —  (517 ) (517 ) Total $ 3,235 $ 7 $ (477 ) $ 2,765 December 31, 2022 Level 1 Level 2 Level 3 Total (U.S. $ in millions) Cash and cash equivalents: Money markets $ 1,222 —  —  $ 1,222 Cash, deposits and other 1,579 —  —  1,579 Investment in securities: Equity securities 9 —  —  9 Other 5 —  1 6 Restricted cash 33 —  —  33 Derivatives: Asset derivatives: Options and forward contracts —  29 —  29 Liability derivatives: Options and forward contracts (101 ) (101 ) Bifurcated embedded derivatives —  —  § —  Contingent consideration* —  —  (251 ) (251 ) Total $ 2,848 $ (73 ) $ (250 ) $ 2,525 § Represents an amount less than $0.5 million. * Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. The contingent consideration liability is recorded under accrued expenses and other taxes and long-term liabilities. The financial data presented in the tables above as of December 31, 2022 have been revised as discussed in note 1b.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs	The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs. December 31, December 31, (U.S. $ in millions) Fair value at the beginning of the period $ (250 ) $ (175 ) Investment in convertible bond ** 40 —  Bifurcated embedded derivatives § § Additional contingent consideration resulting from Novetide acquisition* —  (11 ) Adjustments to provisions for contingent consideration: Allergan transaction*** (422 ) (240 ) Eagle transaction (132 ) (21 ) Novetide transaction 2 —  Settlement of contingent consideration: Allergan transaction 207 109 Eagle transaction 76 88 Novetide transaction 2 —  Fair value at the end of the period $ (477 ) $ (250 ) § Represents an amount less than $ 0.5 * In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies.” This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net,” reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition. ** On September 29, 2023, Teva invested $40 million in subordinated convertible bonds, which were issued by Alvotech, pursuant to a convertible bond instrument dated December 20, 2022. (see note 2). *** The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan in 2022 have been revised as discussed in note 1b.
Summary of Financial Instrument Measured on a Basis Other Than Fair Value	Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value: Estimated fair value* December 31, 2023 2022 (U.S. $ in millions) Senior notes and sustainability-linked senior notes included under senior notes and loans $ 17,214 $ 16,694 Senior notes and convertible senior debentures included under short-term debt 1,651 2,075 Total $ 18,865 $ 18,769 * The fair value was estimated based on quoted market prices.

Long-term Employee-related Ob_2

Long-term Employee-related Obligations (Tables)	12 Months Ended
	Dec. 31, 2023
Schedule of Long Term Employee Related Obligation	December 31,  2023   2022  (U.S. $ in millions) Accrued severance obligations $ 74 $ 74 Defined benefit plans 73 58 Total $ 148 $ 132

Quarterly Financial Data (Una_2

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Company's Revised Unaudited Quarterly Financial Information	The following tables, which present unaudited quarterly financial data for 2023 and 2022, reflect such revision: Three months ended December 31, September 30, June 30, March 31, U.S $ in millions (except per share amounts) Net revenues $ 4,457 3,850 3,878 3,661 Gross profit 2,416 1,851 1,796 1,582 Net income (loss)* 465 78 (905 ) (253 ) Net income (loss) attributable to Teva* 461 70 (871 ) (220 ) Earnings (loss) per share attributable to ordinary shareholders: Basic* $ 0.41 0.06 (0.78 ) (0.20 ) Diluted* $ 0.41 0.06 (0.78 ) (0.20 ) Three months ended December 31, September 30, June 30, March 31, U.S $ in millions (except per share amounts) Net revenues $ 3,884 3,595 3,786 3,661 Gross profit 1,770 1,669 1,794 1,740 Net income (loss)* (1,333 ) 63 (278 ) (952 ) Net income (loss) attributable to Teva* (1,301 ) 61 (251 ) (955 ) Earnings (loss) per share attributable to ordinary shareholders: Basic* $ (1.17 ) 0.05 (0.23 ) (0.86 ) Diluted* $ (1.17 ) 0.05 (0.23 ) (0.86 ) * The data presented for the above quarterly periods (except for the three months ended March 31, 2022 and the three months ended December 31, 2023) have been revised to reflect a revision of the line items in the consolidated financial statements. See tables below and note 1b.
Summary of Restatement of Certain Line Items in the Income Statement	The tables below present the impact of the revision on the line items within the Company’s unaudited quarterly financial data for 2023 and 2022: Consolidated Statements of Income (loss) Three months ended September 30, 2023 June 30, 2023 March 31, 2023 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Other asset impairments, restructuring and other items $ 46 11 57 $ 100 8 108 $ 96 15 110 Operating income (loss) 355 (11 ) 344 (646 ) (8 ) (654 ) 2 (15 ) (13 ) Income (loss) before income taxes 75 (11 ) 64 (914 ) (8 ) (923 ) (258 ) (15 ) (272 ) Income taxes (benefit) (12 ) § (12 ) (16 ) § (16 ) (19 ) § (19 ) Net income (loss) 88 (11 ) 78 (898 ) (8 ) (905 ) (238 ) (15 ) (253 ) Net income (loss) attributable to Teva 80 (11 ) 70 (863 ) (8 ) (871 ) (205 ) (15 ) (220 ) Earnings per share attributable to ordinary shareholders: Basic $ 0.07 (0.01 ) 0.06 $ (0.77 ) (0.01 ) (0.78 ) $ (0.18 ) (0.02 ) (0.20 ) Diluted $ 0.07 (0.01 ) 0.06 $ (0.77 ) (0.01 ) (0.78 ) $ (0.18 ) (0.02 ) (0.20 ) § Represents an amount less than $0.5 million. Three months ended December 31, 2022 September 30, 2022 June 30, 2022 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Other asset impairments, restructuring and other items $ 132 85 217 $ 36 (5 ) 31 $ 118 18 137 Operating income (loss) (855 ) (85 ) (940 ) 419 5 424 (949 ) (18 ) (967 ) Income (loss) before income taxes (1,100 ) (85 ) (1,185 ) 166 5 171 (1,160 ) (18 ) (1,178 ) Income taxes (benefit) 154 (5 ) 149 107 § 107 (900 ) § (900 ) Net income (loss) (1,254 ) (80 ) (1,333 ) 58 5 63 (259 ) (18 ) (278 ) Net income (loss) attributable to Teva (1,221 ) (80 ) (1,301 ) 56 5 61 (232 ) (18 ) (251 ) Basic $ (1.10 ) (0.07 ) (1.17 ) $ 0.05 —  0.05 $ (0.21 ) (0.02 ) (0.23 ) Diluted $ (1.10 ) (0.07 ) (1.17 ) $ 0.05 —  0.05 $ (0.21 ) (0.02 ) (0.23 ) § Represents an amount less than $0.5 million.
Summary of Restatement of Certain Line Items in the Balance Sheets	Consolidated Balance Sheets September 30, 2023 June 30, 2023 March 31, 2023 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Deferred income taxes $ 1,748 7 1,755 $ 1,578 5 1,583 $ 1,572 5 1,577 Total assets 42,088 7 42,095 43,095 5 43,100 43,456 5 43,461 Other taxes and long-term liabilities 3,818 132 3,950 3,973 121 4,094 3,869 113 3,982 Total long-term liabilities 23,182 132 23,314 23,543 121 23,664 24,433 113 24,546 Total liabilities 34,576 132 34,708 35,387 121 35,508 34,844 113 34,957 Teva shareholders’ equity: Accumulated deficit (13,870 ) (125 ) (13,995 ) (13,950 ) (116 ) (14,066 ) (13,086 ) (108 ) (13,194 ) Total equity 7,512 (125 ) 7,387 7,708 (116 ) 7,592 8,612 (108 ) 8,504 Total liabilities and equity $ 42,088 7 42,095 $ 43,095 5 43,100 $ 43,456 5 43,461 December 31, 2022 September 30, 2022 June 30, 2022 As Adjustment As As Adjustment As As Adjustment As U.S $ in millions (except per share amounts) Deferred income taxes $ 1,453 5 1,458 $ 1,546 § 1,546 $ 1,595 § 1,595 Total assets 44,006 5 44,011 44,252 § 44,252 45,932 § 45,932 Other taxes and long-term liabilities 3,847 98 3,945 3,846 13 3,859 3,842 18 3,860 Total long-term liabilities 23,846 98 23,944 23,200 13 23,213 25,107 18 25,125 Total liabilities 35,315 98 35,413 34,734 13 34,747 36,103 18 36,121 Accumulated deficit (12,882 ) (93 ) (12,975 ) (11,660 ) (13 ) (11,673 ) (11,716 ) (18 ) (11,734 ) Total equity 8,691 (93 ) 8,598 9,519 (13 ) 9,506 9,828 (18 ) 9,810 Total liabilities and equity $ 44,006 5 44,011 $ 44,252 —  44,252 $ 45,932 —  45,932 § Represents an amount less than $0.5 million.

Significant Accounting Polici_4

Significant Accounting Policies - Additional information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022		Dec. 31, 2021
Significant Accounting Policies [Line Items]
Percentage of consolidated sales in North America	51%
Shipping and handling costs, which are included in selling and marketing expenses	$ 124	$ 118		$ 111
Advertising expense	$ 162	168		$ 246
Operating lease description	Teva determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, Teva classifies the lease as a finance lease. Otherwise, Teva classifies the lease as an operating lease. When determining lease classification, Teva’s approach in assessing two of the mentioned criteria is: (i) generally, 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally, 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.
Business combination contingent consideration	$ 517	251	[1]
Restatement adjustment [Member]
Significant Accounting Policies [Line Items]
Contingent consideration related expenses	34	$ 98
Business combination contingent consideration	$ 132
Building [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	40 years
Other Machinery and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	20 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Operating Lease Remaining Lease Term	1 year
Minimum [Member] | Other Capitalized Property Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	5 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Operating Lease Remaining Lease Term	76 years
Maximum [Member] | Other Capitalized Property Plant and Equipment [Member]
Significant Accounting Policies [Line Items]
Property plant and equipment useful life	10 years
[1]Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. The contingent consideration liability is recorded under accrued expenses and other taxes and long-term liabilities. The financial data presented in the tables above as of December 31, 2022 have been revised as discussed in note 1b.

Significant Accounting Polici_5

Significant Accounting Policies - Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other asset impairments, restructuring and other items	$ 57	$ 108	$ 110	$ 217	$ 31	$ 137	$ 718	[1]	$ 512	[1]	$ 341	[1]
Operating income (loss)	344	(654)	(13)	(940)	424	(967)	433	[1]	(2,197)	[1]	1,716	[1]
Income (loss) before income taxes	64	(923)	(272)	(1,185)	171	(1,178)	(624)	[1],[2]	(3,163)	[1],[2]	658	[1],[2]
Income taxes (benefit)	(12)	(16)	(19)	149	107	(900)	(7)	[2]	(643)	[2]	211	[2]
Net income (loss)	78	(905)	(253)	(1,333)	63	(278)	(615)		(2,499)		456
Net income (loss) attributable to Teva	$ 70	$ (871)	$ (220)	$ (1,301)	$ 61	$ (251)	$ (559)		$ (2,446)		$ 417
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.5)		$ (2.2)		$ 0.38
Diluted	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.5)		$ (2.2)		$ 0.38
Deferred income taxes	$ 1,755	$ 1,583	$ 1,577	$ 1,458	$ 1,546	$ 1,595	$ 1,812		$ 1,458
Total assets	42,095	43,100	43,461	44,011	44,252	45,932	43,479		44,011
Other taxes and long-term liabilities	3,950	4,094	3,982	3,945	3,859	3,860	4,019		3,945
Total long-term liabilities	23,314	23,664	24,546	23,944	23,213	25,125	23,106		23,944
Total liabilities	34,708	35,508	34,957	35,413	34,747	36,121	35,353		35,413
Teva shareholders' equity:
Accumulated deficit	(13,995)	(14,066)	(13,194)	(12,975)	(11,673)	(11,734)	(13,534)		(12,975)
Total equity	7,387	7,592	8,504	8,598	9,506	9,810	8,126		8,598		$ 11,244		$ 11,061
Total liabilities and equity	42,095	43,100	43,461	44,011	44,252	45,932	$ 43,479		44,011
As previously reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other asset impairments, restructuring and other items	46	100	96	132	36	118			414
Operating income (loss)	355	(646)	2	(855)	419	(949)			(2,099)
Income (loss) before income taxes	75	(914)	(258)	(1,100)	166	(1,160)			(3,065)
Income taxes (benefit)	(12)	(16)	(19)	154	107	(900)			(638)
Net income (loss)	88	(898)	(238)	(1,254)	58	(259)			(2,406)
Net income (loss) attributable to Teva	$ 80	$ (863)	$ (205)	$ (1,221)	$ 56	$ (232)			$ (2,353)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ 0.07	$ (0.77)	$ (0.18)	$ (1.1)	$ 0.05	$ (0.21)			$ (2.12)
Diluted	$ 0.07	$ (0.77)	$ (0.18)	$ (1.1)	$ 0.05	$ (0.21)			$ (2.12)
Deferred income taxes	$ 1,748	$ 1,578	$ 1,572	$ 1,453	$ 1,546	$ 1,595			$ 1,453
Total assets	42,088	43,095	43,456	44,006	44,252	45,932			44,006
Other taxes and long-term liabilities	3,818	3,973	3,869	3,847	3,846	3,842			3,847
Total long-term liabilities	23,182	23,543	24,433	23,846	23,200	25,107			23,846
Total liabilities	34,576	35,387	34,844	35,315	34,734	36,103			35,315
Teva shareholders' equity:
Accumulated deficit	(13,870)	(13,950)	(13,086)	(12,882)	(11,660)	(11,716)			(12,882)
Total equity	7,512	7,708	8,612	8,691	9,519	9,828			8,691
Total liabilities and equity	42,088	43,095	43,456	44,006	44,252	45,932			44,006
Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other asset impairments, restructuring and other items	11	8	15	85	(5)	18			98
Operating income (loss)	(11)	(8)	(15)	(85)	5	(18)			(98)
Income (loss) before income taxes	(11)	(8)	(15)	(85)	5	(18)			(98)
Income taxes (benefit)				(5)					(5)
Net income (loss)	(11)	(8)	(15)	(80)	5	(18)			(93)
Net income (loss) attributable to Teva	$ (11)	$ (8)	$ (15)	$ (80)	$ 5	$ (18)			$ (93)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.07)	$ 0	$ (0.02)			$ (0.08)
Diluted	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.07)	$ 0	$ (0.02)			$ (0.08)
Deferred income taxes	$ 7	$ 5	$ 5	$ 5					$ 5
Total assets	7	5	5	5					5
Other taxes and long-term liabilities	132	121	113	98	$ 13	$ 18			98
Total long-term liabilities	132	121	113	98	13	18			98
Total liabilities	132	121	113	98	13	18			98
Teva shareholders' equity:
Accumulated deficit	(125)	(116)	(108)	(93)	(13)	(18)			(93)
Total equity	(125)	(116)	(108)	(93)	(13)	(18)			(93)
Total liabilities and equity	$ 7	$ 5	$ 5	$ 5	$ 0	$ 0			$ 5
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Certain Transactions - Other Tr

Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions

1 Months Ended

3 Months Ended

12 Months Ended

Nov. 26, 2023

Nov. 09, 2023

Jun. 12, 2023

May 12, 2017

Oct. 31, 2021

Aug. 31, 2021

Dec. 31, 2016

Dec. 31, 2023

Sep. 30, 2022

Jun. 30, 2022

Dec. 31, 2021

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2023

Oct. 03, 2023

Sanofi [Member] | Collaborative Arrangement [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 500

Milestone payment receivable

$ 500

Development and launch milestone payment receivable

$ 1,000

Johnson And Johnson [Member] | Settlement And License Agreement Alvotech And Teva [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Maximum entry date for granting license entry

Feb. 21, 2025

Biolojic Design Ltd [Member] | Collaborative Arrangement [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Additional development and milestone payments receivable

$ 500

500

Biolojic Design Ltd [Member] | Research and Development Expense [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Milestone payment

$ 10

Royalty Pharma [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Collaborative agreement milestone payments

$ 100

Collaborative agreement milestone amount increase

$ 125

Royalty Pharma [Member] | Research and Development Expense [Member] | Collaborative Arrangement [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Reimbursement of research and development expenses incurred

$ 35

Otsuka [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 50

Milestone payment

$ 35

$ 15

Takeda [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Upfront payment

$ 30

Milestone payment

20

$ 25

Collaborative agreement milestone payments

$ 519

Alvotech [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Collaborative agreement milestone payments

$ 400

MedinCell [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Milestone payment

$ 3

Collaborative agreement milestone payments

$ 105

MODAG [Member]

Noncash or Part Noncash Acquisitions [Line Items]

License agreement potential aggregate milestone payments amount

$ 30

MODAG [Member] | Research and Development Expense [Member]

Noncash or Part Noncash Acquisitions [Line Items]

Milestone payment

$ 10

Certain Transactions - Business

Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Business Combinations [Abstract]
Inventories	$ 12	$ 2
Property, plant and equipment, net and others	28	18
Goodwill	30	0
Adjustments of assets held for sale to fair value	0	(10)
Total assets of the disposal group classified as held for sale in the consolidated balance sheet	70	10
Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets, recorded under other current liabilities	$ (13)	$ 0

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue Recognition [Line Items]
Allowance for credit losses	$ 95	$ 91
Accounts receivable from securitization	686	636	$ 685
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member]
Revenue Recognition [Line Items]
Accounts receivable from securitization	437	436
Pledged to PNC Bank, National Association in connection with the U.S. securitization program entered into in November 2022 [Member] | Accounts Receivable Securitization Facility [Member] | PNC Bank [Member]
Revenue Recognition [Line Items]
Accounts receivable from securitization	$ 437	$ 436
United States [Member]
Revenue Recognition [Line Items]
Percentage sales reserves and allowances to U.S. customers	65%

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 15,846		$ 14,925	$ 15,878
Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	12,979		12,766	13,829
Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	681	[1]	212	160
Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,615		1,519	1,390
Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	570	[2]	428	500
International Markets [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,958		1,903	2,032
International Markets [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,840		1,806	1,889
International Markets [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	24	[1]	19	13
International Markets [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	38		46	65
International Markets [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	56	[2]	33	65
Other activities [Member]
Disaggregation of Revenue [Line Items]
Total revenue	926		1,045	1,151
Other activities [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	565		671	739
Other activities [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	5	[1]	4	4
Other activities [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	0		0	0
Other activities [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	357	[2]	370	408
North America [Member]
Disaggregation of Revenue [Line Items]
Total revenue	8,124		7,452	7,809
North America [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	5,944		5,834	6,394
North America [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	601	[1]	139	92
North America [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,577		1,471	1,323
North America [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2	[2]	8	(1)
Europe [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,837		4,525	4,886
Europe [Member] | Sale of Goods [Member]
Disaggregation of Revenue [Line Items]
Total revenue	4,631		4,455	4,807
Europe [Member] | Licensing Arrangements [Member]
Disaggregation of Revenue [Line Items]
Total revenue	51	[1]	51	50
Europe [Member] | Distribution [Member]
Disaggregation of Revenue [Line Items]
Total revenue			1	1
Europe [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 155	[2]	$ 18	$ 27
[1]Revenues from licensing arrangements in North America segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.[2]“Other” revenues in Europe segment mainly related to the sale of certain product rights.

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Parenthetical) (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Sanofi [Member] | Collaborative Arrangement [Member]
Disaggregation of Revenue [Line Items]
Upfront payment	$ 500

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue Recognition [Line Items]
Balance at beginning of period	$ 3,817	$ 4,309
Provisions related to sales made in current year period	12,975	13,278
Provisions related to sales made in prior periods	(101)	(202)
Credits and payments	(13,125)	(13,513)
Translation differences	30	(55)
Balance at end of period	3,596	3,817
Reserves Included in Accounts Receivable, net [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	67	68
Provisions related to sales made in current year period	354	363
Provisions related to sales made in prior periods	0	0
Credits and payments	(360)	(364)
Translation differences	0	0
Balance at end of period	61	67
Rebates [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	1,575	1,655
Provisions related to sales made in current year period	4,015	3,823
Provisions related to sales made in prior periods	(31)	(69)
Credits and payments	(3,974)	(3,798)
Translation differences	18	(36)
Balance at end of period	1,603	1,575
Medicaid and other governmental allowances [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	663	854
Provisions related to sales made in current year period	654	871
Provisions related to sales made in prior periods	(33)	(35)
Credits and payments	(748)	(1,023)
Translation differences	4	(4)
Balance at end of period	540	663
Chargebacks [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	991	1,085
Provisions related to sales made in current year period	7,579	7,819
Provisions related to sales made in prior periods	(54)	(44)
Credits and payments	(7,662)	(7,861)
Translation differences	5	(8)
Balance at end of period	859	991
Returns [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	455	535
Provisions related to sales made in current year period	264	317
Provisions related to sales made in prior periods	17	(3)
Credits and payments	(304)	(390)
Translation differences	4	(4)
Balance at end of period	436	455
Other [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	66	112
Provisions related to sales made in current year period	109	85
Provisions related to sales made in prior periods	0	(51)
Credits and payments	(77)	(77)
Translation differences	(1)	(3)
Balance at end of period	97	66
Total reserves included in sales reserves and allowances [Member]
Revenue Recognition [Line Items]
Balance at beginning of period	3,750	4,241
Provisions related to sales made in current year period	12,621	12,915
Provisions related to sales made in prior periods	(101)	(202)
Credits and payments	(12,765)	(13,149)
Translation differences	30	(55)
Balance at end of period	$ 3,535	$ 3,750

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Inventories [Line Items]
Finished products	$ 2,346	$ 1,987
Raw and packaging materials	993	1,059
Products in process	500	555
Materials in transit and payments on account	183	232
Total	$ 4,021	$ 3,833

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Machinery and equipment	$ 4,807	$ 5,026
Buildings	2,488	2,463
Computer equipment and other assets	2,419	2,323
Assets under construction and payments on account	1,427	1,199
Land	246	246
Subtotal	11,387	11,257
Less- accumulated depreciation	(5,637)	(5,518)
Property, Plant and Equipment, Net, Total	$ 5,750	$ 5,739

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation expense for the year	$ 537	$ 576	$ 528
Impairment charge during the year on property, plant and equipment	28	47	160
Teva [Member]
Property, Plant and Equipment [Line Items]
Impairment charge during the year on property, plant and equipment	$ 28	$ 47	$ 160

Identifiable Intangible Asset_2

Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	$ 18,930	$ 19,131
Accumulated amortization	13,543	12,861
Net carrying amount	5,387	6,270
Product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	17,981	18,067
Accumulated amortization	13,274	12,630
Net carrying amount	4,707	5,437
Trade names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	583	577
Accumulated amortization	269	231
Net carrying amount	314	346
In-process research and development (IPR&D) [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount net of impairment	366	487
Accumulated amortization	0	0
Net carrying amount	$ 366	$ 487

Identifiable Intangible Asset_3

Identifiable Intangible Assets - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets useful life	9 years
Amortization of intangible assets	$ 616	$ 732	$ 802
2024	503
2025	460
2026	462
2027	451
2028	398
Impairment of intangible assets excluding goodwill	$ 350	355	424
Inventory write down		4,200
Change In Tevas Commercial Plans Regarding Certain Program [Member]
Finite-Lived Intangible Assets [Line Items]
Inventory write down		$ 108
Minimum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	8.5
Maximum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input	11
In Process Research and Development [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input		8.5
In Process Research and Development [Member] | Minimum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input		20
In Process Research and Development [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input		10
In Process Research and Development [Member] | Maximum [Member] | Measurement input, discount rate [Member]
Finite-Lived Intangible Assets [Line Items]
Business combination, contingent consideration, liability, measurement input		90
In Process Research and Development [Member] | Generic Pipeline Products [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			127
In Process Research and Development [Member] | Generic Pipeline Products [Member] | Development Progress And Changes In Other Key Valuation Assumptions [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	$ 90	$ 45
Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	260	310
Identifiable product rights [Member] | Regulatory Price And Volume Of Products [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	148
Identifiable product rights [Member] | Updated Market Assumptions [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		256
Identifiable product rights [Member] | Change In Tevas Commercial Plans Regarding Certain Program [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill		$ 54
Identifiable product rights [Member] | Lenalidomide Product [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			267
Actavis [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			297
Japan [Member] | Identifiable product rights [Member] | Updated Market Assumptions [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill	$ 112
United States [Member] | Actavis [Member] | Identifiable product rights [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets excluding goodwill			$ 30

Goodwill - Summary of Changes i

Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail) - USD ($) $ in Millions		3 Months Ended		12 Months Ended
		Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Beginning balance	[1]			$ 17,633	$ 20,040
Goodwill impairment		$ 0	$ (700)	(700)	(2,045)	$ 0
Goodwill reclassified as assets to held for sale				(30)
Goodwill acquired					12
Translation differences				275	(374)
Ending balance	[1]	17,177		17,177	17,633	20,040
North America [Member]
Goodwill [Line Items]
Beginning balance	[1]			6,450	6,474
Goodwill impairment				0	0
Goodwill reclassified as assets to held for sale				0
Goodwill acquired					0
Translation differences				9	(24)
Ending balance	[1]	6,459		6,459	6,450	6,474
Europe [Member]
Goodwill [Line Items]
Beginning balance	[1]			8,302	8,544
Goodwill impairment				0	0
Goodwill reclassified as assets to held for sale				0
Goodwill acquired					0
Translation differences				164	(242)
Ending balance	[1]	8,466		8,466	8,302	8,544
International Markets [Member]
Goodwill [Line Items]
Beginning balance	[1]			1,339	2,328
Goodwill impairment				(700)	(979)
Goodwill reclassified as assets to held for sale				(30)
Goodwill acquired					0
Translation differences				66	(10)
Ending balance	[1]	675		675	1,339	2,328
Other [Member] | Medis Reporting Units [Member]
Goodwill [Line Items]
Beginning balance	[1]			249	277
Goodwill impairment				0	0
Goodwill reclassified as assets to held for sale				0
Goodwill acquired					0
Translation differences				16	(28)
Ending balance	[1]	265		265	249	277
Other [Member] | Tevas API Reporting Unit [Member]
Goodwill [Line Items]
Beginning balance	[1]			1,293	2,417
Goodwill impairment				0	(1,066)
Goodwill reclassified as assets to held for sale				0
Goodwill acquired					12
Translation differences				20	(70)
Ending balance	[1]	$ 1,313		$ 1,313	$ 1,293	$ 2,417
[1]Cumulative goodwill impairment as of December 31, 2023, December 31, 2022 and December 31, 2021 was approximately $28.3 billion, $27.6 billion and $25.6 billion respectively.

Goodwill - Summary of Changes_2

Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail) - USD ($) $ in Billions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Accumulated goodwill impairment	$ 28.3	$ 27.6	$ 25.6

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022
Goodwill [Line Items]
Goodwill impairment	$ 0	$ 700	$ 700	$ 2,045	$ 0
Tevas North America Europe Medis and Tevas API [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount		10%
Tevas International Market [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	6%	3%	6%
Tevas International Market [Member] | Measurement Input Terminal Growth Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	1.79%	1.56%	1.79%
Tevas International Market [Member] | Measurement Input, Discount Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	12.23%	9.96%	12.23%
Tevas Europe Reporting Unit [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	4%	1%	4%			9%
Maximum [Member] | Tevas International Market [Member] | Measurement Input Terminal Growth Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	1.54%	1.31%	1.54%
Maximum [Member] | Tevas International Market [Member] | Measurement Input, Discount Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	12.48%	10.21%	12.48%
Minimum [Member] | Tevas International Market [Member] | Measurement Input Terminal Growth Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	0.25%	0.25%	0.25%
Minimum [Member] | Tevas International Market [Member] | Measurement Input, Discount Rate [Member]
Goodwill [Line Items]
Reporting unit percentage of fair value in excess of carrying amount	0.25%	0.25%	0.25%

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating lease cost:
Fixed payments and variable payments that depend on an index or rate	$ 132	$ 142	$ 135
Variable lease payments not included in the lease liability	5	4	4
Short-term lease cost	3	2	2
Total operating lease cost	$ 139	$ 148	$ 141

Leases - Supplemental cash flow

Leases - Supplemental cash flow information related to leases (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 141	$ 140	$ 143
Right-of-use assets obtained in exchange for lease obligations (non-cash):
Operating leases	$ 121	$ 81	$ 81

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related To Leases (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Operating leases:
Operating lease ROU assets	$ 397	$ 419
Other current liabilities	97	93
Operating lease liabilities	320	349
Total operating lease liabilities	$ 417	$ 442
Weighted average remaining lease term Operating leases	6 years 1 month 6 days	6 years 9 months 18 days
Weighted average discount rate Operating leases	6%	5.60%
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Liabilities, Current	Liabilities, Current

Leases - Maturities of lease l

Leases - Maturities of lease liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
2024	$ 116
2025	98
2026	80
2027	62
2028 and thereafter	140
Total operating lease payments	496
Less: imputed interest	79
Present value of lease liabilities	$ 417	$ 442

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Finance Lease, Right-of-Use Asset	$ 32	$ 29
Finance Lease, Liability	$ 23	$ 22
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Other taxes and long-term liabilities	Other taxes and long-term liabilities

Debt Obligations - Schedule of

Debt Obligations - Schedule of Short-term Debt (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Current maturities of long-term liabilities	$ 1,649	$ 2,086
Total short term debt	$ 1,672	2,109
Convertible debentures [Member]
Debt Instrument [Line Items]
Weighted average interest rate	0.25%
Maturity	2026
Short-term borrowings	$ 23	$ 23

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Senior Notes and Loans (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023		Jul. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total senior notes		$ 19,889			$ 21,266
Less current maturities		(1,649)			(2,086)
Less debt issuance costs	[1]	(80)			(78)
Total senior notes and loans		18,161			19,103
Other Debentures [Member]
Debt Instrument [Line Items]
Total senior notes and loans		$ 1			1
Senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.13%
Maturity		2024
Total senior notes		$ 693			670
Sustainability-linked senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[2],[3]	4.38%
Maturity	[2],[3]	2030
Total senior notes	[2],[3]	$ 1,656			1,606
Senior notes EUR 1,300 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[4]	1.25%
Maturity	[4]	2023
Total senior notes	[4]	$ 0			633
Sustainability-linked senior notes EUR 1,100 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3],[5]	3.75%
Maturity	[3],[5]	2027
Total senior notes	[3],[5]	$ 1,215			1,177
Senior notes EUR 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	6%
Maturity	[6]	2025
Total senior notes	[6]	$ 453			1,070
Senior notes EUR 900 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	4.50%
Maturity	[6]	2025
Total senior notes	[6]	$ 547			963
Sustainability-linked senior notes EUR 800 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3],[7]	7.38%
Maturity	[3],[7]	2029
Total senior notes	[3],[7]	$ 884			0
Senior notes EUR 750 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.63%
Maturity		2028
Total senior notes		$ 826			800
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1.88%
Maturity		2027
Total senior notes		$ 771			748
Sustainability-linked senior notes EUR 500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3],[8]	7.88%
Maturity	[3],[8]	2031
Total senior notes	[3],[8]	$ 552			0
Senior notes USD 3,500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	3.15%
Maturity	[6]	2026
Total senior notes	[6]	$ 3,374			3,496
Senior notes USD 3,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		2.80%	[6],[9]	2.80%
Maturity	[6]	2023
Total senior notes	[6]	$ 0			1,453
Senior notes USD 2,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		4.10%
Maturity		2046
Total senior notes		$ 1,986			1,986
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	6%
Maturity	[6]	2024
Total senior notes	[6]	$ 956			1,250
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.75%
Maturity		2028
Total senior notes		$ 1,250			1,250
Senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[6]	7.13%
Maturity	[6]	2025
Total senior notes	[6]	$ 427			1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3],[5]	4.75%
Maturity	[3],[5]	2027
Total senior notes	[3],[5]	$ 1,000			1,000
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[2],[3]	5.13%
Maturity	[2],[3]	2029
Total senior notes	[2],[3]	$ 1,000			1,000
Senior notes USD 789 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		6.15%
Maturity		2036
Total senior notes		$ 783			783
Sustainability-linked senior notes USD 600 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3],[10]	7.88%
Maturity	[3],[10]	2029
Total senior notes	[3],[10]	$ 600			0
Sustainability-linked senior notes USD 500 million [Member]
Debt Instrument [Line Items]
Weighted average interest rate	[3],[11]	8.13%
Maturity	[3],[11]	2031
Total senior notes	[3],[11]	$ 500			0
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Weighted average interest rate		1%
Maturity		2025
Total senior notes		$ 416			$ 382
[1]Debt issuance costs as of December 31, 2023 include $26 million in connection with the issuance of the sustainability-linked senior notes in March 2023, partially offset by $6 million acceleration of issuance costs related to the cash tender offer.[2]If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.[3]Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 10c.[4]In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity.[5]If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.[6]In March 2023, Teva consummated a cash tender offer and extinguished $631 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $574 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $454 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026.[7]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.[8]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 500 million euro bearing 7.88% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.[9]In July 2023, Teva repaid $1,000 million of its 2.8% senior notes at maturity.[10]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.[11]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail) € in Millions, SFr in Millions, $ in Millions		1 Months Ended	12 Months Ended
		Jul. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)		Dec. 31, 2023 USD ($)		Dec. 31, 2023 CHF (SFr)
Senior Notes [Member]
Debt Instrument [Line Items]
Senior notes repaid amount						$ 646
Senior notes maturity percentage				1.25%		1.25%		1.25%
Senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 1,500
Debt Instrument Maturity Year			2024
Debt instrument, interest rate, effective percentage				1.13%		1.13%		1.13%
Senior notes EUR 1,300 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 1,300
Debt Instrument Maturity Year	[1]		2023
Debt instrument, interest rate, effective percentage	[1]			1.25%		1.25%		1.25%
Senior notes EUR 750 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 750
Debt Instrument Maturity Year			2028
Debt instrument, interest rate, effective percentage				1.63%		1.63%		1.63%
Senior notes EUR 700 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 700
Debt Instrument Maturity Year			2027
Debt instrument, interest rate, effective percentage				1.88%		1.88%		1.88%
Senior notes EUR 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 1,000
Debt Instrument Maturity Year	[2]		2025
Debt instrument, interest rate, effective percentage	[2]			6%		6%		6%
Debt instrument principal amount of debt extinguished			$ 631
Senior notes EUR 900 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 900
Debt Instrument Maturity Year	[2]		2025
Debt instrument, interest rate, effective percentage	[2]			4.50%		4.50%		4.50%
Debt instrument principal amount of debt extinguished			$ 432
Senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 1,000
Debt Instrument Maturity Year	[2]		2025
Debt instrument, interest rate, effective percentage	[2]			7.13%		7.13%		7.13%
Debt instrument principal amount of debt extinguished			$ 574
Senior notes USD 3,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 3,500
Debt Instrument Maturity Year	[2]		2026
Debt instrument, interest rate, effective percentage	[2]			3.15%		3.15%		3.15%
Debt instrument principal amount of debt extinguished			$ 122
Senior notes USD 3,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 3,000
Debt Instrument Maturity Year	[2]		2023
Debt instrument, interest rate, effective percentage		2.80%		2.80%	[2],[3]	2.80%	[2],[3]	2.80%	[2],[3]
Debt instrument principal amount of debt extinguished			$ 454
Senior notes USD 3,000 million [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Repayments of Senior Debt		$ 1,000
Senior notes USD 2,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 2,000
Debt Instrument Maturity Year			2046
Debt instrument, interest rate, effective percentage				4.10%		4.10%		4.10%
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 1,250
Debt Instrument Maturity Year	[2]		2024
Debt instrument, interest rate, effective percentage	[2]			6%		6%		6%
Debt instrument principal amount of debt extinguished			$ 293
Senior notes USD 1,250 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 1,250
Debt Instrument Maturity Year			2028
Debt instrument, interest rate, effective percentage				6.75%		6.75%		6.75%
Senior notes USD 789 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 789
Debt Instrument Maturity Year			2036
Debt instrument, interest rate, effective percentage				6.15%		6.15%		6.15%
Senior notes CHF 350 Million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | SFr								SFr 350
Debt Instrument Maturity Year			2025
Debt instrument, interest rate, effective percentage				1%		1%		1%
Sustainability-linked senior notes EUR 1,500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 1,500
Debt Instrument Maturity Year	[4],[5]		2030
Debt instrument, interest rate, effective percentage	[4],[5]			4.38%		4.38%		4.38%
Sustainability-linked senior notes EUR 1,100 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 1,100
Debt Instrument Maturity Year	[5],[6]		2027
Debt instrument, interest rate, effective percentage	[5],[6]			3.75%		3.75%		3.75%
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 1,000
Debt Instrument Maturity Year	[5],[6]		2027
Debt instrument, interest rate, effective percentage	[5],[6]			4.75%		4.75%		4.75%
Sustainiability Senior Linked Notes Two Thousand Twenty Nine And Two Thousand And Thirty One One And Two [Member]
Debt Instrument [Line Items]
Accumulated Amortization, Debt Issuance Costs						$ 6
Debt issuance costs gross						26
Sustainability Senior Linked Loans Due Two Thousand And Thirty One Two [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 500
Debt instrument month of maturity			2031-09
Long term debt bearing fixed interest rate percentage				8.13%		8.13%		8.13%
Sustainability Senior Linked Loans Due Two Thousand And Thirty One Two [Member] | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.30%
Sustainability Senior Linked Loans Due Two Thousand And Thirty One Two [Member] | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.10%
Sustainability-linked senior notes USD 600 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 600
Debt instrument month of maturity			2029-09
Long term debt bearing fixed interest rate percentage				7.88%		7.88%		7.88%
Sustainability-linked senior notes USD 600 million [Member] | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.30%
Sustainability-linked senior notes USD 600 million [Member] | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.10%
Sustainability-linked senior notes EUR 500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 500
Debt instrument month of maturity			2031-09
Long term debt bearing fixed interest rate percentage				7.88%		7.88%		7.88%
Sustainability-linked senior notes EUR 500 million [Member] | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.30%
Sustainability-linked senior notes EUR 500 million [Member] | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.10%
Sustainability-linked senior notes EUR 800 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount | €				€ 800
Debt instrument month of maturity			2029-09
Long term debt bearing fixed interest rate percentage				7.38%		7.38%		7.38%
Sustainability-linked senior notes EUR 800 million [Member] | Maximum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.30%
Sustainability-linked senior notes EUR 800 million [Member] | Minimum [Member] | From September Fifteenth Two Thousand And Twenty Six [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.10%
Sustainability-linked senior notes USD 500 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 500
Debt Instrument Maturity Year	[5],[7]		2031
Debt instrument, interest rate, effective percentage	[5],[7]			8.13%		8.13%		8.13%
Sustainability-linked senior notes USD 600 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 600
Debt Instrument Maturity Year	[5],[8]		2029
Debt instrument, interest rate, effective percentage	[5],[8]			7.88%		7.88%		7.88%
Sustainability-linked senior notes USD 1,000 million [Member]
Debt Instrument [Line Items]
Debt instrument face amount						$ 1,000
Debt Instrument Maturity Year	[5],[9]		2029
Debt instrument, interest rate, effective percentage	[5],[9]			7.38%		7.38%		7.38%
Interest Rate Increase [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date			May 09, 2026
Interest Rate Increase [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.375%
Interest Rate Increase [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.125%
One Time Premium Payment [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date			May 09, 2026
One Time Premium Payment [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.45%
One Time Premium Payment [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Increase (Decrease)			0.15%
[1]In March 2023, Teva repaid $646 million of its 1.25% senior notes at maturity.[2]In March 2023, Teva consummated a cash tender offer and extinguished $631 million aggregate principal amount of its 1,000 million euro 6% senior notes due in 2025; $432 million aggregate principal amount of its 900 million euro 4.5% senior notes due in 2025; $574 million aggregate principal amount of its $1,000 million 7.13% senior notes due in 2025; $454 million aggregate principal amount of its $3,000 million 2.8% senior notes due in 2023; $293 million aggregate principal amount of its $1,250 million 6% senior notes due in 2024 and $122 million aggregate principal amount of its $3,500 million 3.15% senior notes due in 2026.[3]In July 2023, Teva repaid $1,000 million of its 2.8% senior notes at maturity.[4]If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.125%-0.375% per annum, from and including May 9, 2026.[5]Interest rate adjustments and a potential one-time premium payment related to the sustainability-linked bonds are treated as bifurcated embedded derivatives. See note 10c.[6]If Teva fails to achieve certain sustainability performance targets, a one-time premium payment of 0.15%-0.45% out of the principal amount will be paid at maturity or upon earlier redemption, if such redemption is on or after May 9, 2026.[7]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $500 million bearing 8.13% annual interest and due September 2031. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.[8]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of $600 million bearing 7.88% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.[9]In March 2023, Teva issued sustainability-linked senior notes in an aggregate principal amount of 800 million euro bearing 7.38% annual interest and due September 2029. If Teva fails to achieve certain sustainability performance targets, the interest rate shall increase by 0.100%-0.300% per annum, from and including September 15, 2026.

Debt Obligation - Schedule Requ

Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Detail) $ in Millions	Dec. 31, 2023 USD ($)
Long Term Debt Maturity [Line Items]
2025	$ 1,843
2026	3,397	[1]
2027	2,986
2028	2,076
2029 and thereafter	7,961
Total	$ 18,263
[1]Including $23 million convertible notes. See note 9a.

Debt Obligation - Schedule Re_2

Debt Obligation - Schedule Required Annual Principal Payments of Long-term Debt, Excluding Debt Issuance Cost (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Convertible Debt [Member]
Short-term Debt [Line Items]
Principal amount currently outstanding on the debt instruments	$ 23	$ 23

Debt Obligations - Additional I

Debt Obligations - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended					9 Months Ended	12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2023	Jul. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long term debt currency portion USD					60%		60%
Long term debt currency portion EUR					38%		38%
Long term debt currency portion CHF					2%		2%
Convertible Debt [Member]
Debt Instrument [Line Items]
Principal amount currently outstanding on the debt instruments					$ 23		$ 23		$ 23
Weighted average interest rate					0.25%		0.25%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Description							The RCF can be used for general corporate purposes, including repaying existing debt. In July 2023, a total amount of $700 million was withdrawn under the RCF, of which $200 million was repaid in September 2023 and the remaining amount of $500 million was repaid in the fourth quarter of 2023. As of December 31, 2023, and as of the date of this Annual Report on Form 10-K, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued.
Long Term Debt Payable Under Revolving Credit Facility					$ 0		$ 0
Line of Credit Facility, Maximum Borrowing Capacity					1,800		$ 1,800	$ 700
Debt Instrument, Maturity Date							Apr. 30, 2026
Repayments of Lines of Credit					$ 500	$ 200
Line of credit extension period							one-year
Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Leverage Ratio					4.00
Revolving Credit Facility [Member] | Amended Revolving Credit Facility [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Leverage Ratio	3.50	4.00	4.00	4.00

Derivative instruments and he_3

Derivative instruments and hedging activities - Summary of Notional Amounts for Hedged Items (Detail) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member]
Disclosure In Tabular Form Of Notional Amount Of Derivatives Designated As Hedging Instruments [Line Items]
Cross-currency swap-cash flow hedge	[1]	$ 169	$ 0
[1]On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen.

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]
Derivative [Line Items]
Asset derivatives		$ 0	$ 0
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]
Derivative [Line Items]
Liability derivatives		0	0
Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member]
Derivative [Line Items]
Asset derivatives	[1]	8	0
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Assets [Member]
Derivative [Line Items]
Asset derivatives		38	29
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other Current Liabilities [Member]
Derivative [Line Items]
Liability derivatives		(39)	(101)
Not Designated as Hedging Instrument [Member] | Cross Currency Swap Cash Flow Hedge [Member] | Other Non-current Assets [Member]
Derivative [Line Items]
Asset derivatives	[1]	$ 0	$ 0
[1]On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen.

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Comprehensive Income [Member]
Derivative [Line Items]
Other comprehensive income (loss)		$ 91	$ (270)	$ (391)
Financial expenses [Member]
Derivative [Line Items]
Financial expenses, net		1,057	966	1,058
Cross Currency Swap Cash Flow Hedge [Member] | Other Comprehensive Income [Member]
Derivative [Line Items]
Other comprehensive income (loss)	[1]	1	0	0
Cross Currency Swap Cash Flow Hedge [Member] | Financial expenses [Member]
Derivative [Line Items]
Financial expenses, net	[1]	$ (11)	$ 0	$ 0
[1]On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen.

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Revenues [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		$ (15,846)	$ (14,925)	$ (15,878)
Net Revenues [Member] | Not Designated as Hedging Instrument, Trading [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	0	0	0
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[2]	2	(11)	(31)
Financial expenses [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax		1,057	966	1,058
Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[1]	(54)	(12)	(45)
Financial expenses [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]
Derivative [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	[2]	$ 0	$ 0	$ 0
[1]Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.[2]Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, Swiss franc, Japanese yen, British pound, Russian ruble, Canadian dollar, Polish zloty and some other currencies to protect its projected operating results for 2023 and 2024. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2023, the negative impact from these derivatives recognized under revenues was $2 million. In 2022, the positive impact from these derivatives recognized under revenues was $11 million. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. Cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities - Summary of Sold Receivables Outstanding Balance Net of DPP Asset under Outstanding Securitization Program (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Sold receivables at the beginning of the year	$ 636	$ 685
Proceeds from sale of receivables	4,391	4,653
Cash collections (remitted to the owner of the receivables)	(4,365)	(4,665)
Effect of currency exchange rate changes	24	(37)
Sold receivables at the end of the year	$ 686	$ 636

Derivative Instruments and He_8

Derivative Instruments and Hedging Activities - Additional Information (Detail) - USD ($) $ in Millions			12 Months Ended
	Nov. 07, 2023	Nov. 07, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Jul. 11, 2022
Derivative [Line Items]
Revenues other than USD			47%
Derivative, negative impact			$ 493	$ 2
Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]			Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Forward starting interest rate swaps and treasury lock agreements losses			$ 31	30	$ 37
Deferred purchase asset			247	270
Sold receivables			$ 686	636	$ 685
Derivative, Gain on Derivative				11
Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]			Revenue from Contract with Customer, Excluding Assessed Tax
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]			Liabilities
Supplier finance program obligation			$ 108	34
Proceeds from sale of accounts receivable classified as operating activities one			861	820
March 2024 to November 2025 [Member]
Derivative [Line Items]
Derivative notional amount decrease	$ 875
March 2024 [Member]
Derivative [Line Items]
Derivative notional amount decrease	125
PNC Bank [Member] | March 2024 [Member]
Derivative [Line Items]
Derivative notional Amount Increase	250
Accounts Receivable Securitization Facility [Member] | November 2025 [Member]
Derivative [Line Items]
Derivative notional Amount Increase						$ 750
Accounts Receivable Securitization Facility [Member] | Mizuho Bank [Member] | November 2025 [Member]
Derivative [Line Items]
Derivative notional amount						250
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member]
Derivative [Line Items]
Sold receivables			437	436
Derivative notional amount							$ 1,000
Derivatives term of contract		3 years
Transfer of financial assets sold and derecognized			$ 864	$ 820
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | March 2024 [Member]
Derivative [Line Items]
Derivative notional Amount Increase	$ 1,000
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | November 2025 [Member]
Derivative [Line Items]
Derivative notional amount decrease		$ 500
Accounts Receivable Securitization Facility [Member] | PNC Bank [Member] | November 2023 [Member]
Derivative [Line Items]
Derivative notional amount						$ 1,000

Legal Settlements and Loss Co_2

Legal Settlements and Loss Contingencies - Additional Information (Detail) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 EUR (€)
Loss Contingencies [Line Items]
Legal settlements and loss contingencies, expense	$ 1,043	$ 2,082	$ 717
Accrued amount for legal settlements and loss contingencies	$ 4,771	$ 4,186		€ 60.5
Settlement On Account Of Product Liability [Member] | United States [Member]
Loss Contingencies [Line Items]
Restructuring expense and income	Legal settlements and loss contingencies in 2021 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, the provision for the carvedilol patent litigation as well as a liability which was substantially offset by insurance receivable related to the Ontario Teachers Securities Litigation discussed in note 12b.

Commitments and Contingencies -

Commitments and Contingencies - Commitments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Commitment And Contingencies [Line Items]
Royalty expense	$ 543	$ 560	$ 522
Maximum [Member]
Commitment And Contingencies [Line Items]
Milestone contingent expense	$ 20

Commitments and Contingencies_2

Commitments and Contingencies - Contingencies - Additional Information (Detail) € in Millions

1 Months Ended

9 Months Ended

12 Months Ended

48 Months Ended

Dec. 31, 2023 USD ($)

Nov. 09, 2022 USD ($)

Jun. 02, 2022 USD ($)

Jul. 31, 2023 USD ($)

Jun. 30, 2023 USD ($)

Sep. 30, 2013 USD ($)

Apr. 30, 2013 USD ($)

Aug. 31, 2012 USD ($)

Dec. 31, 2010 USD ($)

Sep. 30, 2021 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2019 USD ($)

Dec. 31, 2014 USD ($)

Aug. 21, 2022 USD ($)

Dec. 31, 2023 EUR (€)

Aug. 21, 2023 USD ($)

Dec. 31, 2022 USD ($)

Jul. 08, 2021 USD ($)

Aug. 31, 2019 USD ($)

Jul. 31, 2008 USD ($)

Feb. 28, 2005 USD ($)

Commitment And Contingencies [Line Items]

Annual sales at the time of settlement

$ 700,000,000

$ 700,000,000

$ 350,000,000

Annual sales of Effexor

$ 2,600,000,000

Annual sales of Lamictal

$ 2,300,000,000

$ 950,000,000

Annual sales of Niaspan

$ 1,100,000,000

$ 416,000,000

Annual sales of Actos

$ 2,800,000,000

$ 3,700,000,000

Annual sales of Acto plus

$ 430,000,000

$ 500,000,000

Litigation settlement amount

$ 4,250,000,000

Annual Sales Of Sensipar

$ 1,400,000,000

Litigation settlement amount awarded distribution period

13 years

Annual sales of Copaxone

$ 373,000,000

Generic modafinil, and imposed fines amount

4,771,000,000

4,771,000,000

€ 60.5

$ 4,186,000,000

Loss Contingency Accrual, Provision

235,500,000

Annual sales of the time of settlement of viread

582,000,000

Annual sales of the time of settlement of Truvada

2,400,000,000

Annual sales of the time of settlement of Atripla

2,900,000,000

Annual sales of the time of New launch of viread

728,000,000

Annual sales of the time of New launch of Truvada

2,100,000,000

Annual sales of the time of New launch of Atripla

444,000,000

Annual sales of Colcrys

187,000,000

Litigation Settlement Amount DistributableIn Kind

1,200,000,000

1,200,000,000

Accrual for Environmental Loss Contingencies

300,000

$ 300,000

Loss Contingencies On Environmental Laws Penalty

$ 1,400,000

Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement

99%

Annual Sales Of Revlimid

3,500,000,000

Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer

300,000,000

Annual Sales Of EpiPen

600,000,000

Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population

$ 1,000,000

Percentage Of Share Of The National Population

1%

Percentgae of amount in cash settlement

20%

20%

20%

Litigation Settlement Amount Distributable in cash

$ 240,000,000

$ 240,000,000

Loss Contingency, Damages Awarded, Value

$ 176,500,000

NEVADA

Commitment And Contingencies [Line Items]

Loss Contingency, Settlement Agreement Terms

20 years

Payment

$ 193,000,000

Maximum [Member]

Commitment And Contingencies [Line Items]

Damage claimed

1,000,000,000

Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and Tobramycin [Member]

Commitment And Contingencies [Line Items]

Other commitment

$ 50,000,000

Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the Antitrust Laws [Member]

Commitment And Contingencies [Line Items]

Other commitment, to be paid, year five

135,000,000

Other commitment to pay for each year

22,500,000

Other commitment

$ 225,000,000

Opioid Litigation [Member]

Commitment And Contingencies [Line Items]

Loss contingency accrual, product liability, undiscounted, to be paid, year five

368,000,000

368,000,000

Loss contingency accrual, product liability, undiscounted, to be paid, year four

368,000,000

368,000,000

Loss contingency accrual, product liability, undiscounted, to be paid, year three

364,000,000

364,000,000

Loss contingency accrual, product liability, undiscounted, to be paid, year two

418,000,000

418,000,000

Loss contingency accrual, product liability, undiscounted, to be paid, year one

$ 424,000,000

$ 424,000,000

Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member]

Commitment And Contingencies [Line Items]

Litigation settlement amount

$ 420,000,000

Litigation With US Hospitals And Other Healthcare Providers [Member]

Commitment And Contingencies [Line Items]

Litigation settlement amount

$ 126,000,000

Litigation settlement amount awarded distribution period

18 years

Product WAC Value

$ 49,000,000

Product WAC Term

7 years

Europe [Member]

Commitment And Contingencies [Line Items]

Damage claimed

$ 50,000,000

Eosinophilic Esophagitis [Member]

Commitment And Contingencies [Line Items]

Damage claimed

200,000,000

Eosinophilic Esophagitis [Member] | United States [Member]

Commitment And Contingencies [Line Items]

Damage claimed

$ 150,000,000

AndroGel Rate at 1% [Member]

Commitment And Contingencies [Line Items]

Annual sales at the time of settlement

$ 140,000,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Before Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended						12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Parent Company and its Israeli subsidiaries							$ (767)		$ (119)		$ 126
Non-Israeli subsidiaries							143		(3,044)		532
Income (loss) before income taxes	$ 64	$ (923)	$ (272)	$ (1,185)	$ 171	$ (1,178)	$ (624)	[1],[2]	$ (3,163)	[1],[2]	$ 658	[1],[2]
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Income Taxes - Schedule of the

Income Taxes - Schedule of the Provision for Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended						12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
In Israel							$ (402)		$ 33		$ 124
Outside Israel							395		(676)		87
Effective consolidated income taxes	$ (12)	$ (16)	$ (19)	$ 149	$ 107	$ (900)	(7)	[1]	(643)	[1]	211	[1]
Current							333		430		270
Deferred							(340)		(1,073)		(59)
Effective consolidated income taxes	$ (12)	$ (16)	$ (19)	$ 149	$ 107	$ (900)	$ (7)	[1]	$ (643)	[1]	$ 211	[1]
[1]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Income Taxes - Accumulated Othe

Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($) $ in Millions		3 Months Ended						12 Months Ended
		Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Income (loss) before income taxes		$ 64	$ (923)	$ (272)	$ (1,185)	$ 171	$ (1,178)	$ (624)	[1],[2]	$ (3,163)	[1],[2]	$ 658	[1],[2]
Statutory tax rate in Israel								23%		23%		23%		23%
Theoretical provision for income taxes	[2]							$ (144)		$ (727)		$ 151
Increase (decrease) in the provision for income taxes due to:
The Parent Company and its Israeli subsidiaries - Tax benefits arising from net deferred taxes, resulting from intellectual property related integration plans, including carryforward losses								(272)
Tax benefits arising from reduced tax rates under benefit programs								14		15		(12)
Mainly nondeductible items and prior year tax										35		20
Non-Israeli subsidiaries, including impairments	[3]							372		941		117
Worthless stock deduction	[4]									(909)
Increase (decrease) in other uncertain tax positions - net								23		2		(65)
Effective consolidated income taxes		$ (12)	$ (16)	$ (19)	$ 149	$ 107	$ (900)	$ (7)	[2]	$ (643)	[2]	$ 211	[2]
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.[3]In 2023 and 2022, income before income taxes includes goodwill impairment in non-Israeli subsidiaries that did not have a corresponding tax effect.[4]In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.

Income Taxes - Accumulated Ot_2

Income Taxes - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Income Before Income Taxes And Income Tax Expense Benefit [Line Items]
Obsolete stock written off	$ 4,200
Effective income tax reconciliation amount inventory written off	$ 909	[1]
[1]In 2022, one of Teva’s U.S. subsidiaries was determined to be insolvent for tax purposes (i.e., its liabilities exceeded the fair market value of its assets), mainly in light of its accumulated operational losses. Consequently, Teva recognized on its 2022 tax return, a worthless stock deduction of approximately $4.2 billion, with related tax benefit of approximately $909 million.

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Defered Income Taxes (Detail) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets Liabilities Net [Line Items]
Inventory related		$ 76	$ 125
Sales reserves and allowances		81	89
Provision for legal settlements		702	703
Intangible assets	[1]	(118)	(567)
Carryforward losses and deductions and credits	[2]	2,463	2,850
Property, plant and equipment		(225)	(238)
Deferred interest		799	800
Provisions for employee related obligations		80	82
Other	[3]	357	138
Long-term deferred tax assets (liabilities)-gross		4,215	3,982
Valuation allowance—in respect of carryforward losses and deductions that may not be utilized		(3,009)	(3,072)
Deferred tax assets liabilities net		$ 1,206	$ 910
[1]The increase in deferred tax is mainly due to intellectual property related integration.[2]The amounts are shown following a reduction for unrecognized tax benefits of $1 million and $10 million as of December 31, 2023 and 2022, respectively.[3]The amounts shown are primarily comprised of Capitalization of R&D Expenses. Other deferred income taxes presented in the table above as of December 31, 2022, have been revised as discussed in note 1b.

Income Taxes - Schedule of De_2

Income Taxes - Schedule of Defered Income Taxes (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets Liabilities Net [Line Items]
Unrecognized tax benefits	$ 2	$ 1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) ₪ in Millions, $ in Millions		1 Months Ended		12 Months Ended
	Jan. 01, 2017	Oct. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)	Dec. 31, 2023 USD ($) Employee	Dec. 31, 2023 ILS (₪) Employee	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020	Dec. 31, 2016
Income Tax [Line Items]
Balance of accrued potential penalties and interest in unrecognized tax benefits				$ 224		$ 212	$ 210
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense				$ 12		$ 2	$ 37
Statutory tax rate in Israel				23%	23%	23%	23%	23%
Annual revenue				$ 15,846		$ 14,925	$ 15,878
Expected impairment of income tax benefit			$ 126
With Effect From January 2025 [Member] | Organization For Economic Cooperation And Development [Member] | Pillar Two Rules [Member]
Income Tax [Line Items]
Global minimum tax rate percentage				15%	15%
Israel Tax Authority [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends									8%
Israel Tax Authority [Member] | Tax Year 2008 To 2011 [Member]
Income Tax [Line Items]
Income Tax Examination, Estimate of Possible Loss		$ 350
Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				$ 50
Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				924
Tax Carryforwards And Deductions No Expiration [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				291
Tax Carryforwards And Deductions Indefinite [Member]
Income Tax [Line Items]
Tax effect of unspecified carryforward losses and deductions				1,196
Amendment 69 to Investment Law [Member]
Income Tax [Line Items]
Payment of corporate tax				577
Exempt Income				9,400
Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel									16%
Amendment 68 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel									9%
Amendment 73 to Investment Law [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel	7.50%
Preferred Enterprise [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends									20%
Preferred Enterprise [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Withholding tax percentage on dividends									5%
Preferred Technological Enterprises [Member]
Income Tax [Line Items]
Venture capital investment				$ 2
Average growth rate in sales or workforce				25%	25%
Average growth preceding period in sales or workforce				3 years	3 years
Preferred Technological Enterprises [Member] | Research and Development Arrangement [Member]
Income Tax [Line Items]
Minimum percentage of investment income				7%	7%
Minimum investment income				$ 22	₪ 75
Minimum percentage of workforce				20%	20%
Minimum number of employees employed | Employee				200	200
Preferred Technological Enterprises [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				12%	12%
Preferred Technological Enterprises [Member] | Israel Tax Authority [Member] | Development Zonea [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				7.50%	7.50%
Special Preferred Technological Enterprise [Member]
Income Tax [Line Items]
Annual revenue				$ 2,900	₪ 10,000
Special Preferred Technological Enterprise [Member] | Israel Tax Authority [Member]
Income Tax [Line Items]
Statutory tax rate in Israel				6%	6%
Withholding tax percentage on dividends				4%	4%
Minimum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2024	Dec. 31, 2024
Minimum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2026	Dec. 31, 2026
Minimum [Member] | Tax Carryforwards And Deductions No Expiration [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2034	Dec. 31, 2034
Maximum [Member] | Tax Carryforwards And Deductions Expiration Period One [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2025	Dec. 31, 2025
Maximum [Member] | Tax Carryforwards And Deductions Expiration Period Two [Member]
Income Tax [Line Items]
Expiration period				Dec. 31, 2033	Dec. 31, 2033

Income Taxes - Schedule of De_3

Income Taxes - Schedule of Deferred Tax Assets and Liabilities By Report Caption (Detail) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Deferred Tax Assets Liabilities Net [Line Items]
Long-term assets—deferred income taxes	[1]	$ 1,812	$ 1,458
Long-term liabilities—deferred income taxes		(606)	(548)
Deferred tax assets liabilities net		$ 1,206	$ 910
[1]Long-term assets—deferred income taxes presented in the tables above as of December 31, 2022, have been revised as discussed in note 1b.

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Unrecognized Tax Benefits [Line Items]
Balance at the beginning of the year	$ 638	$ 672	$ 888
Increase (decrease) related to prior year tax positions, net	(1)	(46)	(106)
Increase related to current year tax positions	15	42	7
Decrease related to settlements with tax authorities and lapse of applicable statutes of limitations	(15)	(31)	(115)
Other	14	1	(2)
Balance at the end of the year	$ 651	$ 638	$ 672

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions			12 Months Ended
	Jul. 13, 2017	Apr. 18, 2016	Dec. 31, 2023	Dec. 31, 2022	Jun. 11, 2020	Sep. 03, 2015	Jun. 29, 2010
Class of Stock [Line Items]
Ordinary shares issuance ADSs			1,200,000	1,200,000
Share price			$ 10.44
Number of shares exercisable			22,703
Number of shares available for future awards			65,800
Vesting period, description			The vesting period of the outstanding options and RSUs is generally between 1 to 4 years from date of grant. The vesting period of PSUs is generally 3 years from date of grant. The rights of ordinary shares obtained from the exercise of options, RSUs or PSUs are identical to those of other ordinary shares of the Company. The contractual term of these options is primarily for ten years.
Unrecognized compensation cost before tax related to RSUs/PSUs			$ 192
Weighted average period			2 years 6 months
Unrecognized compensation costs related to employee stock options			$ 0
2010 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable							70,000
2015 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable	142,000	77,000				43,700
Number of additional shares authorized	65,000	33,300
2020 Long-Term Equity-Based Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares exercisable					68,000

Equity - Summary of Stock Optio

Equity - Summary of Stock Option Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance outstanding at begining of year	24,119	29,015	35,234
Forfeited	(885)	(2,378)	(3,644)
Expired	(531)	(2,518)	(2,575)
Balance outstanding at end of year	22,703	24,119	29,015
Balance exercisable at end of year	22,703	24,119	26,989
Balance outstanding at begining of year	$ 36.83	$ 36.96	$ 37.27
Forfeited	34.65	33.77	36.09
Expired	37.57	41.26	42.4
Balance outstanding at end of year	36.89	36.83	36.96
Balance exercisable at end of year	$ 36.89	$ 36.83	$ 38.3

Equity - Schedule of Ordinary S

Equity - Schedule of Ordinary Shares Issued Upon Vested Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2023 yr $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	22,703
Weighted average exercise price	$ 36.89
Weighted average remaining life Years | yr	2.76
Lower than $15.01 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	592
Weighted average exercise price	$ 11.4
Weighted average remaining life Years | yr	3.84
Range of exercise prices, upper limit	$ 15.01
$15.01 - $25.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	7,374
Weighted average exercise price	$ 18.95
Weighted average remaining life Years | yr	4.14
Range of exercise prices, lower limit	$ 15.01
Range of exercise prices, upper limit	$ 25
$25.01 - $35.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	5,470
Weighted average exercise price	$ 34.66
Weighted average remaining life Years | yr	3.17
Range of exercise prices, lower limit	$ 25.01
Range of exercise prices, upper limit	$ 35
$35.01 - $45.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	61
Weighted average exercise price	$ 37.97
Weighted average remaining life Years | yr	2.78
Range of exercise prices, lower limit	$ 35.01
Range of exercise prices, upper limit	$ 45
$45.01 - $55.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	5,707
Weighted average exercise price	$ 51.26
Weighted average remaining life Years | yr	1.36
Range of exercise prices, lower limit	$ 45.01
Range of exercise prices, upper limit	$ 55
$55.01 - $65.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Balance at end of period (in thousands) Number of shares | shares	3,500
Weighted average exercise price	$ 59.04
Weighted average remaining life Years | yr	1.34
Range of exercise prices, lower limit	$ 55.01
Range of exercise prices, upper limit	$ 65

Equity - Schedule of Number of

Equity - Schedule of Number of RSUs Issued and Outstanding (Detail) - Restricted Stock Units [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance outstanding at beginning of year	32,302	24,412	20,720
Granted	16,608	18,755	12,748
Vested	(10,195)	(7,571)	(6,818)
Forfeited	(3,052)	(3,293)	(2,238)
Balance outstanding at end of year	35,664	32,302	24,412
Weighted-average grant date fair value per share - RSUs at beginning year	$ 9.11	$ 11.58	$ 13.81
Granted	9.77	7.42	10.42
Vested	10.28	13.02	15.6
Forfeited	9.81	9.81	12.18
Weighted-average grant date fair value per share - RSUs at end of year	$ 9.07	$ 9.11	$ 11.58

Equity - Summary of Company Exp

Equity - Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Stock Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 0	$ 2	$ 16
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	121	122	103
Omnibus Long Term Share Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	121	124	119
Tax effect on stock-based compensation expense	11	9	12
Net effect	$ 110	$ 115	$ 107

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		$ (2,838)
Ending Balance		(2,697)	$ (2,838)
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(2,514)	(2,274)	$ (1,919)
Other comprehensive income/(loss) before reclassifications		167	(223)	(386)
Net other comprehensive income/(loss) before tax		167	(223)	(386)
Corresponding income tax		(37)	(17)	31
Net other comprehensive income/(loss) after tax	[1]	130	(240)	(355)
Ending Balance		(2,384)	(2,514)	(2,274)
Derivative Financial Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(295)	(324)	(363)
Other comprehensive income/(loss) before reclassifications		(1)		0
Amounts reclassified to the statements of income		30	29	39
Net other comprehensive income/(loss) before tax		29	29	39
Net other comprehensive income/(loss) after tax	[1]	29	29	39
Ending Balance		(266)	(295)	(324)
Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(28)	(85)	(117)
Other comprehensive income/(loss) before reclassifications		(17)	40	18
Amounts reclassified to the statements of income		(4)	27	18
Net other comprehensive income/(loss) before tax		(21)	67	36
Corresponding income tax		3	(10)	(4)
Net other comprehensive income/(loss) after tax	[1]	(18)	57	32
Ending Balance		(46)	(28)	(85)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		(2,838)	(2,683)	(2,399)
Other comprehensive income/(loss) before reclassifications		149	(183)	(368)
Amounts reclassified to the statements of income		26	56	57
Net other comprehensive income/(loss) before tax		175	(127)	(311)
Corresponding income tax		(34)	(27)	27
Net other comprehensive income/(loss) after tax	[1]	141	(154)	(284)
Ending Balance		$ (2,697)	$ (2,838)	$ (2,683)
[1]Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $50 million loss in 2023, $116 million loss in 2022 and $107 million loss in 2021.

Equity - Accumulated Other Co_2

Equity - Accumulated Other Comprehensive Income/(Loss) (Net of Tax) (Parenthetical) (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Foreign Currency Translation Adjustments Attributable to Non-controlling Interests [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation attributable to non-controlling interests	$ 50	$ 116	$ 107

Other assets impairments, res_3

Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring and Impairment Costs [Line Items]
Impairments of long-lived tangible assets	[1]	$ 28	$ 47	$ 160
Contingent consideration (see note 20)	[2]	548	261	7
Restructuring		111	146	133
Other		30	57	41
Total		$ 718	$ 512	$ 341
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]		Other asset impairments, restructuring and other items
[1]Including impairments related to exit and disposal activities.[2]The contingent consideration presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Other assets impairments, res_4

Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 111	$ 146	$ 133
Employee termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	52	117	117
Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 59	$ 29	$ 16

Other assets impairments, res_5

Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Beginning balance		$ (119)	$ (138)	$ (122)
Provision		(111)	(146)	(133)
Utilization and other	[1]	149	165	117
Ending balance		(82)	(119)	(138)
Employee termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance		(112)	(131)	(115)
Provision		(52)	(117)	(117)
Utilization and other	[1]	90	136	101
Ending balance		(75)	(112)	(131)
Other Exit and Disposal [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance		(7)	(7)	(7)
Provision		(59)	(29)	(16)
Utilization and other	[1]	59	29	16
Ending balance		$ (7)	$ (7)	$ (7)
[1]Includes adjustments for foreign currency translation.

Other assets impairments, res_6

Other assets impairments, restructuring and other items - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring and Impairment Costs [Line Items]
Impairments of property, plant and equipment		$ 28	$ 47	$ 160
Business combination contingent consideration arrangements change in amount of contingent consideration liability	[1]	548	261	7
Restructuring costs		$ 111	$ 146	$ 133
[1]The contingent consideration presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Other Income - Schedule of Othe

Other Income - Schedule of Other Income (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other Income [Line Items]
Gain on divestitures, net of divestitures related costs	[1]	$ 3	$ 46	$ 51
Section 8 and similar payments		5	13	19
Other, net	[2]	16	31	22
Gain (loss) on sale of assets	[3]	25	18	7
Total other income		$ 49	$ 107	$ 98
[1]In 2022 mainly related to the divestment of several activities in North America and International Markets. In 2021, mainly due to capital gains related to the sale of certain OTC assets.[2]In 2022 mainly the result of settlement proceeds related to the International Markets segment.[3]In 2023 mainly related to the divestment of assets in International Markets.

Financial expenses, net - Sched

Financial expenses, net - Schedule of Financial Expenses (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Expenses [Line Items]
Interest expenses and other bank charges		$ 1,029	$ 930	$ 891
(Income) loss from investments	[1]	(68)	(10)	90
Foreign exchange (gains) losses, net		30	(16)	7
Other, net	[2]	66	61	71
Total finance expense, net		$ 1,057	$ 966	$ 1,058
[1]Loss from investments in 2021 comprised mainly of revaluation gains and loss of Teva’s investment in American Well Corporation (“American Well”).[2]Amortization of issuance costs and terminated derivative instruments.

Earnings (Loss) per Share - Sch

Earnings (Loss) per Share - Schedule of Earnings per Share (Detail) - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net income (loss) used for the computation of basic and diluted earnings (loss) per share	[1]	$ (559)	$ (2,446)	$ 417
Weighted average number of shares used in the computation of basic earnings (loss) per share		1,119	1,110	1,102
Weighted average number of shares used in the computation of diluted earnings (loss) per share		1,119	1,110	1,107
[1]Net income (loss) presented in the table above for the year ended December 31, 2022 has been revised as discussed in note 1b.

Earnings (Loss) per Share - Add

Earnings (Loss) per Share - Additional Information (Detail) - $ / shares	3 Months Ended						12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Basic	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.5)	$ (2.2)	$ 0.38
Diluted	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.5)	$ (2.2)	$ 0.38
Weighted average shares with dilutive effect on earnings per share									5,000,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares with anti-dilutive effect on earnings per share							0	0	0

Segments - Summary of Segment P

Segments - Summary of Segment Profit (Detail) - USD ($) $ in Millions	3 Months Ended							12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)		$ 344	$ (654)	$ (13)	$ (940)	$ 424	$ (967)	$ 433	[1]	$ (2,197)	[1]	$ 1,716	[1]
Amounts Not Allocated To Segments [Abstract]
Amortization								616		732		802
Other asset impairments, restructuring and other items		57	108	110	217	31	137	718	[1]	512	[1]	341	[1]
Goodwill impairment	$ 0		700					700		2,045		0
Intangible assets impairments								350		355		424
Legal settlements and loss contingencies								1,043		2,082		717
Other Unallocated Amounts								502		610		402
Revenues								15,846		14,925		15,878
Gross profit								7,645		6,973		7,594
R&D expenses								953		838		967
S&M expenses								2,336		2,265		2,429
G&A expenses								1,162		1,180		1,099
Segment profit		344	(654)	(13)	(940)	424	(967)	433	[1]	(2,197)	[1]	1,716	[1]
Financial expenses, net								1,057		966		1,058
Consolidated income (loss) before income taxes		$ 64	$ (923)	$ (272)	$ (1,185)	$ 171	$ (1,178)	(624)	[1],[2]	(3,163)	[1],[2]	658	[1],[2]
North America [Member]
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)								2,396		1,993		2,224
Amounts Not Allocated To Segments [Abstract]
Revenues								8,124		7,452		7,809
Gross profit								4,421		3,926		4,226
R&D expenses								625		532		618
S&M expenses								1,005		941		988
G&A expenses								403		474		427
Other (income) expense								(8)		(15)		(31)
Segment profit								2,396		1,993		2,224
Europe [Member]
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)								1,478		1,496		1,494
Amounts Not Allocated To Segments [Abstract]
Revenues								4,837		4,525		4,886
Gross profit								2,726		2,700		2,823
R&D expenses								220		213		244
S&M expenses								767		748		846
G&A expenses								263		246		244
Other (income) expense								(2)		(3)		(5)
Segment profit								1,478		1,496		1,494
International Markets [Member]
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)								464		479		529
Amounts Not Allocated To Segments [Abstract]
Revenues								1,958		1,903		2,032
Gross profit								1,050		1,033		1,118
R&D expenses								83		72		68
S&M expenses								420		405		417
G&A expenses								118		119		109
Other (income) expense								(35)		(43)		(5)
Segment profit								464		479		529
Segments and Other Activities [Member]
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)								4,361		4,139		4,401
Amounts Not Allocated To Segments [Abstract]
Segment profit								4,361		4,139		4,401
Other Segments [Member]
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)								24		172		154
Amounts Not Allocated To Segments [Abstract]
Segment profit								24		172		154
Corporate Segment [Member]
Amounts Allocated To Segments [Abstract]
Consolidated operating income (loss)								4,338		3,968		4,246
Amounts Not Allocated To Segments [Abstract]
Segment profit								$ 4,338		$ 3,968		$ 4,246
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Segments - Schedule of Revenues

Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Revenues		$ 15,846	$ 14,925	$ 15,878
North America [Member]
Product Information [Line Items]
Revenues		8,124	7,452	7,809
Europe [Member]
Product Information [Line Items]
Revenues		4,837	4,525	4,886
International Markets [Member]
Product Information [Line Items]
Revenues		1,958	1,903	2,032
Generic products [Member] | North America [Member]
Product Information [Line Items]
Revenues		3,475	3,549	3,769
Generic products [Member] | Europe [Member]
Product Information [Line Items]
Revenues		3,664	3,466	3,569
Generic products [Member] | International Markets [Member]
Product Information [Line Items]
Revenues		1,594	1,586	1,649
AJOVY [Member] | North America [Member]
Product Information [Line Items]
Revenues		230	218	176
AJOVY [Member] | Europe [Member]
Product Information [Line Items]
Revenues		160	124	87
AJOVY [Member] | International Markets [Member]
Product Information [Line Items]
Revenues		44	35	50
AUSTEDO [Member] | North America [Member]
Product Information [Line Items]
Revenues		1,225	963	802
BENDEKA and TREANDA [Member] | North America [Member]
Product Information [Line Items]
Revenues		241	316	385
COPAXONE [Member] | North America [Member]
Product Information [Line Items]
Revenues		320	387	577
COPAXONE [Member] | Europe [Member]
Product Information [Line Items]
Revenues		231	268	391
COPAXONE [Member] | International Markets [Member]
Product Information [Line Items]
Revenues		39	36	37
Anda [Member] | North America [Member]
Product Information [Line Items]
Revenues		1,577	1,471	1,323
Respiratory Product [Member] | Europe [Member]
Product Information [Line Items]
Revenues		265	273	356
Other [Member] | North America [Member]
Product Information [Line Items]
Revenues	[1]	1,056	549	777
Other [Member] | Europe [Member]
Product Information [Line Items]
Revenues	[2]	516	393	483
Other [Member] | International Markets [Member]
Product Information [Line Items]
Revenues		$ 281	$ 246	$ 295
[1]Other revenues were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.[2]Other revenues in 2023 were mainly related to the sale of certain product rights.

Segments - Schedule of Revenu_2

Segments - Schedule of Revenues by Major Products and Activities (Parentheticals) (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Collaborative Arrangement [Member] | Sanofi [Member]
Product Information [Line Items]
Upfront Payments	$ 500

Segments - Schedule of Sales Pe

Segments - Schedule of Sales Percentage by Therapeutic Category (Detail)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
McKesson Corporation [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Third party net sales present	9%	10%	11%
AmerisourceBergen Corporation [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Third party net sales present	9%	10%	11%

Segments - Schedule of Net Sale

Segments - Schedule of Net Sales by Product Line - Schedule of Property, Plant and Equipment by Geographic Location (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 5,750	$ 5,739
Israel [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,312	1,401
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	1,318	1,143
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	596	625
Croatia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	447	445
Czech republic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	309	318
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	266	268
Hungary [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	279	294
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	$ 1,222	$ 1,245

Segments - Additional Informati

Segments - Additional Information (Detail) - Segment	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Number of reportable segments	3
Israel [Member] | Sales Revenue, Net [Member] | Revenue from Rights Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	2%	2%	2%
UNITED STATES | Sales Revenue, Net [Member] | Revenue from Rights Concentration Risk [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	49%	47%	46%

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ (517)	$ (251)	[1]
Total	$ 2,765	2,525
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Current
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Current
Asset Derivatives - Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	$ 38	29
Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	8
Convertible Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	40
Liabilities Derivatives Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	(39)	(101)
Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,704	1,222
Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,522	1,579
Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	7	9
Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	1	6
Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	1	33
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	3,235	2,848
Level 1 [Member] | Money Markets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,704	1,222
Level 1 [Member] | Cash, Deposits and Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,522	1,579
Level 1 [Member] | Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	7	9
Level 1 [Member] | Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	1	5
Level 1 [Member] | Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	1	33
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	7	(73)
Level 2 [Member] | Asset Derivatives - Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	38	29
Level 2 [Member] | Liabilities Derivatives - Interest Rate and Cross Currency Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	8
Level 2 [Member] | Liabilities Derivatives Options and Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	(39)	(101)
Level 2 [Member] | Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	(517)	(251)	[1]
Total	(477)	(250)
Level 3 [Member] | Convertible Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	40
Level 3 [Member] | Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in securities	$ 0	1
Level 3 [Member] | Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash
[1]Contingent consideration represents liabilities recorded at fair value in connection with acquisitions. The contingent consideration liability is recorded under accrued expenses and other taxes and long-term liabilities. The financial data presented in the tables above as of December 31, 2022 have been revised as discussed in note 1b.

Fair value measurement - Additi

Fair value measurement - Additional Information (Detail)	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage increase in significant unobservable input percentage business combination contingent consideration	1%
Percentage decrease in significant unobservable input percentage business combination contingent consideration	1%
Maximum [Member] | Measurement input, discount rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	11
Minimum [Member] | Measurement input, discount rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	8.5
Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business combination, contingent consideration, liability, measurement input	8.8

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value at the beginning of the period		$ (250)	$ (175)
Fair value at the end of the period		(477)	(250)
Nove Tide Acquisition [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Redemption of debt securities	[1]	0	(11)
Eagle Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments to provisions for contingent consideration		(132)	(21)
Settlement of contingent consideration		76	88
Allergan transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Allergan transaction	[2]	(422)	(240)
Settlement of contingent consideration		207	$ 109
Novetide transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments to provisions for contingent consideration		2
Settlement of contingent consideration		2
Convertible Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in convertible bond	[3]	$ 40
[1]In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies.” This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net,” reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition.[2]The financial data presented in the tables above with respect to adjustments to provisions for contingent consideration related to Allergan in 2022 have been revised as discussed in note 1b.[3]On September 29, 2023, Teva invested $40 million in subordinated convertible bonds, which were issued by Alvotech, pursuant to a convertible bond instrument dated December 20, 2022. (see note 2).

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Parenthetical) (Detail) - USD ($) $ in Millions	Sep. 29, 2023	Jan. 01, 2022
Nove tide Acquisition [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition, Percentage of voting interests acquired		100%
Subordinated Convertible Bonds [Member] | Alvotech [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument face amount	$ 40

Fair Value Measurement - Summ_4

Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail) - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	[1]	$ 18,865	$ 18,769
Senior Notes And Sustainability Linked Senior Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	[1]	17,214	16,694
Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	[1]	$ 1,651	$ 2,075
[1]The fair value was estimated based on quoted market prices.

Long-term Employee-related Ob_3

Long-term Employee-related Obligations - Schedule of Long Term Employee Related Obligation (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Accrued severance obligations	$ 74	$ 74
Defined benefit plans	73	58
Total	$ 148	$ 132

Long-term Employee-related Ob_4

Long-term Employee-related Obligations - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Long-term investments earmarked for severance pay liabilities in Israel	$ 90	$ 79
Expected contributions to pension funds	115
2024	14
2025	13
2026	13
2027	13
2028	15
2029 to 2033	$ 80

Quarterly Financial Data (Una_3

Quarterly Financial Data (Unaudited) - Summary of Company's Revised Unaudited Quarterly Financial Information (Detail) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended								12 Months Ended
		Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Quarterly Financial Information [Line Items]
Net revenues										$ 15,846	$ 14,925	$ 15,878
Gross profit										7,645	6,973	7,594
Net income (loss)			$ 78	$ (905)	$ (253)	$ (1,333)	$ 63	$ (278)		(615)	(2,499)	456
Net income (loss) attributable to Teva			$ 70	$ (871)	$ (220)	$ (1,301)	$ 61	$ (251)		$ (559)	$ (2,446)	$ 417
Earnings per share attributable to ordinary shareholders:
Basic			$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)		$ (0.5)	$ (2.2)	$ 0.38
Diluted			$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)		$ (0.5)	$ (2.2)	$ 0.38
Adjustment
Quarterly Financial Information [Line Items]
Net revenues		$ 4,457	$ 3,850	$ 3,878	$ 3,661	$ 3,884	$ 3,595	$ 3,786	$ 3,661
Gross profit		2,416	1,851	1,796	1,582	1,770	1,669	1,794	1,740
Net income (loss)	[1]	465	78	(905)	(253)	(1,333)	63	(278)	(952)
Net income (loss) attributable to Teva	[1]	$ 461	$ 70	$ (871)	$ (220)	$ (1,301)	$ 61	$ (251)	$ (955)
Earnings per share attributable to ordinary shareholders:
Basic	[1]	$ 0.41	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.86)
Diluted	[1]	$ 0.41	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.86)
[1]The data presented for the above quarterly periods (except for the three months ended March 31, 2022 and the three months ended December 31, 2023) have been revised to reflect a revision of the line items in the consolidated financial statements. See tables below and note 1b.

Quarterly Financial Data (Una_4

Quarterly Financial Data (Unaudited) - Summary of Restatement of Certain Line Items in the Income Statement (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Quarterly Financial Information [Line Items]
Other asset impairments, restructuring and other items	$ 57	$ 108	$ 110	$ 217	$ 31	$ 137	$ 718	[1]	$ 512	[1]	$ 341	[1]
Operating income (loss)	344	(654)	(13)	(940)	424	(967)	433	[1]	(2,197)	[1]	1,716	[1]
Income (loss) before income taxes	64	(923)	(272)	(1,185)	171	(1,178)	(624)	[1],[2]	(3,163)	[1],[2]	658	[1],[2]
Income taxes (benefit)	(12)	(16)	(19)	149	107	(900)	(7)	[2]	(643)	[2]	211	[2]
Net income (loss)	78	(905)	(253)	(1,333)	63	(278)	(615)		(2,499)		456
Net income (loss) attributable to Teva	$ 70	$ (871)	$ (220)	$ (1,301)	$ 61	$ (251)	$ (559)		$ (2,446)		$ 417
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.5)		$ (2.2)		$ 0.38
Diluted	$ 0.06	$ (0.78)	$ (0.2)	$ (1.17)	$ 0.05	$ (0.23)	$ (0.5)		$ (2.2)		$ 0.38
As previously reported [Member]
Quarterly Financial Information [Line Items]
Other asset impairments, restructuring and other items	$ 46	$ 100	$ 96	$ 132	$ 36	$ 118			$ 414
Operating income (loss)	355	(646)	2	(855)	419	(949)			(2,099)
Income (loss) before income taxes	75	(914)	(258)	(1,100)	166	(1,160)			(3,065)
Income taxes (benefit)	(12)	(16)	(19)	154	107	(900)			(638)
Net income (loss)	88	(898)	(238)	(1,254)	58	(259)			(2,406)
Net income (loss) attributable to Teva	$ 80	$ (863)	$ (205)	$ (1,221)	$ 56	$ (232)			$ (2,353)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ 0.07	$ (0.77)	$ (0.18)	$ (1.1)	$ 0.05	$ (0.21)			$ (2.12)
Diluted	$ 0.07	$ (0.77)	$ (0.18)	$ (1.1)	$ 0.05	$ (0.21)			$ (2.12)
Adjustment [Member]
Quarterly Financial Information [Line Items]
Other asset impairments, restructuring and other items	$ 11	$ 8	$ 15	$ 85	$ (5)	$ 18			$ 98
Operating income (loss)	(11)	(8)	(15)	(85)	5	(18)			(98)
Income (loss) before income taxes	(11)	(8)	(15)	(85)	5	(18)			(98)
Income taxes (benefit)				(5)					(5)
Net income (loss)	(11)	(8)	(15)	(80)	5	(18)			(93)
Net income (loss) attributable to Teva	$ (11)	$ (8)	$ (15)	$ (80)	$ 5	$ (18)			$ (93)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.07)	$ 0	$ (0.02)			$ (0.08)
Diluted	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.07)	$ 0	$ (0.02)			$ (0.08)
[1]The data presented for 2022 have been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. See note 1b.[2]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Quarterly Financial Data (Una_5

Quarterly Financial Data (Unaudited) - Summary of Restatement of Certain Line Items in the Income Statement (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended						12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2023	[1]	Dec. 31, 2022		Dec. 31, 2021	[1]
Quarterly Financial Information [Line Items]
Income Tax Expense (Benefit)	$ (12)	$ (16)	$ (19)	$ 149	$ 107	$ (900)	$ (7)		$ (643)	[1]	$ 211
Restatement adjustment [Member]
Quarterly Financial Information [Line Items]
Income Tax Expense (Benefit)	(12)	(16)	(19)	$ 154	107	(900)			$ (638)
Maximum [Member] | Restatement adjustment [Member]
Quarterly Financial Information [Line Items]
Income Tax Expense (Benefit)	$ 0.5	$ 0.5	$ 0.5		$ 0.5	$ 0.5
[1]The financial data presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Quarterly Financial Data (Una_6

Quarterly Financial Data (Unaudited) - Summary of Restatement of Certain Line Items in the Balance Sheets (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information [Line Items]
Deferred income taxes	$ 1,812	$ 1,755	$ 1,583	$ 1,577	$ 1,458	$ 1,546	$ 1,595
Total assets	43,479	42,095	43,100	43,461	44,011	44,252	45,932
Other taxes and long-term liabilities	4,019	3,950	4,094	3,982	3,945	3,859	3,860
Total long-term liabilities	23,106	23,314	23,664	24,546	23,944	23,213	25,125
Total liabilities	35,353	34,708	35,508	34,957	35,413	34,747	36,121
Teva shareholders' equity:
Accumulated deficit	(13,534)	(13,995)	(14,066)	(13,194)	(12,975)	(11,673)	(11,734)
Total equity	8,126	7,387	7,592	8,504	8,598	9,506	9,810	$ 11,244	$ 11,061
Total liabilities and equity	$ 43,479	42,095	43,100	43,461	44,011	44,252	45,932
As previously reported [Member]
Quarterly Financial Information [Line Items]
Deferred income taxes		1,748	1,578	1,572	1,453	1,546	1,595
Total assets		42,088	43,095	43,456	44,006	44,252	45,932
Other taxes and long-term liabilities		3,818	3,973	3,869	3,847	3,846	3,842
Total long-term liabilities		23,182	23,543	24,433	23,846	23,200	25,107
Total liabilities		34,576	35,387	34,844	35,315	34,734	36,103
Teva shareholders' equity:
Accumulated deficit		(13,870)	(13,950)	(13,086)	(12,882)	(11,660)	(11,716)
Total equity		7,512	7,708	8,612	8,691	9,519	9,828
Total liabilities and equity		42,088	43,095	43,456	44,006	44,252	45,932
Adjustment [Member]
Quarterly Financial Information [Line Items]
Deferred income taxes		7	5	5	5
Total assets		7	5	5	5
Other taxes and long-term liabilities		132	121	113	98	13	18
Total long-term liabilities		132	121	113	98	13	18
Total liabilities		132	121	113	98	13	18
Teva shareholders' equity:
Accumulated deficit		(125)	(116)	(108)	(93)	(13)	(18)
Total equity		(125)	(116)	(108)	(93)	(13)	(18)
Total liabilities and equity		$ 7	$ 5	$ 5	$ 5	$ 0	$ 0

Quarterly Financial Data (Una_7

Quarterly Financial Data (Unaudited) - Summary of Restatement of Certain Line Items in the Balance Sheets (Parenthetical) (Detail) - USD ($) $ in Millions	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Quarterly Financial Information [Line Items]
Deferred income tax assets	$ 1,812	$ 1,755	$ 1,583	$ 1,577	$ 1,458	$ 1,546	$ 1,595
Total assets	$ 43,479	42,095	43,100	43,461	44,011	44,252	45,932
Restatement adjustment [Member]
Quarterly Financial Information [Line Items]
Deferred income tax assets		1,748	1,578	1,572	1,453	1,546	1,595
Total assets		$ 42,088	$ 43,095	$ 43,456	$ 44,006	44,252	45,932
Maximum [Member] | Restatement adjustment [Member]
Quarterly Financial Information [Line Items]
Deferred income tax assets						0.5	0.5
Total assets						$ 0.5	$ 0.5

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	$ 3,596	$ 3,817	$ 4,309
Deductions		(13,125)	(13,513)
Balance at end of period		3,596	3,817
Allowance For Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	162	164	200
Charged to costs and expenses	10	8	(8)
Charged to other accounts	(6)	(2)	0
Deductions	(2)	(8)	(28)
Balance at end of period	164	162	164
Valuation Allowance in Tax Carryforward Losses And Deductions [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of period	3,072	2,723	2,547
Charged to costs and expenses	161	443	336
Deductions	(224)	(93)	(160)
Balance at end of period	$ 3,009	$ 3,072	$ 2,723